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The cover photo depicts a bunch of individual kidney beans, symbolizing human kidneys 
coming from various individuals. Although unrecognizable from one another at a first 
glance, they are not the same. As this work suggests, individual kidneys differ in their 
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In recent decades, cardiovascular medicine has witnessed a tremendous progress in 
understanding the mechanisms governing the regulation of vascular tone. Moreover, by 
discovering the crucial role of the endothelium in vasomotor control1, the concept of 
endothelial dysfunction has been defined and the involvement of vasomotor mechanisms in 
the pathophysiology of cardiovascular disease and end-organ damage has been proposed2-4. 
Conditions characterized by chronic end-organ failure, such as cardiac or renal failure, are 
no more regarded as diseases of isolated organs, but rather as syndromes associated with 
multiple vascular changes. However, the role of peripheral and intraorgan vascular 
dysfunction in the initiation and progression of end-organ damage is far from being 
understood. Endothelial dysfunction has been shown to occur early in the course of 
cardiovascular disease and proposed to predict cardiovascular outcome5-7. This suggests 
that vascular dysfunction might be crucially involved in the development of end-organ 
damage. This thesis aims to investigate the role of intraorgan and peripheral vasoreactivity 
as a determinant of renal end-organ damage potentially representing novel renoprotective 
therapeutic strategy. 
 
Vascular tone regulation 
Small arteries (diameter < 500 µm) crucially regulate organ blood supply and are 
responsible for a major portion of the vascular resistance8,9. Vascular tone of small arteries 
is controlled by nervous, hormonal and local mechanisms. Reactivity of a given vascular 
bed is the result of interplay between vascular smooth muscle cells (VSMC) and locally 
produced endothelium-derived mediators. Pressurized vessels exhibit constrictive response 
against the intraluminal pressure, which determines the level of basal vascular tone. This 
reaction, termed myogenic response10, is an intrinsic property of VSMC. VSMC sense 
mechanical stretch, which leads to the depolarization of the cell membrane, opening of 
voltage-sensitive Ca2+ channels, subsequent Ca2+ influx, and activation of the contractile 
apparatus. On top of the basal vascular tone, determined by myogenic reactivity, vascular 
diameter is controlled by additional local constrictive and dilatory mechanisms. 
Endothelium, an inner lining of the vessel is of major importance in the regulation of 
vascular tone. By releasing several vasoconstrictive and dilative substances (see Chapter 2 
of this thesis for details), it modulates the tone of the underlying VSMC. Endothelium-
derived relaxing factors include cyclooxygenase (COX)-derived vasodilatory 
prostaglandins, nitric oxide synthase (NOS)-derived nitric oxide (NO), and the yet 
unidentified endothelium-derived hyperpolarizing factor (EDHF). Endothelial cells 
however also play an important role in multiple other processes, such as hemostasis, 
inflammation, permeability, and angiogenesis11. Improper functioning of endothelial 
regulation is reflected by altered release of endothelial vasodilative mediators and may be 
assessed by the vasodilatory response of the vessel to agonists, such as acetylcholine 
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(ACh). Impaired endothelium-mediated ACh-induced vasodilation is believed to be a 
marker of endothelial dysfunction, a condition associated with various aspects of 
cardiovascular disease2,12. Myogenic response and endothelium-mediated reactivity 
represent the principal local mechanisms controlling the tone of small arteries and as such 
are the major focus of investigation in the present thesis.  
 
Myogenic response and endothelial function in small renal and mesenteric arteries 
Myogenic reactivity sets the basal tone of vessels and thus co-determines the basal level of 
resistance in the vascular tree. It is pronounced in small arteries known to serve as 
resistance vessels, whereas mostly absent in large conduit vessels10,13. Small mesenteric 
artery, employed in our experiments, represents the prototype of a peripheral resistance 
artery. Increased peripheral resistance is a hallmark of several cardiovascular diseases, such 
as hypertension, cardiac or renal failure14. Several authors have proposed that excessive 
myogenic reactivity might be responsible for elevated peripheral resistance in spontaneous 
hypertension or heart failure, whereas not much is known about chronic renal failure15,16. 
However, in other organs such as the kidney and the brain, myogenic response may serve 
an additional function. In the kidney, myogenic reactivity of renal preglomerular arteries is 
responsible for renal autoregulation, a mechanism that keeps renal hemodynamics optimal 
under changes in systemic blood pressure. In particular, the glomerulus is protected from an 
increase in intraglomerular pressure and the induction of hyperfiltration17. Hyperfiltration 
represents one of the key events in the development of proteinuria and renal end-organ 
damage. Indeed, several lines of evidence suggest that myogenic reactivity of renal vessels 
may be impaired in chronic renal failure18. However, mechanisms underlying 
heterogeneous changes of myogenic tone between systemic and renal vasculature in 
chronic renal disease are not yet understood. Also, endothelial regulation may differ 
between intrarenal and extrarenal vascular beds. The contribution of endothelial mediators 
to endothelium-mediated vasodilation seems to be crucially dependent on location and the 
artery investigated. For instance, whereas in the large conduit arteries NO is the major 
endothelial vasodilator, in smaller vessels EDHF prevails19,20. Therefore, the physiological 
characteristics of vasomotor regulation in a given vascular bed might be important to define 
their role in the pathogenesis of cardiovascular and/or renal damage. Although 
heterogeneity in endothelial function between renal and systemic vessels may be 
anticipated, it has been proposed that the kidney can be regarded as an organ reflecting 
generalized vascular changes, such as in case of urinary leakage of small amounts of 
protein (microalbuminuria), as explained below.  
 
Chronic kidney disease- a vasculopathic state 
Chronic kidney disease (CKD) refers to a condition characterized either by a decline in 
glomerular filtration rate (GFR of less than 60 ml/min/1.73 m2) or the presence of any other 
marker of renal damage, such as by histology confirmed renal injury or abnormal protein 
excretion21. The most evident outcome of CKD is chronic renal failure requiring treatment 
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by transplantation and/or dialysis. However, many more individuals suffer from early 
stages of CKD with only mildly decreased or even normal to increased GFR. Early and late 
stages of CKD are currently no longer regarded as a disease of an isolated organ, but rather 
a vasculopathic state with generalized vascular changes in multiple vascular beds. CKD is 
associated with increased prevalence of cardiovascular disease and in fact, patients with 
CKD have even higher chance to experience a cardiovascular event than to progress to 
renal failure22. Microalbuminuria predicts the rate of renal function decline as well as an 
increase in cardiovascular morbidity and mortality in several populations23-26, giving rise to 
the hypothesis that excessive protein leakage in kidney is a reflection of generalized 
vascular or endothelial function27. Moreover, it suggests that vascular changes occur in 
early stages of the disease and might actively participate in the development of renal and 
cardiovascular end-organ damage. However, the mechanisms underlying the relation 













































































































































































































































Figure 1. Endothelial function of healthy rat predicts development of renal damage after 
5/6 nephrectomy. Endothelium-dependent vasodilation to acetylcholine (A) and the 
contribution of endothelial vasodilatory mechanisms prostaglandins (B), NO (C) and 
EDHF (D) measured in small renal arteries of healthy rats correlate with the severity of 
proteinuria after subsequent 5/6 nephrectomy. Adapted from28. 
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Predictive value of endothelial function in renal end-organ damage 
The early occurrence of vascular dysfunction in the course of progressive renal disease 
leads to the question whether vascular function might condition the susceptibility of a 
healthy individual to renal damage. The severity of CKD varies considerably among 
patients with similar systemic risk factor profiles, such as hypertension and diabetes, and 
seems to be also dependent on intrinsic, probably genetically conditioned factors. Likewise, 
in experimental animal models of CKD, the individuals of outbred rat strains develop renal 
damage and renal function loss of highly variable severity after a relatively uniform injury, 
such as subtotal nephrectomy. In our laboratory, the hypothesis that variability in renal 
endothelial function among healthy animals might be responsible for the observed 
differences in susceptibility to end-organ damage was recently tested. To this end, 
endothelium-dependent vasodilation of small intrarenal arteries in vitro was measured in 
healthy rats, including the contribution of three principal endothelial dilatory mediators, 
e.g., NO, EDHF, and prostaglandins. Indeed, vascular function was remarkably variable 
among the individuals. Following these measurements, renal injury was induced by 5/6 
nephrectomy. The endothelium-dependent vasodilation of small renal arteries predicted the 
subsequent development of end-organ damage, measured as proteinuria and decline in 
GFR. Thus, rats with more pronounced total endothelial relaxation, NO-mediated or 
prostaglandin-mediated vasodilation, were protected against the end-organ damage, 
whereas prevalence of EDHF was associated with worse renal outcome28 (Figure 1). These 
data suggest that variability in endothelial function among healthy individuals accounts for 
the differences in susceptibility to renal damage induced by a reduction in nephron number. 
However, it remains unknown, whether this prognostic value is specific for this particular 
type of renal injury or it might be extended to other forms of renal disease. 
 
Aims of the thesis 
The aim of this thesis was to investigate the role of vasomotor mechanisms in the 
development and progression of CKD and related systemic cardiovascular complications, 
providing novel potential therapeutic targets. More specifically, two principal mechanisms 
of vascular regulation in small arteries, namely myogenic and endothelium-mediated 
responses were tested in several experimental as well as spontaneous models of chronic 
renal disease. The following main research questions were addressed: 
1. Does vascular function measured in the healthy individual (rat) predict the susceptibility 
of an individual to a renal insult? 
2. If so, is this predictive value of vascular function dependent on the type of insult inflicted 
to the kidney?  
3. Is renal vascular reactivity in CKD related to vasomotor function in peripheral vascular 
beds?  
4. Does vascular function represent an early renal risk marker and a potential target for 
renoprotective preventive therapy? 
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Given the above, the following problems were studied in specific chapters of this thesis: 
Chapter 2 summarizes the relation between microalbuminuria and endothelial function, 
providing a clinical basis for the experimental work in this thesis and suggesting potential 
preventive therapeutic strategies. Chapters 3 and 4 investigate the hypothesis, that 
interindividual heterogeneity in renal endothelial function determines the susceptibility to 
experimentally-induced renal damage of various etiologies, namely myocardial infarction-
induced and nephrotoxic renal damage. Chapter 5 provides evidence of impaired renal 
vasomotor function in a model of spontaneous renal disease prior to the development of 
end-organ damage and explores the related vascular alterations in systemic vessels. 
Chapter 6 addresses the role of peripheral myogenic and endothelial responses in a 
hypertensive CKD model. Chapter 7 summarizes the current knowledge on renal and 
systemic endothelial changes in various stages of CKD, and provides experimental 
evidence for the predictive value of endothelial function with respect to the antiproteinuric 
therapeutic response by ACE inhibitors. 
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A minor increase in urinary albumin excretion (microalbuminuria) is known to predict 
adverse renal and cardiovascular events in diabetic and hypertensive patients. Recent 
intriguing findings show that microalbuminuria is an early and sensitive marker of future 
cardiovascular events even in healthy subjects. The mechanisms linking microalbuminuria 
with end-organ damage have not been fully explained yet, however generalized endothelial 
dysfunction might play an important role. Prevailing experimental and clinical data suggest 
that generalized endothelial dysfunction, frequently characterized by decreased nitric oxide 
bioavailability, actually precedes the development of microalbuminuria. This review 
summarizes the current knowledge about the intricate relationship between 
microalbuminuria and endothelial dysfunction. Based on the current evidence we propose 
that microalbuminuria and endothelial dysfunction are an emerging target for primary 
prevention strategies in cardiovascular disease. In near future, dietary components 
improving nitric oxide bioavailability, such as cocoa -derived flavanols may play important 








End-organ damage associated with cardiovascular disease is the leading cause of morbidity 
and mortality in the Western world. Moreover, the costs related to the end-organ damage, 
such as chronic kidney or heart failure, constitute the majority of expenditures in the total 
health care budget1. Therefore, a shift is required from secondary prevention of renal and 
cardiac end-organ damage to primary prevention targeting the individuals with an increased 
risk profile at an early stage of the disease. Disclosure of novel markers for increased risk 
may help to identify specific individuals and assist in tailoring prevention according to their 
individual risk profile. 
In addition to traditional cardiovascular risk factors, such as hypertension, dyslipidemia, 
central obesity, hyperglycemia and smoking, microalbuminuria has recently received a 
great deal of attention as a new, accessible and sensitive marker of renal and cardiovascular 
risk2-4. The mechanisms linking microalbuminuria to increased renal and cardiovascular 
risk are not fully understood, but it has been proposed that microalbuminuria is a reflection 
of generalized endothelial dysfunction5. This review summarizes the current knowledge 
about the intricate relationship between microalbuminuria and endothelial dysfunction. It 
focuses on the role of these two parameters as early markers of both renal and 
cardiovascular disease. Based on the current evidence we suggest that microalbuminuria 
and endothelial dysfunction represent emerging targets for primary prevention strategies. 
Since endothelial dysfunction is frequently characterized by decreased bioavailability of 
nitric oxide (NO), we propose that dietary components improving NO bioavailability, such 





Albumin is the major constituent of proteins excreted in urine. The widely used dipstick 
method detects only albumin excretion exceeding 300 mg per 24h, a range currently 
defined as macroalbuminuria or proteinuria. However, studies in diabetic patients 
demonstrated that much lower values of albumin excretion are associated with increased 
risk for the development of diabetic nephropathy6,7 Currently, the range between 30 and 
300 mg per 24h, or 20-200 µg/min measured overnight is defined as microalbuminuria. 
Methods for the measurements of urinary albumin, its definition and classification have 
been extensively summarized elsewhere8,9 
 
Microalbuminuria is not rare in normal healthy population 
Prevalence of microalbuminuria has been initially studied in individuals with diabetes and 
later in hypertensive cohorts. Still, a large variability is reported in distinct clinical trials, 
probably due to heterogeneity of the study population, regarding age, race, severity of 
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hypertension, coexistence of nephropathy, antihypertensive medication and associated lipid 
abnormalities. Methods of detection and sampling techniques might form an additional 
source of variation among trials. In general, a prevalence of 20-40% in patients with 
diabetes mellitus is reported in large studies10-13. In the individuals with essential 
hypertension the prevalence of microalbuminuria seems somewhat lower14,15. As an 
example, microalbuminuria was found in 23% of patients with essential hypertension and 
left ventricular hypertrophy included in the Losartan Intervention for Endpoint Reduction in 
Hypertension (LIFE) study16. 
Increased incidence of microalbuminuria is not exclusively limited to the populations with 
elevated cardiovascular risk. An increasing number of large trials suggest that 
microalbuminuria is also common in a general, “healthy” population. In one of the largest 
cohorts studying a general population, the Prevention of Renal and Vascular End stage 
Disease (PREVEND) study, a prevalence of 7.2% was reported in 40.856 subjects and 
6.6% after exclusion of the subjects with diabetes mellitus and hypertension17. Several 
other cross-sectional studies confirm 5-8% prevalence of microalbuminuria in the general 
population18-20, suggesting that among healthy individuals a considerable variability in 
urinary albumin excretion already exists without the presence of any clinical condition. 
This phenomenon renders microalbuminuria a promising candidate as the integrated marker 
of cardiovascular risk in the general population.  
 
Microalbuminuria predicts renal and cardiovascular outcome in diseased and healthy 
population 
Considerable attention for microalbuminuria as a predictive parameter stemmed from the 
publication of Viberti et al. establishing the predictive value of microalbuminuria for 
nephropathy in insulin-dependent diabetes mellitus7. Since then several studies have 
confirmed elevated albumin excretion as a marker for the development of diabetic 
nephropathy and progressive renal failure both in patients with type I6 and type II 
diabetes21. However, the predictive value of microalbuminuria in diabetics is not only 
limited to renal events, as microalbuminuria predicts total and especially cardiovascular 
mortality and morbidity in several studies in non-insulin-dependent diabetic populations23 
even after adjustment for other conventional cardiovascular risk factors. Yudkin et al. were 
the first to report this association also in non-diabetic subjects24. By now, it is well 
established that microalbuminuria identifies the individuals with adverse prognosis among 
hypertensive patients. In one of the largest longitudinal studies performed to investigate a 
predictive role of microalbuminuria, the Danish MONICA study, hypertensive subjects 
with albuminuria showed almost 4-fold increased risk of ischemic heart disease as 
compared to normoalbuminuric hypertensive subjects25. In the prospective LIFE trial in 
non-diabetic hypertensive patients with left ventricular hypertrophy, levels of albumin 
excretion at entry were predictive for composite end-point26. Since there was no threshold 
for the increased risk, correlation between albuminuria and risk exists also at albumin levels 
below the current definition of microalbuminuria. 
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Whereas microalbuminuria is clearly related to cardiovascular risk in high risk populations, 
it is important to mention that its predictive value also extrapolates to the general 
population. In the previously mentioned prospective Danish MONICA study, 
microalbuminuric subjects in general population were at increased risk for ischemic heart 
disease27. Furthermore, Hillege et al. demonstrated that microalbuminuria was 
independently associated with cardiovascular risk factors and morbidity in the general 
population, based on cross-sectional analysis of the baseline data from the PREVEND 
study17. In a more recent prospective analysis of this study, microalbuminuria 
independently predicted cardiovascular and all-cause mortality in the general population 
(Figure 1)22. Moreover, the relationship was already apparent at levels of albumin excretion 
considered to be normal. Within the same cohort, Verhave et al. showed that subjects with 
microalbuminuria at baseline had a higher chance to develop de novo impairment of renal 




Figure 1. Urinary albumin excretion predicts cardiovascular mortality in the general 
population; Relationship between urinary albumin excretion and hazard ratio. The dotted 
lines represent 95% confidence limits and the squared area indicates the definition of 
microalbuminuria. Reproduced from 22 
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Taken together, these data demonstrate the usefulness of microalbuminuria as a valuable 
and clinically relevant tool for the identification of individual patients at risk for the 
development of end-organ damage, e.g. renal as well as systemic cardiovascular disease. 
An important question is how such a relationship may be explained and what the link is 
between increased urinary excretion of albumin and end-organ damage. Currently, the 
evidence points towards the hypothesis that microalbuminuria is a reflection of generalized 




The concept of endothelial dysfunction 
The concept of endothelial dysfunction has emerged from cardiovascular research over the 
past 25 years, recognizing the principal role of the endothelium in regulation of vascular 
function in healthy individuals and its impairment in diseased states29,30. Endothelial 
dysfunction is now considered to play a principal role in the initiation and progression of 
atherosclerosis. Since endothelial dysfunction is also a common denominator for a wide 
variety of conditions such as hypertension, diabetes or chronic renal failure, it may provide 
a link to increased cardiovascular risk in above mentioned conditions. 
Endothelial dysfunction may be defined as alterations in the normal properties of 
endothelium that are inappropriate for preservation of organ function31. Under 
physiological circumstances, the endothelium maintains homeostasis at the vascular wall. 
Normal healthy endothelium reduces vascular tone, regulates vascular permeability, limits 
platelets adhesion and aggregation, prevents activation of the coagulation cascade and 
restricts leukocyte adhesion. The specific term endothelial activation denotes the loss of 
endothelial anti-inflammatory properties characterized by elevated expression of adhesive 
molecules, such as E-selectin, intracellular adhesion molecule-1 (ICAM-1), vascular 
adhesion molecule-1 (VCAM-1) and chemoattractant molecules e.g. monocyte chemotactic 
protein-1 (MCP-1), and consequently pronounced interaction with blood leukocytes. 
Functional properties of endothelium and involved mediators are summarized in Table 1. 
One of the most important mediators released by endothelium is nitric oxide (NO)32. NO 
acts a potent vasodilator, inhibits inflammation, growth of vascular smooth muscle and 
aggregation of platelets. Altered production and/or bioavailability of NO are frequently 
reported in the conditions associated with endothelial dysfunction. However, the 
mechanisms responsible for the development of endothelial dysfunction are not yet 
completely understood. Probably the convergence of traditional and non-traditional risk 
factors, genetic predisposition and local, yet unknown mechanisms all contribute to 
endothelial perturbations32. Summary of the mechanisms playing a role in endothelial cell 
dysfunction is given in Table 2. 
Several methods are available for investigation of endothelial function in humans, which 
however assess only certain aspects of endothelial function. Measurements of endothelium-
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dependent vasodilation assess determines abilities of endothelium in coronary, forearm 
resistance or brachial arteries. Transcapillary escape rate of intravenously injected 
radioactive albumin is employed as a surrogate for endothelial microvascular permeability. 
Finally, plasma levels of endothelium-derived regulatory mediators, such as Von 
Willebrand factor (vWF), soluble thrombomodulin, tissue-type plasminogen-activator 
(tPA), plasminogen activator inhibitor-1 (PAI-1), soluble adhesive (selectins, ICAM-1, 
VCAM-1) and chemoattractant molecules (MCP-1) could be used to estimate systemic 
endothelial activation. The current evidence for the association of microalbuminuria with 
several aspects of endothelial dysfunction in humans is summarized below. 
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Table 2. Classical risk factors and putative mechanisms leading to endothelial dysfunction 
 













Advanced glycation end-products (AGE) 
 
 
Endothelial dysfunction precedes the development of microalbuminuria 
Increased vascular permeability 
Increased permeability of albumin through the vascular wall is considered to be a marker of 
endothelial dysfunction. The evidence that increased albumin leakage in the glomerulus is 
associated with enhanced capillary permeability for albumin in the systemic vasculature 
comes from several studies testing 125I-albumin escape rate in diabetic microalbuminuric 
patients. Feldt-Rasmussen et al. showed that patients with type I diabetes and 
microalbuminuria exhibit higher transcapillary leakage of albumin than those without 
microalbuminuria33. Similar findings were later reported in type II diabetic patients34. 
Furthermore, one study demonstrated that microalbuminuria was related to systemic 
vascular leakage even in healthy subjects35. Although microalbuminuria seems to be 
consistently associated with increased systemic leakage of albumin, some studies found 
increased albumin escape rate also in the hypertensive subjects with normoalbuminuria36,37, 
suggesting that increased permeability of systemic microvessels is not always reflected in 
glomerular protein leakage. Although it is difficult to draw final conclusion from these 
findings, it might be suggested that in these states development of systemic vascular protein 
leakage actually precedes the appearance of microalbuminuria. 
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Impaired systemic endothelium-dependent vasodilation 
Another aspect of systemic endothelial dysfunction, the loss of vasomotor control in the 
peripheral vessels has been repeatedly found in microalbuminuric patients. Most of the data 
support the hypothesis on generalized endothelial dysfunction in albuminuria. In patients 
with diabetes type I38,39 and type II40,41 the endothelium-dependent dilation of the peripheral 
arteries is impaired in microalbuminuric subjects when compared to normoalbuminuric or 
healthy subjects. Furthermore, the presence of microalbuminuria is inversely related to 
flow-mediated dilation of the brachial artery in insulin-dependent diabetic patients42, in 
elderly individuals with or without diabetes43 and in asymptomatic type II diabetics44. 
Intriguing is the fact that these findings could be extended from high risk populations to 
cohorts with clinically healthy subjects. Clausen et al. found that brachial artery flow-
dependent dilation was significantly impaired in healthy individuals with microalbuminuria 
as compared to those with normoalbuminuria45. However, it should be noted that some 
studies failed to find direct relationship between endothelial dysfunction and urinary 
albumin excretion in essential hypertensives46 and healthy subjects47. In fact, blunted 
systemic endothelium-mediated dilatory response is often found also in normoalbuminuric 
diabetic subjects48-50, strongly suggesting that impaired endothelial function precedes the 
development of microalbuminuria. 
 
Elevated plasma levels of pro-thrombotic and pro-inflammatory endothelial markers 
Increased plasma levels of inflammatory and pro-thrombotic markers have also been 
reported from the various cohorts of patients with microalbuminuria suggesting that 
elevated urinary excretion of albumin is associated with generalized endothelial activation 
and a low-grade inflammatory state. Higher circulating levels of von Willebrand factor 
(vWF) were found in patients with hypertension and microalbuminuria as compared to 
those without microalbuminuria51. In addition to vWF, other markers of a procoagulant 
state, such as plasminogen activator inhibitor-1 (PAI-1) and coagulation factor VII are 
elevated in both insulin-dependent52 and non-insulin dependent diabetic patients53,54 with 
microalbuminuria. Therefore, systemic hemostatic dysfunction is frequently present in 
microalbuminuric patients. Elevations of vWF levels are also paralleled by increased 
markers of oxidative stress in type II diabetic microalbuminuric individuals55-57. Activation 
of endothelial cells is characterized by excessive levels of soluble adhesive molecules 
(ICAM-1, VCAM-1 and E-selectin) and is present in microalbuminuric type I58,59 and type 
II60 diabetics. Similar findings have also been reported in low-risk populations. Agewall et 
al. showed that plasma levels of PAI-1 were independently related to the level of urinary 
albumin in healthy subjects61 in a cross-sectional manner. 
Intriguing data from several groups provide compelling evidence that endothelial 
dysfunction might actually precede the occurrence of microalbuminuria. In a longitudinal 
study performed in patients with type I diabetes, Stehouwer et al. demonstrated that 
increases in vWF levels precede the appearance of microalbuminuria by approximately 3 
years62. Similar findings were reported in prospective study by Verrotti et al. in children 
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with type I diabetes63. Furthermore, baseline levels of vWF were strongly related to the de 
novo development of microalbuminuria in the follow-up of non-insulin-dependent diabetic 
cohort64. Comparable data have also been found in a low-risk population. In a 4-year 
prospective study performed in healthy subjects, baseline elevated levels of vWF and tissue 
plasminogen activator (t-PA) predicted the development of increased urinary albumin 
excretion65. Simultaneously to impaired endothelium-dependent dilation, increased levels 
of soluble adhesive molecules are already present in normoalbuminuric diabetic subjects, a 
finding consistent with the hypothesis on the endothelial dysfunction appearing prior to 
microalbuminuria66. 
In conclusion, microalbuminuria is associated with increased in systemic albumin 
permeability, impaired endothelium-vasodilation of systemic vasculature and elevated 
levels of pro-inflammatory and pro-thrombotic endothelium-derived mediators. This is not 
only true in diabetic and hypertensive patients, but also in healthy subjects. Prevailing 
evidence suggests that in some of these states endothelial dysfunction actually precedes the 
development of microalbuminuria. 
 
Prognostic value of endothelial function for cardiovascular risk  
Present data consistently confirm that increased urinary excretion of albumin might be a 
useful integrated early marker of renal and cardiovascular risk. On the other hand, 
prognostic value of endothelial function is still a matter of debate. Since recognition of 
principal role of endothelial dysfunction in the development of atherosclerosis, several 
studies have been designed to investigate prognostic value of endothelial dysfunction for 
cardiovascular outcome. However, reports from microalbuminuric cohorts are scarce.  
Most of the studies investigated endothelial dilatory reactivity as a marker of endothelial 
dysfunction. Coronary or peripheral endothelium-mediated response in patients with mild, 
moderate or established coronary artery disease predicted the adverse event rates in several 
studies67-70. Prognostic value of peripheral endothelial vasodilation has been also shown in 
patients with end-stage renal disease71 and chronic heart failure72. The predictive value of 
endothelial function in patients with normal coronary angiograms73, cohort of essential 
hypertensives74 and hypertensive postmenopausal women75 might suggest that this 
measurement could identify patients at risk at very early stage of the cardiovascular disease.  
Alternatively, the prognostic value of endothelium-derived regulatory markers in plasma 
has been reported from several studies. Once more, the majority of studies was performed 
in patients with known coronary disease. In these cases, vWF, t-PA76, PAI-177, soluble 
ICAM-178 and endothelin79 were predictors of cardiovascular events. In one of the few 
studies with a low risk population, Ridker et al. found elevated plasma levels of soluble 
ICAM-1 to predict the risk for future myocardial infarction in healthy men80.  
Studies investigating the predictive value of endothelial dysfunction in patients with 
microalbuminuria are sporadic and the relation between these two parameters in predicting 
the cardiovascular outcome is not straightforward. Jager et al. have found plasma levels of 
VCAM-1 being predictive for cardiovascular outcome in type II diabetics independently 
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from microalbuminuria81, suggesting that increased plasma levels of VCAM-1 might reflect 
a different aspect of endothelial dysfunction than microalbuminuria. The same group 
showed that cardiovascular risk predicted by microalbuminuria is modified by presence of 
elevated levels of vWF and retinopathy in type II diabetics, favouring the conclusion, that 
“benign” microalbuminuria (without concomitant presence of endothelial dysfunction) has 
more favourable prognosis than “malign” microalbuminuria (with endothelial 
dysfunction)82,83.  
In conclusion, predictive value of the endothelial dysfunction for cardiovascular outcome 
has been shown mostly in high risk patients. Although some data suggest that this 
relationship exists in low risk, healthy or microalbuminuric populations, further studies will 
be needed to establish it conclusively. 
 
Microalbuminuria and endothelial dysfunction as therapeutic target  
 
Presence of microalbuminuria is consistently associated with worse cardiovascular outcome 
in several diseased conditions and in the general population. Therefore, it is of importance 
to explore, whether limiting of microalbuminuria provides benefit for decreased 
cardiovascular risk. Given the early occurrence of endothelial dysfunction in 
microalbuminuric patients, modulation of endothelial function might provide an additional 
strategy to limit adverse cardiovascular events. Furthermore, the both parameters emerge as 
therapeutic targets for primary prevention in the general population.  
 
Lowering of albumin excretion is associated with reduction of cardiovascular risk 
Several therapeutic approaches reverse the excessive urinary excretion of proteins. Strict 
glucose control may prevent the development of microalbuminuria in diabetics84. 
Furthermore, several studies showed that angiotensin-converting enzyme inhibitors 
(ACEi)85-87, angiotensin II AT1 receptor blockers (ARB)88,89, lipid-lowering drugs, such as 
statins90,91 or fibrates92 and recently also oral glycosaminoglycane sulodexide93,94 all reduce 
or even regress microalbuminuria in patients with type I or type II diabetes. Tight blood 
pressure control is required to halt the progression of microalbuminuria in hypertensive 
patients, however drugs interfering with renin-angiotensin-aldosterone system (RAAS) 
might provide more benefit than diuretic, beta-blocking agents or calcium channel blockers 
in lowering albuminuria95.  
Importantly, available evidence suggests, that specific lowering of microalbuminuria 
translates in the reduction of renal and cardiovascular adverse events in several populations. 
Parving et al. showed that lowering of albuminuria with ARB irbesartan is dose-
dependently associated with reduced progression to diabetic nephropathy in hypertensive 
type II diabetics independent of blood pressure control88. Comparably, several other studies 
demonstrated efficacy of ACEi in preventing diabetic nephropathy in diabetic 
microalbuminuric patients85,96. In the LIFE study among hypertensive patients with left 
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ventricular hypertrophy, a reduction in albumin excretion was inversely related to the risk 
of cardiovascular mortality and morbidity97. It seems that drugs interfering with the RAAS 
are superior to other antihypertensives, also in reducing cardiovascular events in 
microalbuminuric subjects. This is however largely based on the data from hypertensive 
diabetic populations, which are known to have high incidence of microalbuminuria98-100.  
Recent compelling evidence for microalbuminuria as a justified target for primary 
prevention comes from the PREVEND-IT study101. Healthy individuals with 
microalbuminuria, but without hypertension or hypercholesterolemia, were treated either 
with placebo or the ACEi fosinopril. At 4-year’s follow-up, the microalbuminuria was 
effectively reduced by ACEi treatment, which was associated with a 44% reduction in 
cardiovascular events. 
In conclusion, lowering of urinary albumin excretion, preferably by RAAS inhibitory 
agents substantially reduces the number of cardiovascular events in both high risk and 
healthy population. 
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Modulation of endothelial dysfunction in microalbuminuric patients 
A wide spectrum of treatments (Table 3) has been shown to improve endothelial 
dysfunction in several conditions. However, the hypothesis, that reversal of endothelial 
dysfunction is associated with risk reduction has not been directly tested. Nevertheless, 
some of endothelium-protective therapeutic strategies, such as ACEi102, ARB103, and 
statins104 have been consistently shown to reduce cardiovascular events in multiple 
populations. It is however unclear to what extent the improvement in endothelial function 
governs cardiovascular risk reduction. 
A limited number of studies is available on reversing endothelial dysfunction in patients 
with microalbuminuria. Strikingly, all therapeutic approaches associated with lowering 
microalbuminuria are also known to improve endothelial function. Therefore it is tempting 
to speculate that improvement of endothelial function plays role in the beneficial effects of 
these drugs on albumin urinary excretion and probably in cardiovascular risk reduction. 
However, the current data from diabetic patients do not allow such conclusion on this issue. 
Several trials investigated the effect of ACEi and ARB treatment on the peripheral 
endothelial function in diabetic microalbuminuric patients. While in type I diabetics Arcaro 
et al.105 found ACEi to improve endothelium-dependent vasodilation of femoral artery 
without affecting microalbuminuria, Schalkwijk et al. reported unchanged peripheral 
endothelium-dependent dilation after short-term therapy with ACEi quinapril106. However, 
in the latter study ACEi reduced plasma levels of soluble E-selectin, suggesting that some 
aspects of endothelial dysfunction were selectively improved. Similarly, reversal of 
elevated VCAM-1 levels paralleled the decrease of microalbuminuria by fosinopril in 
hypertensive type II diabetics107. In contrast, a low dose of ARB losartan, which did not 
affect blood pressure, did not have any impact on peripheral endothelial dilation, while it 
reduced microalbuminuria108. Overall, studies with RAAS interfering agents suggest that 
these drugs may improve several aspects of endothelial function in microalbuminuric 
diabetic subjects, but it is not clear whether these effects play role in their anti-albuminuric 
action. Factors such as duration of treatment, population and agent characteristics might 
underlie these discrepancies. 
In addition to ACEi and ARB, one study investigated the effect of atorvastatin on brachial 
artery flow-mediated dilation in microalbuminuric type I diabetics. Six weeks treatment 
improved vasodilation, but had no effect on albumin excretion, probably due to the short 
duration of the treatment109. Therefore also statins may prove beneficial in reversing 
endothelial dysfunction in microalbuminuric diabetic patients.  
In conclusion, the available data provide evidence that lowering microalbuminuria 
especially by RAAS modulating agents in diabetics, hypertensives and even in healthy 
subjects might provide benefits in terms of reduced cardiovascular events. Majority of the 
agents efficiently lowering microalbuminuria might also reverse endothelial dysfunction. 
However a role of the endothelial modulation in risk reduction remains unclear. 
Nevertheless, experimental evidence suggesting that endothelial dysfunction precedes 
microalbuminuria and that variability in endothelial dysfunction among healthy individuals 
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determines the end-organ damage renders endothelial dysfunction the important modifiable 
factor for primary prevention.  
 
Future potential of dietary flavonoids in primary prevention of microalbuminuria 
Data from the PREVEND-IT study clearly show that reduction of microalbuminuria among 
healthy subjects might prevent future cardiovascular events. Although modulation of 
microalbuminuria and endothelial dysfunction might be the most efficiently achieved by 
ACEi or ARB, additional strategies might prove useful in primary prevention. Furthermore, 
as reported from PREVEND-IT cohort, in otherwise-healthy microalbuminuric population 
only 63% of subjects were compliant to ACEi treatment. Therefore, for primary prevention, 
dietary supplements might provide more acceptable and inexpensive alternative to 
pharmaceutical compounds.  
Recently, attention has been drawn to several nutritional factors in prevention of 
cardiovascular disease. Majority of the research concentrated on n-3 fatty acids, antioxidant 
vitamins, L-arginine, folic acid and plant-derived polyphenols. The latter can be present in 
relatively high concentrations in certain plant-based foods and beverages, such as red wine, 
tea, grapefruit juice or cocoa-based products110. This makes them potentially interesting 
candidates for primary prevention. Several studies performed both in high and low risk 
populations suggest beneficial effect of these supplements on cardiovascular outcome111,112. 
These benefits seem to be mediated by improved endothelial function. Indeed, plant 
polyphenols, especially flavonoids have been shown to improve endothelial function in 
experimental and human studies113,114. Even more important for primary prevention is the 
fact that endothelium-protective characteristics of flavonoids, such as increase in nitric 
oxide bioavailability due to antioxidant properties or stimulating effects on endothelial 
nitric oxide synthase, have been found in healthy individuals. This suggests the potential of 
flavonoids to modify healthy endothelial function and thereby modulate individual 
sensitivity to cardiovascular injury. 
Although the flavonoids content is variable among the various dietary products and is also 
dependent on food processing practices, it appears that raw cocoa might contain the 
concentrations of specific flavonoids substantially exceeding most other known sources115. 
Beneficial vascular effects of cocoa-based products, probably attributed to subclass of 
flavonoids known as flavanols, has been recently extensively reported116,117. Impressive 
studies in healthy humans have shown that ingestion of flavanol-rich cocoa is associated 
with increased NO-dependent vasodilation118, reduced wave reflections119, decrease in 
blood pressure and even an increase in insulin sensitivity120. Beneficial effects on 
endothelial function and insulin sensitivity were also confirmed in smokers121 and 
hypertensives122. Although the effects of cocoa flavanols on renal vasculature and albumin 
excretion await further investigation, dietary strategies utilizing flavanol-rich cocoa hold a 
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Conclusion 
In conclusion, microalbuminuria is an early and sensitive marker of renal and 
cardiovascular risk in both high and low risk patients. Most likely, it reflects a state of 
generalized endothelial dysfunction. Modulation of microalbuminuria and endothelial 
function might provide beneficial effects on future cardiovascular outcome even in the 
general or healthy population. Therefore, targeting microalbuminuria and endothelial 
dysfunction by several agents, such as ACE inhibitors or angiotensin receptor blockers 
might provide an effective strategy for primary prevention of renal and cardiovascular 
disease. Inexpensive and well tolerated dietary strategies utilizing plant-based products 
such as flavanol-rich cocoa might prove useful for primary prevention of end-organ damage 
in the general population. 
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Introduction: We have demonstrated that individual renal endothelial dilatory function of 
the healthy rat predicts susceptibility to subsequent renal damage induced by 5/6 
nephrectomy. Additionally, we reported that myocardial infarction (MI) performed upon 
unilateral nephrectomy (UnX) induced highly variable renal damage. Therefore, we studied 
whether the variability in renal damage after MI could be explained by the variation in 
individual renal endothelial function prior to the induction of injury. 
 
Methods: Endothelium-dependent relaxation to acetylcholine was investigated in in vitro in 
small arteries isolated from the extirpated kidney at UnX. MI was induced one week after 
UnX by ligation of the left coronary artery. Proteinuria and systolic blood pressure (SBP) 
were evaluated weekly for 16 weeks thereafter using metabolic cages and the tail-cuff 
method, respectively. Upon termination of the study, focal glomerulosclerosis (FGS) was 
evaluated by histology as additional marker of renal damage. 
 
Results: After MI nephrectomized male Wistar rats (n=15) gradually developed variable 
proteinuria, ranging from 20 to 507 mg/24h at week 16, with an average SBP of 131 ± 7 
mmHg. The individual renal endothelial function of the healthy animals predicted the 
extent of renal damage in terms of proteinuria (r=-0.62, p=0.008) and FGS (r=-0.70, 
p=0.003). 
 
Conclusions: Individual level of renal endothelial function in the healthy rat is able to 
predict the severity of renal damage induced by MI. Further exploration of the underlying 
mechanisms may lead to discovery of preventive renoprotective therapies. 
 




The susceptibility of the individuals to develop proteinuria and subsequent renal damage 
shows large variability. Some individuals develop the renal damage, while others do not. 
This interindividual variability can not be explained by variation in blood pressure levels1 
or by differences in the degree of injury, such as subtotal nephrectomy2. Therefore, the 
variation in susceptibility has been proposed to be intrinsic to the kidney itself3. Indeed, we 
previously we demonstrated individual differences in the renal endothelial function of the 
healthy animal to predict severity of renal impairment after subtotal (5/6) nephrectomy4. 
Recently, we have reported that myocardial infarction (MI) leads to the development of 
proteinuria in the rat after unilateral nephrectomy (UnX)5. Although the large infarcts 
induced more pronounced proteinuria than the small ones, proteinuria still varied to a great 
extent among the rats with relatively uniform MI sizes. 
Given the above, we hypothesize that the variation in the renal endothelial function among 
healthy animals predicts their susceptibility to develop proteinuric renal damage after 
UnX+MI. We employed the rat model of cardiorenal interaction, in which MI is performed 
following unilateral nephrectomy (UnX). In the healthy kidneys removed at nephrectomy 
endothelial function of small renal arteries was investigated. Subsequently, this baseline 
endothelial function was related to markers of renal damage (proteinuria, 





Animal experimentation was conducted in accordance with the National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals and approved by the Animal 
Ethical Committee of the University of Groningen. Male Wistar rats (250-275 g, n=15, 
Harlan, Zeist, The Netherlands) were housed under standard conditions. Rats underwent 
surgical procedures for UnX (followed by in vitro measurements of renal endothelial 
function) and MI. Subsequently, the animals were followed for 16 weeks. Then the left 
kidney and the heart were removed under anesthesia, weighted and analyzed for the 
markers of organ damage. 
 
Surgical procedures  
Unilateral nephrectomy (UnX) 
Rats underwent unilateral nephrectomy (UnX) of the right kidney by laparotomy and under 
anesthesia with isoflurane 3% in N2O/O2 (1:2). The removed kidney was weighted, put into 
cold Krebs solution and one small renal (interlobar) artery per kidney was immediately 
prepared for measurement of renal endothelial function in vitro.  
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Myocardial infarction (MI) 
One week after nephrectomy, rats were intubated, ventilated (Amsterdam Infant Ventilator, 
Hoek/Loos, Schiedam, The Netherlands), and anesthetized by the administration of 
isoflurane 3% in N2O/O2 (1:2). Myocardial infarction was induced by ligation of the left 
ascending coronary artery (LAD) as described previously5. Variation in the infarct sizes 
was limited by the standard localization of the suture around LAD. Subsequently, the 
wound was closed and anesthetics replaced by 100% oxygen for a short while until the rat 
was able to breathe sufficiently on its own.  
 
In vitro measurements of the renal endothelial function 
Endothelial function of isolated small renal (interlobar) arteries was investigated in an 
arteriograph system for pressurized arteries (Living System Instrumentation, Burlington, 
VT, USA) as described previously4 and measured as endothelium-dependent relaxation to 
cumulative doses of acetylcholine (ACh; 10-8 mol/L - 10-4 mol/L) in the vessels 
preconstricted to 45-50% by phenylephrine (3x10-7 - 10-6 mol/L). We previously 
established that endothelial function measured in this way does not differ between arteries 
of left and right kidney of the same animal4. 
 
Markers of the renal damage 
Urinary protein excretion 
Urinary protein excretion was determined weekly by nephelometry (Dade Behring III, The 
Netherlands) by placing the rats in metabolic cages for 24h (Tecniplast, Buggugiate, Italy).  
Focal glomerulosclerosis (FGS) 
The left kidneys removed at autopsy were cut longitudinally, fixed and processed for 
paraffin embedding according to standard procedures. Section of 3 µm were stained with 
periodic acid Schiff (PAS) and microscopically evaluated for the incidence of FGS as 
described previously5. 
 
Cardiovascular parameters  
Systolic blood pressure (SBP) was measured weekly in restrained awake animals by means 
of the tail-cuff method (IITC Inc, USA). Infarct sizes were measured in hearts removed at 
autopsy. Mid-sagittal slices of the left ventricle were fixed in Bouin’s solution, embedded 
in paraffin and stained with 0.1% Fast Green FCF. Infarct sizes were determined by 
computerized planimetric measurements as described previously5. 
 
Statistical analysis 
Data are expressed as mean ± standard error of the mean (SEM). Concentration-response 
curves to acetylcholine (ACh) were expressed as percentage of preconstriction to 
phenylephrine. The Area Under each individual Curve (AUC) was determined (Sigma Plot, 
Jandell Scientific) and expressed in arbitrary units. The AUC was used to represent renal 
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endothelial function of the individual animals. The relationship between the baseline 
endothelial function and markers of renal damage 16 weeks afterwards were determined by 


















Figure 1. The time course of systolic blood pressure (SBP, mmHg) and proteinuria 
(mg/24h) in rats undergoing unilateral nephrectomy (UnX, week 0) and myocardial 






Out of 15 rats undergoing MI operation, 4 died due to acute heart failure within 24 hours 
after MI (27%). These rats were excluded from further analysis. Remaining 11 rats were 
followed during the entire period of 16 weeks.  
 
Endothelial function in the healthy nephrectomized kidney  
The renal arteries isolated at the time point 0 from the healthy nephrectomized kidney 
responded to acetylcholine to a variable extent. The endothelium-dependent relaxation 
characterized by the Area Under the acetylcholine Curve (AUC) averaged 175.6 ± 6.0 
arbitrary units with individual values ranging from 155.0 to 216.9 arbitrary units. 
 
Renal damage induced by MI 
After UnX and MI, proteinuria gradually increased with time from the mean value of 15 ± 3 
mg/24h at week 0 up to 125 ± 37 mg/24h at week 16 (Figure 1, p<0.001). Individual values 
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showed large variation (factor 25.4), ranging from 20 to 507 mg/24h. The renal damage 
induced by MI in the remaining left kidney was characterized by an increased FGS 
incidence (17.7 ± 3.4 % compared with the baseline value of the right healthy kidney 0.8 ± 
0.5 %, p<0.001). Further, a marked increase of renal mass/body weight ratio was observed 
at the end of the study in the left kidney (5.1 ± 0.1 x 10-3) as compared with the baseline 
value of the right healthy kidney (4.1 ± 0.1 x 10-3, p<0.01). 
 
Cardiovascular parameters 
Systolic blood pressure (SBP) did not increase with time, as with the values amounting 133 
± 3 mmHg at week 0 and 131 ± 7 mmHg at week 16 (Figure 1). Histologically assessed MI 
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Figure 2. Correlation between the baseline renal endothelial function measured in the 
healthy nephrectomized kidney and the development of A) proteinuria, B) incidence of focal 
glomerular sclerosis 16 weeks after the unilateral nephrectomy and myocardial infarction. 





The endothelial function measured in the healthy kidney removed by UnX predicted the 
renal damage inflicted on the remaining kidney by myocardial infarction. The baseline 
endothelial function negatively correlated with the proteinuria at week 16 (Figure 1A, r=-
0.62, p=0.008), indicating that rats with more pronounced endothelial function developed 
less proteinuria after UnX and MI. A similar correlation was found between the baseline 
renal endothelial function and focal glomerulosclerosis (FGS) at week 16 (Figure 1B, r=-
0.70, p=0.003). Finally, the weight of the kidney measured at autopsy at week 16 was also 
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predicted by the renal endothelial function at the baseline (r=-0.59, p=0.01). Consecutively, 
all the parameters of renal damage were interrelated (proteinuria versus FGS r=0.96, 
p<0.001; proteinuria versus kidney weight r=0.72, p=0.01, FGS versus kidney weight 
r=0.60, p=0.01). In contrast, baseline renal endothelial function and the parameters of renal 




In the current study, we found that myocardial infarction (MI) of similar size induces a 
highly variable damage in the remaining kidney of rats with unilateral nephrectomy (UnX). 
The severity of the renal damage was predicted by the renal endothelial function measured 
in isolated interlobular arteries prepared from the healthy kidney prior to the MI.  
It is intriguing, that myocardial infarction of relatively uniform size induces highly variable 
renal damage characterized by both proteinuria and focal glomerulosclerosis. The 
considerable variation in the proteinuria and the renal damage has been shown also for the 
other models of progressive renal disease in spite of the relative stable and uniform injury, 
such as subtotal nephrectomy4, adriamycin-induced nephrosis6 or hypertensive-induced 
renal damage7.  
The mechanisms responsible for the development of renal damage after MI and UnX are 
largely unexplored. Interestingly, no proteinuria or histological damage occurs in animals 
with MI or UnX alone5. Unilateral nephrectomy (UnX) already represents a state of mild 
renal damage as the hemodynamic adaptations occur in the remaining glomeruli to 
compensate for the nephron loss. Several mechanisms by which MI accelerates mild renal 
damage may be hypothesized, including neurohumoral activation occurring after the MI 
and subsequent heart failure8,9 the endothelial dysfunction of the systemic arteries10,11 or the 
generalized inflammatory reaction associated with acute MI. Our data, however, indicate 
that the renal effects of MI depend, at least partially, on intrarenal factors that are present 
previous to the injury (MI) triggering renal damage. These factors are reflected by the 
intrinsic variation in the endothelial dilatory capacity of renal arteries of healthy 
individuals, as the renal endothelial function predicted the renal outcome after MI. 
Consequently, the animals with pronounced endothelial dilatory capacity of renal arteries 
seem to be more protected against proteinuric renal damage induced by an MI.  
One of the possible explanations for the relationship between pronounced renal endothelial 
dilation and protection from injury may be that such vessels have spare capacity to deal 
with the deleterious hemodynamic alterations associated with neurohumoral activation. The 
endothelial function of the healthy renal arteries has been already shown to predict 
proteinuria in the model of subtotal (5/6) nephrectomy4, in which the glomerular 
hemodynamic adaptation has also been implicated. It may be suggestive to speculate that 
similar hemodynamic mechanisms operate in the development of proteinuria in both 5/6Nx 
and UnX+MI model. Alternatively, the pronounced vasodilatory function may reflect 
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different endothelial protective properties which deal with other deleterious systemic 
factors. e.g. the inflammatory response12,13. Finally, even the model of combined UnX and 
MI represents the complex relation between heart and kidney. Proteinuric disease itself is 
associated with worsening of cardiovascular prognosis14,15 and thus has an impact on the 
cardiac damage16. Indeed, Dikow et al. has shown increased infarct size in uremic rats25. 
Although in our study, care was taken to limit the variability of infarct size at the operation, 
the infarct size was measured at the end of the study and thus under the influence of renal 
disease. However, the resulting variation was relatively small and the individual infarct 
sizes did not correlate with either proteinuria or renal endothelial function. Furthermore, 
another cardiovascular extrarenal parameter, systolic blood pressure, did not change 
throughout the study and did not correlate with the renal damage. Therefore it is likely that 
an intrarenal factor was responsible for the variation in renal damage.  
In this study we demonstrated, that the extent of renal impairment induced by MI upon 
subclinical renal dysfunction is predicted by the intrarenal endothelial function prior to the 
induction of MI. This observation would imply that measurements of intrarenal endothelial 
function may be used as a tool to identify the individuals prone to the renal impairment. 
Further, should renal endothelial function actually determine the sensitivity of the kidney to 
deleterious events, the modulation of the renal endothelial function may provide protection 
against the progressive renal damage. Finally, the progression of the renal damage is most 
likely (co)-dependent on an intrarenal mechanism, emphasizing further the need for 
renoprotection in patients with cardiovascular disease. Further exploration of the intrarenal 
mechanism(s) of the individual susceptibility to renal damage may lead to improved 
prevention of both cardiovascular mortality and renal function loss. 
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Background: Susceptibility to renal injury varies among individuals. Previously, we found 
that individual baseline endothelial function of healthy renal arteries in vitro predicts 
severity of renal damage after 5/6 nephrectomy. Here we sought to establish this relation in 
adriamycin-induced nephropathy and questioned whether this predictive value might be 
detected in vivo as well. We hypothesized that individual differences in endothelial function 
and renal perfusion predict the severity of adriamycin-induced renal damage. 
 
Methods: Total endothelial relaxation and the contribution of its dilatory mediators 
prostaglandins, nitric oxide (NO) and endothelium-dependent hyperpolarizing factor 
(EDHF) were evaluated in small renal arteries isolated from healthy rat kidneys (n=16) 
using pressurized vessel set-up. In an additional group of healthy spontaneously voiding 
rats (n=16), baseline glomerular filtration rate- GFR and effective renal plasma flow- ERPF 
was measured as clearance of iothalamate and para-amino hippuric acid, respectively. 
Following functional measurements, adriamycin (1.75 mg/kg i.v.) was injected and 
subsequent renal damage after 6 weeks was related to baseline parameters.  
 
Results: Animals developed highly variable renal damage. Pronounced individual baseline 
total endothelial and EDHF-mediated relaxation, as well as baseline ERPF was correlated 
with more severe proteinuria 6 weeks after injection (r= 0.51, p= 0.04; r= 0.68, p= 0.01 and 
r= 0.66, p= 0.005, respectively). In contrast, baseline NO-mediated dilation was inversely 
correlated with proteinuria (r= -0.71, p= 0.006).  
 
Conclusion: Individuals with pronounced baseline endothelial dilatory ability measured in 
vitro and high renal blood flow in vivo are vulnerable to renal damage after adriamycin 
injection. Therefore interindividual variability in renal hemodynamics might be crucially 
involved in susceptibility to renal damage.  
 




The development and progression of chronic renal damage is largely variable among 
individuals both in experimental and clinical settings. Environmental systemic factors, such 
as severity of diabetes or hypertension, cannot fully explain this variation, suggesting some 
individuals might be intrinsically predisposed to develop renal impairment1. Several 
specific animal strains spontaneously develop renal function loss2,3, indicating that 
predisposition of an individual to renal damage involves genetically conditioned factors4. 
However, variable susceptibility to renal damage could also be observed among individuals 
within a given animal strain. For instance, after a standardized nephrotoxic challenge, such 
as 5/6 nephrectomy (5/6Nx), outbred Wistar rats develop renal impairment of highly 
variable severity5. Seeking for the factors responsible for this variability we previously 
observed that in vitro measured endothelium-dependent dilatory capacity of small renal 
arteries in healthy Wistar rats predicts the severity of subsequent renal damage inflicted by 
5/6 nephrectomy (5/6Nx)6. This indicates that intrinsic variability in renal vascular function 
might be responsible for variable susceptibility to renal injury. However, at present it is 
unclear whether this finding is specific for hemodynamically-induced renal impairment, 
such as seen in 5/6Nx, or whether variability in renal vascular function might also be 
involved in other types of renal injury.  
Therefore, in the present study we investigated whether the concept of predictive value of 
renal endothelial function is valid in a model of nephropathy induced by the nephrotoxic 
drug adriamycin. In adriamycin nephropathy, a single injection of cytostatic agent 
adriamycin leads to progressive renal damage with proteinuria, glomerulosclerosis and 
interstitial damage7-9. Remarkably, this relatively uniform challenge (standard adriamycin 
injection), results in largely variable renal damage among individuals10,11, indicating that 
some individuals might be more susceptible to adriamycin challenge than others. To 
elucidate the factors responsible for this variability we measured total endothelium-
mediated and specific endothelial mediators (e.g. nitric oxide- NO, endothelium-dependent 
hyperpolarizing factor- EDHF, prostaglandins- PGs)-dependent relaxation of small 
intrarenal arteries prior to the administration of adriamycin and related this baseline in vitro 
vascular reactivity to the severity of subsequent renal damage. We also explored whether 
the concept of renal vascular function predictive value might be confirmed in vivo. 
Therefore, in an additional study we sought to determine whether variability in renal 
hemodynamic function (GFR, ERPF) measured in conscious healthy rats predicts the 
nephrotoxic effect of subsequent adriamycin administration. We here report that both renal 
endothelium-dependent reactivity measured in vitro and renal blood flow (ERPF) measured 
in vivo in healthy individuals predict the development of adriamycin-induced nephropathy.  
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Materials and Methods 
 
The experiments were performed using outbred male Wistar rats (300-350 g, Harlan, Zeist, 
The Netherlands) housed under standardized conditions in animal facilities of the 
University of Groningen with free access to food and drinking water. All animal 
experiments were conducted in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals and approved by the Committee for Animal Experiments of the 
University of Groningen. 
 
Study I: Relation between baseline in vitro endothelial function and the severity of 
adriamycin-induced nephropathy 
To investigate the relationship between individual renal endothelial function in vitro and 
subsequent renal damage in adriamycin-induced nephropathy, rats (n=16) underwent 
unilateral nephrectomy (UnX) under 3% isoflurane in N2O/O2 anesthesia. Small renal 
arteries isolated from nephrectomized kidney were employed for in vitro measurements of 
vascular function as described below. Following UnX, a single i.v. injection of adriamycin 
in tail vein in a dose of 1.75 mg/kg (Pharmachemie BV, Haarlem, The Netherlands) was 
administered to induce renal damage. Subsequently, the animals were followed for 6 weeks, 
during which systolic blood pressure (SBP) was measured weekly in restrained awake 
animals by means of the tail-cuff method (IITC Inc, Ithaca, USA). Urinary protein 
excretion was determined weekly by nephelometry (Dade Behring III, Mannheim, 
Germany) in 24-hour urine samples obtained by putting the animals in metabolic cages. At 
the end of the study, animals were sacrificed under anesthesia. Remaining kidney and blood 
samples were harvested for assessment of renal functional and structural damage. Plasma 
creatinine was measured by means of a colorimetric assay with the Jaffé method without 
deproteinization (Chema Diagnostica, Jesi, Italy). Focal glomerulosclerosis (FGS) score 
was determined according to standard procedures in kidneys removed at nephrectomy and 
autopsy and subjected to fixation and embedding in paraffin. Sections of 3 µm were stained 
with periodic acid Schiff (PAS) and microscopically evaluated for the incidence of FGS as 
described previously12. 
 
Measurements of baseline renal endothelial function in vitro 
Small renal (interlobar) arteries (250-350 µm) were isolated from the nephrectomized 
kidney and transferred to an arteriograph system for pressurized arteries (Living System 
Instrumentation, Burlington, VT, USA) as described previously6. Artery segments were 
cannulated on glass micropipettes and intraluminal pressure was held constant at 70 mmHg. 
The vessel chamber was continuously recirculated with warmed (37°C) and oxygenated 
(5% CO2 in O2) Krebs solution with a pH of 7.4 (120.4 NaCl, 5.9 KCl, 2.5 CaCl2, 1.2 
MgSO4, 25.0 NaHCO3, 1.2 NaH2PO4, 11.5 mmol glucose). An inverted light microscope 
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attached to a video camera and video dimension analyzer was used to continuously register 
lumen diameter.  
Following 40 minutes equilibration period, arteries were pre-constricted submaximally with 
phenylephrine (PE, 3x10-7- 10-6 mol/l) and studied for endothelium-dependent and 
endothelium-independent relaxation by administering cumulative doses of acetylcholine 
(ACh; 3x10-8 mol/l- 3x10-5 mol/l) and sodium nitroprusside (SNP, 10-9- 10-4 mol/l) to the 
recirculating bath, respectively. ACh-induced relaxation was also studied in the same artery 
in the presence of either indomethacin (10-5 mol/l, to inhibit prostaglandins- PGs); 
indomethacin and Nω-monomethyl-L-arginine (L-NMMA, 10-4 mol/l, to additionally inhibit 
nitric oxide- NO) or indomethacin plus L-NMMA and a combination of charybdotoxin 
(chtx, 10-7 mol/l) and apamin (apa, 5x10-7 mol/l), applied into the lumen of the artery as 
well as to the superfusion medium (to additionally inhibit endothelium-derived 
hyperpolarizing factor- EDHF). ACh and SNP concentration-response curves were 
successfully obtained in all 16 animals, whereas curves in the presence of all inhibitors 
were obtained in 13 individuals. Previously, we established that endothelial dilatory 
function did not differ between renal arteries within the used diameter range isolated from 
the same kidney and therefore ACh-induced relaxation of one artery can be considered 
representative6. 
 
Study II: Relation between baseline in vivo renal hemodynamic function and severity 
of adriamycin-induced nephropathy 
To investigate whether in vivo determinants of renal hemodynamics in the healthy rat 
predict subsequent renal damage in adriamycin nephropathy measurements of renal 
function were performed prior to the injection of adriamycin (1.75 mg/kg) in an additional 
group of rats (n=16). Following the injection, SBP and urinary protein excretion were 
measured weekly in the same way as in the first experimental study.  
 
Measurements of baseline renal hemodynamic function in vivo 
Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by 
clearance of simultaneously infused iothalamate and para-amino hippuric acid (PAH) 
respectively, in freely moving and spontaneously voiding rats as described previously13. 
Briefly, the rats instrumented with a jugular and carotid catheter were infused with a bolus 
of iothalamate (9 mg/kg) and PAH (12 mg/kg) followed by continuous intra-arterial 
infusion of these markers (iothalamate 0.9 mg/h and PAH 4.5 mg/h). Following an initial 
equilibration period of two hours, clearance period was determined by the urine collection 
depending on spontaneous voiding of the rat and a blood sample was drawn via jugular 
catheter after each urine collection. Plasma and urine levels of iothalamate and PAH in the 
samples were determined by HPLC14. ERPF and GFR were calculated as a plasma 
clearance of PAH and urinary clearance of iothalamate respectively, according to the 
method described by Donker et al.15 in man, which was adapted for rats at our laboratory 
by de Vries et al.13. Mean arterial pressure (MAP) was measured continuously during the 
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experiment by connecting the carotid catheter to a pressure transducer (Baxter Healthcare, 
Irvine, USA). Renal vascular resistance was calculated as the ratio of MAP and ERPF. 
 
 
Table 1. Clinical parameters of animals in both studies measured prior to the 
administration of adriamycin (baseline) and 6 weeks thereafter and in vivo measurements 
of renal hemodynamics at baseline in study II.  
 
 Study I Study II 
 Baseline Week 6 Baseline Week 6 
Clinical parameters 
Body weight (g) 320 ± 15 406 ± 22 328 ± 14 410 ± 24 
SBP (mmHg) 135 ± 5 136 ± 11 132 ± 4 135 ± 8 
Proteinuria (mg/24h) 21 ± 6 430 ± 195* 22 ± 4 420 ± 241* 
FGS (%) 0 ± 1 24 ± 10* ND ND 
Plasma creatinine (µmol/l) 46 ± 16 69 ± 22* ND ND 
Renal hemodynamic measurements 
ERPF (ml/min/100g BW) - - 2.85 ± 0.89 - 
GFR (ml/min/100g BW) - - 0.53 ± 0.15 - 
MAP (mmHg) - - 114 ± 15 - 
RVR (mmHg.min/ml) - - 15 ± 7 - 
 
SBP- systolic blood pressure, FGS- focal glomerulosclerosis, BW- body weight, ERPF- 
effective renal plasma flow, GFR- glomerular filtration rate, RVR- renal vascular 
resistance, MAP- mean arterial pressure, ND- not determined; data are presented as mean ± 




Data are expressed as mean ± standard deviation (SD), unless stated otherwise. In the 
analysis of vascular experiments, concentration-response curves to ACh or SNP were 
expressed in percentage of pre-constriction to PE. The concentrations of drugs causing half-
maximal responses were expressed as negative logarithm of the molar concentration (pD2 
values). The Area Under each individual acetylcholine Curve (AUC) was determined 
(Sigma Plot, SPSS Inc.) and expressed in arbitrary units. The contribution of three 
endothelial mediators (PGs, NO and EDHF) to endothelial relaxation was calculated as a 
difference between corresponding AUCs (Figure 1A). Statistical comparisons between 
 
Endothelial function in adriamycin-induced renal damage    59 
 
parameters at the baseline and at the end of the study were performed by a Student’s paired 
t-test. The characteristics of the concentration-response curves were compared by one-way 
ANOVA or ANOVA for repeated measures when appropriate. Significance was accepted at 
p<0.05. The relationship between individual endothelial or renal function and renal damage 
was calculated using Pearson’s parametric or Spearman’s non-parametric correlation test 


























































Figure 1. A) Concentration-response curves to endothelium-dependent vasodilator 
acetylcholine (ACh) in small renal arteries isolated before the administration of 
adriamycin. The curves were constructed in absence of any inhibitor (total), in presence of 
indomethacin (indo, 10-5 mol/l), in additional presence of L-NMMA (10-4 mol/l) and in 
additional presence of charybdotoxin (chtx, 10-7 mol/l) and apamin (apa, 5x10-7 mol/l). 
Data are given as mean ± SEM. B) Variability in total endothelium-dependent relaxation, 
prostaglandins (PGs)-, nitric oxide (NO)- and EDHF-mediated relaxation of small renal 
arteries isolated from healthy rats before the administration of adriamycin. AUC- Area 
Under Curve expressed in arbitrary units; box whisker plot: central box encloses middle 
50% of all the data, horizontal line inside the box represents median and the whiskers 




Markers of renal damage in adriamycin nephropathy 
Clinical characteristics of the rats used in both studies are presented in Table 1. 
Six weeks after injection of adriamycin, rats in the first study developed overt nephropathy, 
characterized by elevated proteinuria, FGS and increased plasma creatinine when compared 
to values measured in healthy animals before the injection. SBP remained stable over the 
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entire experimental period. Interestingly, despite the standardized injection of adriamycin, 
proteinuria varied considerably among individual rats, similarly ranging from 145 to 883 
mg/24h in the first and from 124 to 869 mg/24 h in the second experimental group. Both 
plasma creatinine and FGS score correlated positively with proteinuria (r= 0.56, p< 0.01 
and r= 0.63, p= 0.01 respectively), suggesting that proteinuria adequately reflects renal 
damage in this model.  
 
 
Table 2. Baseline characteristics of the concentration-response curves to endothelium-
dependent vasodilator acetylcholine and endothelium-independent vasodilator sodium-
nitroprusside (SNP) in small renal arteries isolated from healthy rats prior to the 
administration of adriamycin. The effect of endothelial vasodilatory pathway inhibitors on 




Acetylcholine total 80 ± 8 6.4 ± 0.2 
+ indomethacin 82 ± 9 6.2 ± 0.2 
+ indomethacin 
+ L-NMMA 




3 ± 2a,b,c - 
Endothelium-independent relaxation 
SNP 88 ± 9 6.9 ± 0.4 
 
Data are means ± SD; Emax- maximal relaxation to acetylcholine in % of precontraction to 
phenylephrine, pD2- negative logarithm of molar concentration of acetylcholine causing 
half of maximal response (EC50), chtx + apa: charybdotoxin + apamin, a p<0.05 versus 
control, b p<0.05 versus indomethacin, c p<0.05 versus indomethacin + L-NMMA 
 
 
Study I: endothelial function predicts renal damage in adriamycin nephropathy 
Variability of renal endothelial function in healthy rat  
ACh induced concentration-dependent relaxation of small renal arteries. The average group 
response and curve characteristics are presented in Figure 1A and Table 2. Relaxation to 
ACh was highly variable prior to injection of adriamycin in these –at that time- healthy 
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animals (Figure 1B) and was independent from the level of PE-induced pre-constriction or 
endothelium-independent relaxation to SNP. Blockade of PGs by indomethacin resulted in 
variable small changes of the ACh curve in individual rats, however on average not being 
significantly different (Figure 1A, Table 2). Additional administration of the NO inhibitor 
consistently decreased endothelium-dependent relaxation (Figure 1A, Table 2), however to 
a highly variable extent in individual animals (Figure 1B). As a result, the remaining 
EDHF-mediated relaxation also displayed considerable variability (Figure 1B). This 
relaxation was completely blocked by the combination of indomethacin, L-NMMA and 
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Figure 2. A) Correlation between individual total endothelium-dependent relaxation of 
small renal arteries measured prior to the administration of adriamycin and proteinuria 
determined 6 weeks after the administration of adriamycin (n=16). B) Correlation between 
individual relative effective renal plasma flow (ERPF) measured prior to the 
administration of adriamycin and proteinuria determined 6 weeks after adriamycin 




Correlation analysis was performed to investigate the relation between baseline endothelial 
dilatory function and the level of renal damage 6 weeks after the administration of 
adriamycin. ACh-induced relaxation (expressed as AUC) positively correlated with the 
level of proteinuria (Figure 2A). Endothelium-dependent relaxation also predicted plasma 
creatinine levels in individual animals (r= 0.68, p< 0.01). Thus, the rats with a pronounced 
endothelium-dependent dilation at baseline developed more severe renal damage after 
adriamycin injection. There was no correlation between the individual level of PE pre-
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constriction or endothelium-independent relaxation by SNP on one hand and renal damage 
on the other.  
Additionally, we studied the relation between the endothelial mediators of relaxation and 
proteinuria. PGs-mediated relaxation tended to correlate positively with proteinuria, but this 
was of marginal statistical significance (Figure 3C). A positive correlation was also found 
between the individual EDHF-mediated relaxation and proteinuria (Figure 3B). In contrast, 
individual NO-mediated relaxation was inversely correlated with the level of proteinuria 
(Figure 3A) as well as FGS (r= -0.69, p= 0.01), suggesting that individuals with a large 
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Figure 3. Correlation between individual nitric oxide (A)-, EDHF (B)- and prostaglandins 
(C)- mediated endothelium-dependent relaxation of small renal arteries measured prior to 
the administration of adriamycin and proteinuria determined 6 weeks after administration 
of adriamycin (n=13 each). AUC- Area Under Curve expressed in arbitrary units. 
 
 
Study II: renal blood flow predicts renal damage in adriamycin nephropathy 
Baseline values of renal functional parameters have been included in Table 1. GFR, ERPF 
and RVR displayed considerable variability in healthy animals prior to adriamycin 
injection.  
Individual ERPF just prior to adriamycin injection markedly correlated with the proteinuria 
6 weeks after the induction of the disease (Figure 2B), indicating that individuals with 
highly perfused kidney at the time of adriamycin administration developed more renal 
damage. Additionally, a negative correlation was found between individual RVR and 
proteinuria 6 weeks after adriamycin injection (r= -0.65, p= 0.007). In contrast, no 
correlation was found between individual baseline GFR and proteinuria at week 6 (r= 0.24, 
p= NS).  
 




In the present study we found that the individual level of renal endothelial function of 
healthy rats measured in vitro predicts their susceptibility to renal damage after injection of 
adriamycin. Additionally, baseline level of renal blood flow and renal vascular resistance 
measured in vivo were related to adriamycin-induced renal damage as well. These data 
indicate that state of renal vasculature measured both in vitro and in vivo might predispose 
certain healthy individuals to a more severe course of toxic renal damage.  
Endothelium-dependent relaxation of intrarenal arteries varies considerably in healthy 
animals of an outbred rat strain, which allows to test for the predictive value of this 
parameter in the development of renal damage. In the model of adriamycin nephropathy 
employed in our study, animals progressively developed highly variable renal damage 
indicated by increased urinary protein excretion. As shown both in present and previous 
experiments10, proteinuria represents a good indicator of renal damage severity in this 
model, since it remains relatively stable after 6 weeks and it is correlated with other 
structural and functional markers of renal damage.  
The animals with pronounced baseline acetylcholine-induced relaxation in small renal 
arteries developed more severe proteinuria after adriamycin injection. This finding might 
seem surprising since acetylcholine-induced relaxation is considered to be a measure of 
protective abilities of vascular endothelium16 and preserved endothelial relaxation has been 
shown to be associated with lower rate of future cardiovascular events in high risk 
populations17,18. Furthermore, in contrast to our present data, we previously observed that 
individuals with large renal endothelial relaxation were protected against renal injury after 
5/6Nx6. It should be noted, however, that the nature of renal injury crucially differs between 
adriamycin nephropathy and 5/6Nx, involving direct nephrotoxicity in the former and 
hyperfiltration of remnant nephrons in the latter model5. A crucial role of the specific 
etiology of renal injury in adriamycin nephropathy is also suggested by the striking finding 
of our in vivo study. Enhanced baseline level of renal blood flow and reduced renal vascular 
resistance measured in conscious rats prior to the administration of adriamycin were 
associated with more severe renal outcome. It has been previously shown that transient 
clipping of the renal artery for only several minutes prevents adriamycin-induced renal 
damage10, indicating that the acute cytotoxic effect of adriamycin in the kidney is 
responsible for the initial renal injury. Therefore it seems conceivable, that highly perfused 
kidneys, such as seen in individuals with high ERPF and low RVR, may be exposed to a 
larger amount of the toxic agent leading to more adverse renal damage. Since endothelium 
crucially participates in the regulation of renal hemodynamics19,20, in vivo data might 
provide a hemodynamic explanation for predictive value of in vitro acetylcholine-induced 
relaxation. However, neural, humoral and local mechanisms other than endothelial 
participate in the regulation of blood flow in vivo. This fact might also contribute to a 
stronger relation we observed between blood flow and proteinuria than between endothelial 
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function and proteinuria. Overall, the relation between endothelial function and blood flow 
on one hand and severity of renal damage on the other hand indicates that the basal state of 
the renal vasculature, measured both in conscious animals and in isolated preparations, may 
reflect the susceptibility to renal damage in adriamycin nephropathy. Combined results of 
our previous (in 5/6Nx)6 and present (adriamycin nephropathy) data suggest that variability 
in renal endothelial function is involved in the susceptibility to renal injury under various 
experimental conditions, however its exact role might be critically dependent on type of 
renal injury and etiology of progressive renal damage.  
To further elucidate contrasting findings of endothelial prediction in diverse experimental 
models of renal disease we investigated the role of specific mechanisms underlying 
endothelial relaxation. Acetylcholine-mediated relaxation such as measured in this 
experiment reflects the sum of functional activity of prostaglandins (PGs), nitric oxide 
(NO), and EDHF, as evidenced by complete blockade of endothelial response by the 
combination of respective inhibitors of these pathways indomethacin, L-NMMA and 
charybdotoxin plus apamin. The view of a protective role of endothelial relaxation is 
largely based on the concept of beneficial activity of NO16. Interestingly, when addressing 
NO-mediated vasodilation specifically, the individuals with large NO relaxation were 
protected from adriamycin-induced renal damage. A similar relation was also found in rats 
subjected to 5/6Nx6, suggesting a protective role of NO in the development of renal injury 
with various etiologies. Beneficial effects of NO might go far beyond its vasodilatory 
abilities: NO limits inflammation, proliferation, leucocyte adhesion and other processes 
involved in the progression of renal damage21. Several authors propose a crucial role of NO 
also in the initiation and development of renal injury. Erdely et al. report that mild nitric 
oxide synthase (NOS) inhibition might convert a rat strain resistant to renal injury after 
5/6Nx into a model of rapidly progressing renal disease22. In humans, several studies have 
found an association between endothelial NOS polymorphism and end-stage renal 
disease23,24. Collectively, these data indicate that variation in NO bioactivity might be 
crucially involved in interindividual susceptibility to renal injury.  
Contribution of additional endothelial mediator, termed EDHF, predicted the development 
of proteinuria in agreement with total acetylcholine-induced relaxation. EDHF exerts its 
effects by hyperpolarization of underlying smooth muscle cells, however its identity 
remains elusive25. Therefore its role is more difficult to interpret than that of NO. However, 
one intriguing aspect of EDHF is its putative inverse relationship with NO. Based on this 
assumption, it was proposed that EDHF might serve as a backup dilatory mechanism under 
circumstances when NO production is decreased26,27. Indeed, in present study, individual 
NO contribution inversely correlated with contribution of EDHF to endothelium-mediated 
relaxation, thus possibly reflecting the lack of NO-mediated protection. Relaxation 
mediated by yet another endothelial mechanism, release of prostaglandins (PGs) tended to 
predict the severity of renal damage. We previously proposed that despite a minimal net 
effect of cyclooxygenase blockade on acetylcholine-induced relaxation, interindividual 
variation in the proportion of the relaxing and constrictive PGs might still be detected6. The 
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reason for the potential protective role of vasoconstrictive PGs in adriamycin nephropathy 
remains unclear. One might speculate that predominant release of PGs with constrictive 
properties in preglomerular vessels may protect glomeruli against a deleterious increase in 
intraglomerular pressure and hyperfiltration, or could be involved in the regulation of renal 
blood flow during adriamycin injection. Overall, these data suggest that measurement of 
endothelium-dependent relaxation attributed to specific mediators, such as NO, EDHF and 
PGs, might provide additional important information on the interindividual susceptibility to 
renal damage. 
Perspectives 
If consistently confirmed, the predictive value of renal vascular function might have broad 
potential clinical implications. Measurements of baseline endothelial or hemodynamic 
function and organ blood flow might identify individuals with increased risk for future 
adverse renal outcomes. More important, one may speculate on interventional strategies to 
prevent end-organ damage, for instance by specifically targeting NO, EDHF and/or 
cyclooxygenase pathways. Additionally, findings in a model of adriamycin nephropathy 
might have potential implications for adriamycin-induced long-term organ toxicity 
associated with chemotherapy in humans. In addition to nephrotoxicity, severe 
cardiomyopathy often manifests after adriamycin treatment in humans28. Whether 
interindividual differences in endothelial function and/or organ perfusion predict the extent 
of damage also in this condition, needs to be investigated further. If so, then lowering blood 
flow to a specific organ at the time of drug administration may provide a protection from 
unwanted toxicity.  
 
Conclusion 
In this study, we showed that both baseline endothelial function of isolated renal vessels 
and renal blood flow measured in vivo in conscious animals predict the severity of renal 
damage imposed by subsequent administration of a nephrotoxic drug. Together with 
previous findings in other experimental models of renal damage, these data suggest that 
interindividual variability in baseline renal hemodynamics might be responsible for 
susceptibility to renal impairment. The predictive value of total renal endothelial function 
seems to be critically dependent on the etiology of renal injury, whereas nitric oxide-
dependent relaxation provides the consistent information in different experimental models. 
Further investigation into the nature of renal vascular variability may help us to reveal the 
mechanisms involved in the development of progressive renal disease. 
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Background: Chronic kidney disease is associated with abnormal regulation of arterial tone 
throughout various vascular beds. It is however unknown whether generalized vascular 
dysfunction precedes the development of kidney disease. We studied myogenic constriction 
and endothelium-mediated dilatory responses in two inbred Fawn-Hooded (FH) rat strains, 
one of which (FHH) spontaneously develops hypertension, proteinuria and 
glomerulosclerosis, whereas other (FHL) does not.  
 
Methods: Small renal, mesenteric resistance arteries and aorta isolated from FH rats prior to 
(7 weeks old) and following the development of mild proteinuria (12 weeks old), were 
mounted in perfused and isometric set-ups, respectively. Myogenic response, acetylcholine-
induced endothelium-dependent relaxation and the contribution of nitric oxide (NO), 
cyclooxygenase (COX)-derived prostaglandins and endothelium-derived hyperpolarizing 
factor (EDHF) were studied using the inhibitors L-NMMA, indomethacin and 
charybdotoxin+apamin, respectively.  
 
Results: In small renal arteries, markedly impaired myogenic reactivity and endothelial 
dysfunction due to excessive COX1-mediated production of constrictive prostaglandins 
were selectively present in FHH as compared to FHL even prior to the development of 
proteinuria. In contrast, myogenic reactivity was intact in mesenteric resistance artery of 
FHH. In addition, meseneteric endothelial dysfunction was observed attributed to the loss 
of EDHF. Renal myogenic and peripheral EDHF alterations were further attenuated after 
the development of proteinuria. Aortic reactivity did not differ between FHL and FHH at 
the time points studied.  
 
Conclusion: The present study shows that vascular dysfunction in both small renal and 
systemic arteries precedes renal end-organ damage in a spontaneous model of hypertension-
associated renal damage. Renal and peripheral vasomotor mechanisms are affected 
heterogeneously and differentially modulated by renal disease. These early vascular 
changes might be potentially involved in the increased susceptibility of FHH rats to renal 
injury. 
 




In chronic kidney disease, a progressive deterioration in renal function is associated with 
abnormal regulation of arterial tone, both on the level of endothelium and vascular smooth 
muscle1,2. A growing body of evidence indicates that even patients with microalbuminuria, 
an earliest marker of renal structural damage, exhibit generalized endothelial dysfunction in 
both renal and systemic vascular beds3-5. In fact, it has been suggested that endothelial 
dysfunction might precede the development of microalbuminuria6,7, thus potentially 
representing a determinant of renal disease progression. Endothelium-dependent relaxant 
responses, a surrogate of endothelial function, are mediated by the release of vasoactive 
factors, such as nitric oxide (NO), cyclooxygenase-derived prostaglandins (PGs) and the yet 
unidentified endothelium-derived hyperpolarizing factor (EDHF)8. We have previously 
shown, that the interindividual variability in endothelium-dependent reactivity of intrarenal 
arteries, including NO-, PGs- and EDHF-mediated responses, among healthy rats of an 
outbred Wistar rat strain predicts their susceptibility to subsequent renal damage induced by 
renal mass reduction9 or nephrotoxic drug10. This suggests that endothelial function might 
be one of the factors governing the susceptibility to experimental renal end-organ damage. 
In addition to experimental models, specific inbred animal strains have been described 
spontaneously developing progressive renal disease11. Fawn-hooded (FH) rat provides a 
genetically well-defined model comprised of two inbred strains with different occurrence of 
renal injury. Hypertensive fawn-hooded rats (FHH) spontaneously develop moderate 
hypertension, proteinuria and severe glomerulosclerosis at a young age, subsequently 
followed by progressive renal failure12-15. In contrast, Fawn-hooded rats with low blood 
pressure (FHL) seem to be resistant to the development of hypertension and renal 
damage14. It has been proposed that altered vascular-smooth muscle-mediated reactivity to 
intraluminal pressure, termed myogenic response, in preglomerular arteries might be 
responsible for different sensitivity of these strains to renal injury16. Yet, the data 
comparing renal myogenic response in FHL and FHH rats provide inconsistent results16,17, 
whereas the role of endothelial reactivity is unknown.  
In the present study we aim to define the role of vasomotor changes in the course of 
spontaneous hypertension-associated renal disease. First, we explored whether renal 
vascular dysfunction precedes the development of renal damage. To this end, in animals 
prone (FHH) and resistant (FHL) to renal damage, we compared endothelium-mediated 
(NO-, PGs and EDHF-dependent) and myogenic responses of small renal arteries at early 
age, prior to the appearance of renal damage. In addition, we explored whether renal 
vascular changes reflect generalized vasomotor dysfunction by studying endothelial and 
myogenic responses in small resistance (mesenteric) and large conduit arteries (aorta). 
Finally, we evaluated the the observed vascular changes in time, by investigating 
vasomotor reactivity in animals at the older age, when mild proteinuria had already 
developed. 
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Materials and methods 
Animals and in vivo measurements 
Experiments were performed in young male FHL and FHH rats at week 7 and week 12 
after birth (n= 9-12 per strain and per time point). In FHH rats, this time frame represents 
the ages in which none and minor proteinuria is detected, respectively. All animals were 
bred at the animal facilities of Erasmus University, Rotterdam, the Netherlands and housed 
under standard conditions in animal facility of University of Groningen, the Netherlands 
receiving food and water ad libitum. Short before reaching their target age, animals were 
put in metabolic cages to measure fluid intake and urine output. Urinary protein excretion 
was determined by nephelometry (Dade Behring III, Mannheim, Germany) in 24-hour urine 
samples. Subsequently, animals were anesthetized by 2% isoflurane in N2O/O2 (2:1), the 
right carotid artery was cannulated, and systolic and diastolic blood pressure was measured 
by a pressure transducer catheter (Millar Instruments, Germany) in the aortic root. 
Following these measurements, blood was drawn via abdominal aorta. Subsequently, 
mesenterium, kidneys and thoracic aorta were harvested for the analysis of vascular 
function and end-organ damage. All animal experiments were conducted in accordance 
with the NIH Guide for the Care and Use of Laboratory Animals and approved by the 
Committee for Animal Experiments of the University of Groningen. 
 
Determination of renal damage 
Plasma and urine creatinine was measured by means of a photometric assay with the Jaffé 
method without deproteinization (DiaSys Diagnostic Systems, Holzheim, Germany) and 
creatinine clearance was calculated as creatinine clearance= (urine creatinine x urine flow) / 
(plasma creatinine x bodyweight). Paraffin embedded kidneys were cut in 3 µm sections 
and stained with periodic acid Schiff (PAS) and the incidence of focal glomerulosclerosis 
(FGS) score was microscopically evaluated according to standard procedures as described 
previously18.  
 
Vascular reactivity of small renal and systemic resistance arteries 
Small renal (interlobar) arteries and third-order branches of superior mesenteric arteries 
were cleaned from perivascular tissue and transferred to an arteriograph system for 
pressurized arteries (Living System Instrumentation, Burlington, VT, USA) as described 
previously9. Artery segments were cannulated on glass micropipettes and the vessel 
chamber was continuously recirculated with warmed (37°C) and oxygenated (5% CO2 in 
O2) Krebs solution with a pH of 7.4. An inverted light microscope attached to a video 
camera and video dimension analyzer was used to continuously register lumen diameter.  
 
Myogenic reactivity of small renal and systemic resistance arteries 
Intraluminal pressure was set at 80 mmHg, arteries were allowed to equilibrate for 40 
minutes and checked by a single dose of phenylephrine (PE, 3x10-7 mol/l) and 
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acetylcholine (ACh; 3x10-5 mol/l), for smooth muscle and endothelium viability, 
respectively. Following a wash out, intraluminal pressure was decreased to 20 mmHg and 
myogenic reactivity was studied by obtaining active pressure-diameter curves over a 
pressure range of 20-160 mmHg in steps of 20 mmHg. Each pressure step was maintained 
for 5 minutes to reach the stable contractile response. Following the myogenic protocol, 
preparations were washed with Krebs solution and employed for investigation of 
endothelial function as described below. Thereafter, calcium containing Krebs solution was 
exchanged for calcium-free Krebs solution supplemented with ethyleneglycol-bis-(b-
aminoethylether)tetraacetic acid (EGTA, 2 mmol/l) and passive pressure-diameter curves 
were obtained over the same 20-160 mmHg pressure range.  
To explore the role of endothelium in myogenic tone regulation, the effect of endothelium 
removal was investigated in additional renal arteries (n=10 for each strain) isolated from 12 
weeks old animals. Endothelium was removed by perfusing the preparation with 5 ml of air 
and endothelial removal was confirmed by the absence of dilative response to ACh (3x10-5 
mol/l) following a submaximal pre-constriction with PE (3x10-7 mol/l). Subsequently to the 
wash-out, active and passive myogenic curves were recorded as described above.  
 
Endothelium-dependent relaxation of small renal and systemic resistance arteries 
Following the measurement of active myogenic curves, intraluminal pressure was set to 80 
mmHg and arteries were washed and stabilized for 20 minutes. Because the level of 
spontaneous tone was not sufficient for the subsequent relaxation studies, arteries were pre-
constricted with phenylephrine (3x10-7- 10-6 mol/l) to 50-60% of initial baseline diameter. 
Endothelium-dependent relaxation was assessed by administering cumulative doses of 
acetylcholine (ACh; 10-9- 3x10-5 mol/l) to the recirculating bath. After the construction of a 
full ACh concentration-response curve and wash out, the response to ACh was studied in 
the same artery in the presence of indomethacin (10-5 mol/l) to inhibit prostaglandins (PGs) 
production. Subsequently, the same procedure was repeated in the combined presence of 
indomethacin and the nitric oxide (NO) production inhibitor Nω-monomethyl-L-arginine 
(L-NMMA, 10-4 mol/l). In some arteries of both vascular types (FHL and FHH, n=4 each), 
we found that this remaining relaxation in the presence of indomethacine and L-NMMA 
was caused by the release of endothelium-derived hyperpolarizing factor (EDHF), as it was 
completely attenuated by the combination of the potassium channels blockers 
charybdotoxin (chtx, 10-7 mol/l) and apamin (apa, 5x10-7 mol/l). By analyzing the above-
mentioned protocols of endothelium-dependent relaxation, the contribution of all three 
mediators (PGs, NO and EDHF) to endothelial relaxation was calculated as a difference 
between Area Under the Curve (AUC) of respective ACh-concentration-response curves.  
 
Involvement of cycloxygenase (COX) pathway in endothelium-dependent contractions 
of small renal arteries 
To investigate the underlying mechanisms of prostanoid-dependent endothelium-mediated 
contractions observed in small renal arteries of FHH rats, in separate set of arteries (n=6), 
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ACh-concentration responses were obtained in a presence of either the COX-1 selective 
inhibitor valeryl salicylate (VAS, 10-4 mol/l), the COX-2 selective inhibitor NS398 (10-6 
mol/l), the TXA2/PGH2 receptor antagonist SQ29548 (10-6 mol/l) or the superoxide 
scavenger superoxide dismutase (SOD, 50 U/ml).  
 
General smooth muscle reactivity of small renal and systemic arteries  
Additional arteries were used to control for the potential variation in depolarization-and 
receptor-mediated smooth muscle reactivity. After a stabilization period, concentration-
response contractile curves were obtained using KCl (20- 120 mmol/l) and phenylephrine 
(10-8- 10-5 mol/l) with a wash out period between the protocols. Additionally, 
concentration-response curves to the direct smooth muscle vasodilator sodium nitroprusside 
(SNP, 10-9- 3x10-5 mol/l) were constructed after submaximal preconstriction with 
phenylephrine (3x10-7- 10-6 mol/l).  
 
Vascular reactivity of isolated aortic rings 
The thoracic aorta was cleaned from the connective tissue and cut into 2 mm rings, which 
were mounted in isotonic contraction organ baths filled with aerated, warmed Krebs 
solution and subjected to 14 mN preload. After one hour stabilization period, arteries were 
stimulated by KCl (60 mmol/l) to check their viability, washed out and pre-constricted 
submaximally by 10-6 mol/l phenylephrine. Endothelium-dependent relaxation was 
investigated similarly to the protocol performed in perfused small arteries, e.g. 
concentration-response curves to acetylcholine (10-9- 10-4 mol/l) were obtained in absence 
and subsequently in presence of indomethacin (10-5 mol/l) and indomethacin+L-NMMA 
(10-4 mol/l) to investigate the contribution of PGs, NO and EDHF to endothelium-mediated 
relaxation. In other rings, dose-response curves to phenylephrine (10-9- 10-5 mol/l) were 
followed by measurements of reactivity to sodium nitroprusside (10-10- 10-5 mol/l). 
 
Chemicals 
Krebs solution had a following composition (mM): 120.4 NaCl, 5.9 KCl, 2.5 CaCl2, 1.2 
MgSO4, 25.0 NaHCO3, 1.2 NaH2PO4, 11.5 glucose. All these compounds were purchased 
from Merck (Darmstadt, Germany). VAS, NS398 and SQ29548 were purchased from 
Cayman Chemical (Ann Harbor, MI, USA). All other drugs were obtained from Sigma-
Aldrich Chemie, the Netherlands. They were dissolved either in ethanol (VAS, NS398, 
SQ29548) or in de-ionized water and diluted with Krebs solution. Stock solution for 
indomethacin was prepared in 96 mmol NaHCO3.  
 
Statistical analysis and calculations 
Data are expressed as mean ± standard error of means (SEM). Myogenic tone, describing 
myogenic behaviour of an artery at a given pressure, was expressed as percent decrease in 
active diameter from the maximally dilated (passive) diameter determined at the same 
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pressure in calcium-free/EGTA solution, i.e., myogenic tone (%)= 100 [(DCa-free– DCa)/DCa-
free], where D is the diameter in calcium-free (DCa-free) or calcium-containing (DCa) Krebs.  
 
 
Table 1. In vivo characteristics of FHL and FHH rats showing either no (7 weeks of age) 
or minor (12 weeks of age) renal damage. 
 
 No renal damage  Minor renal damage 
 FHL FHH  FHL FHH 
Body weight (g) 215 ± 3 211 ± 3  308 ± 4# 307 ± 5# 
SBP (mmHg) 118 ± 3 130 ± 4*  123 ± 3 132 ± 3* 
DBP (mmHg) 76 ± 3 86 ± 3*  78 ± 3 87 ± 3* 
Fluid intake (ml/24h) 33 ± 5 40 ± 3  36 ± 3 39 ± 2 
Urine output (ml/24 h) 19 ± 2 23 ± 2  24 ± 1 28 ± 1 
Proteinuria (mg/ 24 h) 19 ± 1 17 ± 2  28 ± 1# 46 ± 4*# 
Plasma creatinine (µmol/l) 51 ± 3 50 ± 2  41 ± 1# 43 ± 1# 
Creatinine clearance 
(ml/min/100g body weight) 
7.4 ± 0.4 6.2 ± 0.2  9.7 ± 0.3# 9.2 ± 0.4# 
Kidney weight (g) 1.1 ± 0.03 1.02 ± 0.03  1.28 ± 0.02# 1.31± 0.03# 
FGS score (%) 1 ±1 1 ±1  1 ±1 2 ±1 
 
* p<0.01 versus FHL of the same age 
# p<0.01 versus the same strain at age of 7 weeks 
SBP- systolic blood pressure, DBP- diastolic blood pressure, FGS- focal glomerulosclerosis  
 
 
The myogenic index, describing myogenic reactivity of an artery in response to a pressure 
change, i.e. the slope of active pressure-diameter relationship, was calculated for every 20 
mmHg pressure step (∆P) as a percentage change in corresponding active diameter DCa, i.e. 
myogenic index (%/mmHg) = 100 [(∆DCa/DCa)/∆P]. For each individual artery maximal 
myogenic tone and peak myogenic index were determined from all the pressures and 
pressure steps studied, respectively. Concentration-response curves to the vasoconstrictors 
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KCl and phenylephrine (PE) were calculated as a percentage change from baseline artery 
diameter and from maximal KCl response for small arteries and aorta, respectively. 
Concentration-response curves of the vasodilators ACh and SNP were expressed in 
percentage of pre-constriction to PE. The curves were characterized by the maximal 
relaxation (Emax) and the negative logarithm of acetylcholine molar concentration causing 
half-maximal relaxation (pD2). Area Under ACh concentration-response curve (AUC) was 
determined (Sigma Plot, SPSS Inc., Chicago, IL, USA) and expressed in arbitrary units. 
The contribution of three endothelial mediators (PGs, NO and EDHF) to endothelial 
relaxation was calculated as a difference between corresponding AUCs. Full myogenic and 
concentration-response curves of ACh and SNP were compared by ANOVA for repeated 
measures followed by Bonferroni post hoc test for multiple comparisons. Group-
comparison of animal and vascular parameters was performed by unpaired Student’s t-test. 





Characteristics of FHL and FHH rats in both experimental periods are given in Table 1. In 7 
weeks old FHL and FHH rats, no renal damage was present, as evidenced by similar levels 
of proteinuria, FGS, plasma creatinine and creatinine clearance. Both SBP and DBP were 
marginally elevated in FHH rats as compared to FHL. Five weeks later, FHH rats 
developed significant proteinuria, without an increased incidence of FGS or loss of renal 
function. This suggests that in 12 weeks old FHH rats, mild renal damage is present. In 
contrast to proteinuria, blood pressure did not increase in both strains as compared to week 
7. Additional animals (n=10 each strain) were followed for 26 weeks to confirm 
development of renal damage. At this age, hypertension, profound proteinuria and 
structural damage were present in FHH rats, but not in FHL rats (data not shown).  
 
Myogenic reactivity is selectively impaired in the renal vasculature of FHH rats prior 
to the development of renal end-organ damage 
At the age of 7 weeks, passive diameters of small renal arteries did not differ between FHL 
and FHH rats in the pressure range studied (Figure 1A). However, as evidenced by the 
differences in active curves (Figure 1A), renal arteries isolated from kidneys of FHH rats 
developed significantly lower myogenic tone as compared to FHL (Figure 2A). 
Consequently, young FHH demonstrated reduced maximal myogenic tone (22 ± 4.8 versus 
10.8 ± 2.0 %, p= 0.03) and the peak myogenic index (-6.9 ± 4.8 versus 0.6 ± 0.8 %/mmHg, 
p= 0.07 for FHL versus FHH, respectively). In contrast to small renal arteries, active 
myogenic curves obtained in mesenteric arteries isolated from 7 weeks old rats did not 
differ between both strains (Figure 1C), demonstrating a similar level of systemic 
myogenic tone in FHL and FHH rats (Figure 2C). Therefore, before any renal end-organ 
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Figure 1. Reactivity of small renal (A, B) and small mesenteric (C, D) arteries to increase 
of intraluminal pressure. Curves were recorded in presence (active) and in absence 
(passive) of extracellular calcium. Arteries were isolated from FHL and FHH rats showing 
either no (7 weeks of age; A, C) and or minor (12 weeks of age; B, D) renal damage.  
 
 
Selective renal impairment of myogenic reactivity is more pronounced after the 
development of proteinuria  
At 12 weeks of age, small renal arteries from FHL rats showed marked difference between 
active and passive myogenic curves (Figure 1B), developing more pronounced myogenic 
tone (Figure 2B) when compared to 7 weeks old animals (Figure 2A). In contrast, the level 
of myogenic tone in 12 weeks old FHH rats remained minimal and significantly different 
from FHL animals (Figure 2B), as reflected by markedly impaired maximal myogenic tone 
and peak myogenic index in FHH rats as compared to FHL (Table 2). In small mesenteric 
arteries at 12 weeks, active myogenic curves (Figure 1D) and myogenic tone (Figure 2D) 
development were comparable in FHL and FHH. As a result, maximal myogenic tone and 
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peak myogenic index in mesenteric arteries (Table 2) did not differ between FHL and FHH 
rats. Therefore, selective impairment of myogenic reactivity in small renal arteries is even 






































































































Figure 2. Changes in myogenic tone of small renal (A, B) and small mesenteric (C, D) 
arteries in FHL and FHH rats showing either no (7 weeks of age; A, C) or minor (12 weeks 
of age; B, D) renal damage. * p<0.05 
 
 
To investigate whether impaired contractile ability of small arteries is confined to 
myogenic stimuli or a general impairment of vascular contraction, we investigated 
depolarization- and receptor-mediated contraction to KCl and PE, respectively. 
Depolarization- and receptor-mediated contractile ability in both vascular beds studied were 
similar between FHL and FHH rats, as evident from the characteristics of the 
concentration-response curves to KCl and PE shown in Table 2,. To explore whether the 
endothelium plays a role in the impairment of myogenic tone in renal arteries of FHH rat, 
we repeated the myogenic protocol after removal of the endothelium. As shown in Figure 
3, removal of the endothelium did not attenuate the differences in myogenic reactivity 
between FHL and FHH rats. 
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Table 2. Characteristics of vasoreactivity of small renal, small mesenteric arteries and 
aorta isolated from FHL and FHH rats at the age of 12 weeks:  
parameters of response curves to potassium chloride (KCl), α-agonist phenylephrine (PE), 
increased intraluminal pressure (myogenic tone), endothelium-dependent vasodilator 
acetylcholine (ACh) and endothelium-independent vasodilator sodium nitroprusside (SNP); 
Emax- maximal contractile response in % of baseline vascular diameter (contractility) or in 
% of pre-constriction (relaxation), pD2- negative logarithm of the molar concentration of 
agonist causing half of the maximal responses, PMI- peak myogenic tone- maximal slope of 
active myogenic curve (%/mmHg), * p<0.05 
 
  FHL FHH 
Renal artery 
Contractility KCl  Emax (%) 68 ± 4 71 ± 3 
  pD2 1.33 ± 0.08 1.40 ± 0.04 
 PE Emax (%) 68 ± 4 70 ± 3 
  pD2 6.6 ± 0.1 6.8 ± 0.2 
 Myogenic Emax (%) 34 ± 5 16 ± 2* 
  PMI (%/mmHg) -3.2 ± 1.0 -0.9 ± 0.4* 
Relaxation ACh Emax (%) 66 ± 4 60 ± 4 
  pD2 6.5 ± 0.1 6.8 ± 0.2 
 SNP Emax (%) 88 ± 3 86 ± 3 
  pD2 6.9 ± 0.2 6.9 ± 0.2 
Mesenteric artery 
Contractility KCl  Emax (%) 83 ± 4 82 ± 3 
  pD2 1.37 ± 0.06 1.39 ± 0.04 
 PE Emax 81 ± 4 82 ± 4 
  pD2 6.5 ± 0.1 6.7 ± 0.1 
 Myogenic Emax (%) 42 ± 1 39 ± 4 
  PMI (%/mmHg) -4.3 ± 0.8 -3.1 ± 0.9 
Relaxation ACh Emax (%) 100 ± 1 97 ± 1* 
  pD2 7.2 ± 0.1 6.6 ± 0.1* 
 SNP Emax (%) 98 ± 2 97 ± 2 
  pD2 7.3 ± 0.2 7.3 ± 0.2 
Aorta 
Contractility PE Emax (% of KCl) 75 ± 5 78 ± 5 
  pD2 (% of KCl) 6.7 ± 0.1 6.7 ± 0.1 
Relaxation ACh Emax (%) 56 ± 4 57 ± 8 
  pD2 6.6 ± 0.1 6.5 ± 0.1 
 SNP Emax (%) 98 ± 1 100 ± 1 
  pD2 7.9 ± 0.1 7.7 ± 0.2 
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Intraluminal pressure (mmHg)























Renal artery  without endothelium
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Figure 3. The influence of endothelium removal on myogenic reactivity of small renal 
arteries of FHL and FHH rats with minor renal damage. A) Passive and active curves 
recorded in presence or absence of extracellular calcium, respectively. B) myogenic 
constriction upon increase of intraluminal pressure in % of passive diameters. * p<0.05 
 
 
Renal and systemic endothelial dysfunction in FHH rats prior to the development of 
renal end-organ damage 
Acetylcholine (ACh) relaxed small renal arteries isolated from 7 weeks old FHL rats, 
resulting in monophasic concentration-response curve (Figure 4A). In FHH rats however, a 
biphasic curve was observed as higher concentrations of ACh induced a contractile 
response (Figure 4A). In contrast to renal artery, ACh incubation resulted in monophasic 
concentration-response curve in both FHL and FHH rats in small mesenteric arteries, 
although the curve was shifted to the right in FHH rats (Figure 4C). Unlike in small 
arteries, no difference between ACh-induced relaxations of the two strains was observed in 
aortic rings (Figure 4E). All observed alterations specifically indicated the presence of 
endothelial dysfunction, since no differences were found in the reactivity to endothelium-
independent vasodilator SNP in any vascular bed between FHL and FHH rats (Table 2).  
 
Progression of systemic endothelial dysfunction in FHH rats after the development of 
proteinuria 
At the age of 12 weeks, animals showed a similar pattern of endothelial dysfunction in the 
investigated vascular beds as observed at the age of 7 weeks. In 12 weeks old animals, 
endothelial dysfunction was present in small renal (Figure 4B) and mesenteric artery 
(Figure 4D), but not in aorta (Figure 4F). In small mesenteric artery, endothelial 
dysfunction in FHH was aggravated when compared to 7 weeks old rats, as evidenced by a 
further shift of the response curve to the right (Figure 4D). SNP-induced relaxation 
remained unchanged in all vascular beds. 
 











































































































































































Figure 4. Endothelial dysfunction in various vascular beds of FH rats. Endothelium-
mediated vasodilation to acetylcholine measured in small renal arteries (A, B), small 
mesenteric arteries (C, D) and aorta (E, F) isolated from FHL and FHH rats showing 
either no (7 weeks of age; A, C, E) or minor (12 weeks of age; B, D, F) renal damage. * 
p<0.05
 





























C FHL- mesenteric artery
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Figure 5. Heterogeneous mechanisms of endothelial dysfunction between 12 weeks old 
FHL (A, C, E) and FHH (B, D, F) rats in small renal (A, B), small mesenteric arteries (C, 
D).and aorta (E, F). Endothelium-mediated vasodilation to acetylcholine in absence (total) 
of any inhibitors and in the presence of indomethacin (indo, 10-5 mol/l), combination of 
indomethacin and L-NMMA (10-4 mol/l) and eventually in additional presence of 
charybdotoxin (chtx, 10-7 mol/l) and apamin (apa, 3x10-7 mol/l). * p<0.05 indo versus 
indo+L-NMMA, # p<0.05 indo+L-NMMA+chtx+apa versus all other curves, & p<0.05 
indo versus total. 
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Heterogeneous mechanisms underlying endothelial dysfunction in FHH rats 
To explore the mechanisms responsible for the endothelial dysfunction in studied vascular 
beds, we constructed ACh concentration response-curve in presence of the inhibitors of 
endothelium-derived vasodilatory mediators in both 7 and 12 weeks old animals. Since 
similar curves were obtained at both time points, for reasons of clarity only data from week 
12 are presented in Figure 5. Indomethacin, an inhibitor of cyclooxygenase (COX), 
completely reversed endothelium-dependent contractions associated with higher doses of 
ACh in small renal arteries of FHH rats (Figure 5B), while it had no significant effect in 
FHL rats (Figure 5A). Additional blockade of NO by L-NMMA resulted in significant 
attenuation of ACh-vasodilation in renal arteries of FHH rats (Figure 5B), while affecting 
the relaxation to a lesser extent in FHL animals (Figure 5A). The remaining ACh-relaxation 
was completely blocked by the combined application of potassium channels inhibitors 
charybdotoxin and apamin suggesting this response is mediated by EDHF (Figure 5A, B).  
Indomethacin did not affect the endothelial dilation in either FHL or FHH rats in small 
mesenteric artery (Figure 5C, D). Additional block of NO led to a small right-shift of the 
curve in FHL (Figure 5C), with even less pronounced effect in FHH (Figure 5D). Similar 
to renal vessels, the remaining relaxation was completely inhibited by charybdotoxin and 
apamin (Figure 5C, D). 
In aorta, the ACh-induced response was not altered in the presence of indomethacin, 
whereas it was almost completely attenuated by NO blockade. No differences were 
observed between FHL and FHH rats (Figure 5E, F).  
Based on these observations, the contribution of the principal endothelial mediators (PGs, 
NO, EDHF) to endothelial function was calculated. The release of constrictive PGs seems 
responsible for endothelial dysfunction in small renal arteries of FHH prior to the 
development of renal damage, as indicated by negative value of PGs contribution in Figure 
6A. At the same time, PGs do not play any role in endothelial dysfunction in the mesenteric 
artery, in which rather a reduction in EDHF is found (Figure 6C). In aorta, no changes in 
endothelial mediators could be detected (Figure 6E). 
After the development of renal damage, endothelial dysfunction persists in FHH rats with 
similar mechanisms involved. Renal arteries showed comparable production of contractile 
PGs (Figure 6B) as observed prior to the development of renal damage (Figure 6A). In 
contrast, mesenteric arteries displayed even more pronounced loss of EDHF-mediated 
relaxation compared to 7 weeks old FHH rats (Figure 6D). No significant changes were 
observed in the responses of aorta (Figure 6F). Additionally, small renal arteries of FHH 
rats with renal damage rely relatively more on NO-mediated vasodilation than FHL rats 
(Figure 6B).  
 
 











































































































































Figure 6. Heterogeneous contribution of endothelial mediators prostaglandins (PGs), 
nitric oxide (NO) and endothelium-dependent hyperpolarizing factor (EDHF) to 
endothelium-dependent relaxation shown in arbitrary units of Area Under acetylcholine 
concentration-response curve (AUC) in small renal (A, B), small mesenteric arteries (C, D) 
and aorta (E, F) of FHL and FHH rats showing either no (7 weeks of age, A, C, E) or 
minor (12 weeks of age; B, D, F) renal damage. * p<0.05  
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Mechanisms underlying endothelium-mediated contractions in renal arteries of FHH 
rats 
To identify the mechanisms underlying ACh-mediated indomethacin-sensitive contractile 
response in renal arteries of FHH rats, additional experiments were performed in 12 week 
old rats. As shown in Figure 7, endothelium-dependent contractions to ACh are reversed to 
relaxations in the presence of COX-1 inhibitors, but unaffected by COX-2 inhibitors. 
Furthermore, the contractions were blunted by a TXA2/PGH2 receptor antagonist and by 
superoxide dismutase, identifying the target receptor of the COX1-derived prostanoids and 



































Figure 7. The effect of cyclooxygenase pathway inhibitors on prostanoid-mediated 
endothelium-dependent contractions in small renal arteries of 12 weeks old FHH rats. 
VAS- valeryl salicylate (10-4 mol/l)- COX-1 selective inhibitor, NS398 (10-6 mol/l)- COX-2 
selective inhibitor,  SQ29548 (10-6 mol/l)- TXA2/PGH2 receptor antagonist, SOD- 





The present study reports a severely impaired myogenic contractility of small renal arteries 
in an inbred rat model of spontaneous renal disease (FHH) when compared to its disease-
resistant counterpart (FHL). Moreover, FHH rats displayed a COX-1-dependent endothelial 
dysfunction. These renal vascular changes were detected prior to the manifestation of renal 
damage, thus being potentially involved in the increased susceptibility of FHH rats to renal 
injury. Furthermore, these alterations were selectively observed in small renal, but not in 
small mesenteric arteries, in which only endothelial dysfunction due to impaired EDHF-
mediated vasodilation was found. Finally, impaired vascular reactivity was further 
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aggravated during the course of spontaneous renal damage. Therefore, heterogeneous 
vascular dysfunction is present in various vascular beds in animal models of spontaneous 
renal disease prior to the development of end-organ damage.  
A progressive pattern of spontaneous hypertension-associated renal disease in young 
Fawn-Hooded rats as observed in our study is in agreement with previous reports19,20. 
Seven weeks old FHH rats showed minor elevation in blood pressure as compared to age-
matched FHL counterparts. However, blood pressure of both strains remained in the 
normotensive range at that age. At this time point, markers of renal damage did not differ 
between experimental strains. Although blood pressure did not increase further in FHH rats 
over the following 5 weeks, a marked elevation in urinary protein excretion was observed. 
Renal damage progresses rapidly in FHH strain and eventually leads to end-stage renal 
failure-related death before the age of 70 weeks21, whereas FHL rats do not develop early 
hypertension and renal lesions14. Therefore, FHH rats studied at an early age provide a 
useful model to investigate the role of vascular changes in the development of spontaneous 
renal damage and systemic vascular complications. 
Our observation of marked attenuation of myogenic reactivity in small renal arteries of 
FHH rat as compared to FHL strain is in agreement with observations of van Dokkum et 
al.16, who reported significantly lower myogenic constriction in renal interlobular artery of 
proteinuric FHH rats. We extend these data by showing that the difference in myogenic 
reactivity between FHL and FHH is detected prior to development of proteinuria. In 
addition, we found that myogenic reactivity increases with age in FHL, whereas this 
increase is absent in FHH. rats. This observation suggests that the myogenic mechanism in 
FHH rats fails to adapt to increased hemodynamic load during the progression of 
hypertension or associated renal disease. Altered myogenic reactivity may result in an 
impaired autoregulatory ability of the kidney, leading to elevated glomerular capillary 
pressure, subsequent hyperfiltration and progressive proteinuria. Although we were not able 
to detect hyperfiltration, as calculated creatinine clearance was similar in both studied 
groups, Simons et al. demonstrated an elevation of intraglomerular capillary pressure in 
FHH rats at the age of 7 weeks15, i.e. before the development of proteinuria. Furthermore, 
an attenuated autoregulation of renal blood flow has been reported in 12 weeks old FHH 
rats as compared to FHL22. Recently, it has been shown that autoregulation is restored  and 
proteinuria reduced by the transfer of a specific region of chromosome 1 from Brown-
Norway rats to FHH23, indicating that altered autoregulation may be responsible for the 
genetic susceptibility of FHH strain to renal disease. Collectively, these data indicate that 
impaired myogenic reactivity may represent the mechanism rendering a given animal strain 
susceptible to renal injury. 
Interestingly, the impairment of myogenic constriction is specific for the renal vasculature, 
since no differences in myogenic reactivity between FHH and FHL rats were found in the 
systemic resistance arteries. This suggests that myogenic response of various vascular beds 
is heterogeneously affected in FHH rats and that differential mechanisms underlie 
myogenic reactivity in renal and mesenteric arteries. However, only few studies reported 
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heterogeneity of myogenic mechanisms among vascular beds24 and differential mechanisms 
have not been characterized yet. Generally, myogenic constriction is a result of intrinsic 
reactivity of smooth muscle cells associated with membrane depolarization and increase in 
intracellular calcium levels. Several mechanosensitive ion channels and integrins may be 
involved in a stretch-induced mechanotransduction, whereas other factors have been 
implicated in the myogenic signal transduction, including activation of calmodulin/ myosin 
light chain kinase pathway, PKC, MAP kinases, cytochrome P450-derived metabolites of 
arachidonic acid (20-HETE) and several potassium channels25. Altered activity of any of 
these components may underlie the impairment of renal myogenic constriction FHH rats, 
although several of these mechanisms participate also in receptor- or depolarization-
mediated contraction. Since these contractions were intact, the affected mechanism in FHH 
seems rather specific for the stretch-induced reactivity, such as mechanotransduction. 
Moreover, the defect is independent of basal reactivity of endothelium, since impairment of 
myogenic constriction in FHH persisted after removal of the endothelium. Thus, reduced 
myogenic reactivity in small renal arteries may explain the susceptibility of FHH rats to 
renal damage. In addition, its selective impairment in renal arteries indicates that different 
mechanisms are involved in the generation of myogenic responses across different vascular 
beds.  
We have previously shown that variation in renal endothelial function of healthy rats from 
an outbred Wistar strain predicts their susceptibility to the development of renal end-organ 
damage after renal mass reduction9 and combined unilateral nephrectomy and myocardial 
infarction26. Healthy individuals with pronounced endothelium-dependent relaxation 
developed less severe renal damage. The current finding that endothelial function in FHH is 
already impaired at an early age prior to the development of renal damage is in agreement 
with these observations in outbred strains and suggests that endothelium actively 
participates in the susceptibility to end-organ damage.  
The primary mechanism underlying endothelial dysfunction in renal arteries of FHH rats is 
COX-1-mediated endothelium-dependent contraction, in which the production of 
vasoconstrictive endoperoxides and/or thromboxanes and superoxide radical were involved. 
In a previous report from our lab, we showed that pronounced production of endothelial 
contractile prostanoids in healthy rats was associated with the excessive renal damage 
induced by subsequent renal mass reduction. Interestingly, early hyperfiltration in FHH rats 
was reported to coincide with an excessive urinary excretion of contractile prostaglandins27. 
These observations may suggest the role of prostaglandins in the development of 
spontaneous renal injury. However, spontaneously hypertensive rat (SHR), a strain 
relatively resistant to the development of renal injury also displays COX-mediated renal 
endothelial dysfunction at an early, pre-hypertensive stage28. Therefore alternatively, renal 
vasoconstrictive prostaglandins may play the critical role in the development of 
spontaneous hypertension29. Interestingly, while endothelium-dependent contraction is 
confined exclusively to renal vasculature in FHH, it is found also in systemic resistance 
arteries and aorta in SHR30-32. However, the implications of this observation remain unclear 
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and further research is needed to clarify the role of early renal endothelium-dependent 
contractions in the pathophysiology of hypertension-associated renal damage in FHH rats.  
Reduced bioavailability of nitric oxide (NO) is considered to be a key mechanism for renal 
endothelial dysfunction in various experimental models of hypertension and renal 
damage33,34. We previously reported that pronounced renal NO-mediated vasodilation is 
associated with protection against the development of renal damage in several models of 
renal injury9,10. However, in the present study, no difference was found in NO-mediated 
vasodilation between FHL and FHH rats prior to the development of renal damage. 
Moreover, in proteinuric FHH animals, the NO-dependent vasodilation is increased rather 
than reduced, suggesting that NO bioactivity is modified during the course of renal disease. 
Likewise, increased NO activity has been described in early stages of diabetic nephropathy 
and has been linked to hyperfiltration35,36. One might speculate about a similar mechanism 
in FHH rats, leading to elevated glomerular pressure and the development of proteinuria. 
Alternatively, increased NO release might represent a compensatory mechanism in 
response to the production of COX-derived reactive oxygen species. Interestingly, 
increased constitutive nitric oxide synthase-1 (NOS-1) expression has been described in 
macula densa of young FHH rats37, however it is unclear whether NO signaling in 
preglomerular arteries is affected. NO-related changes in FHH rats seem to be limited to the 
renal vasculature and was not observed in systemic vascular beds, even though 
acetylcholine-induced relaxation almost entirely relies on NO in the aorta. Taken together, 
these data indicate that reduced NO-mediated relaxation does not seem to represent a major 
mechanism of early vascular dysfunction in spontaneous renal disease.  
In small arteries, such as renal or mesenteric artery, the majority of endothelial relaxation 
under physiological condition is mediated by EDHF9,38,39. Interestingly, this mechanism 
was intact in small renal, but impaired in mesenteric resistance artery of FHH rats at both 
time points investigated. This heterogeneity might be explained by the variable identity of 
EDHF in different vascular beds40-44. Nevertheless, it is well established that in all vascular 
beds activation of the endothelial calcium-regulated potassium KCa channels is critical for 
EDHF-response, as evidenced in our study by the complete blockade of EDHF-mediated 
vasodilation in the different arteries by charybdotoxine and apamin, inhibitors of the 
large/intermediate (BKCa/IKCa) and small conductance (SKCa) channels, respectively. 
Selectively altered EDHF-mediated relaxation in systemic arteries appears before the 
development of proteinuria, suggesting that generalized endothelial dysfunction may 
precede renal injury. EDHF reduction in resistance arteries may possibly be related to the 
minor blood pressure increase in FHH rats. However, it seems unlikely, because during the 
course of the study EDHF further progressed with proteinuria increase, despite unchanged 
blood pressure. Moreover, impaired EDHF-mediated relaxation observed in various 
vascular beds following experimental renal disease induced by renal mass reduction45,46 is 
independent from blood pressure increase. Changes in the expression of endothelial SKCa 
and IKCa channels underlying the EDHF loss in this model45, might be also involved in 
endothelial dysfunction in FHH. Collectively, impaired EDHF-mediated relaxation 
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represents the earliest systemic vascular alterations in spontaneous hypertension-associated 
renal disease.  
In conclusion, the present study shows that vascular dysfunction in both small renal and 
systemic arteries precedes renal damage in FHH rats, a model of spontaneous hypertension-
associated damage. This study confirms the early presence of vascular impairment 
throughout various vascular beds in individuals susceptible to renal disease, however it 
reports marked heterogeneity in affected vasomotor mechanisms between small renal, 
resistance and conduit arteries. Future research should be warranted to define the role of 
endothelial and smooth muscle reactivity in the development of renal end-organ damage. 
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Objectives: Chronic renal failure (CRF) is associated with altered systemic arterial tone and 
hypertension. Myogenic constriction and endothelium-derived hyperpolarizing factor 
(EDHF)-dependent relaxation represent major vasoregulatory mechanisms in small 
systemic arteries. Elevated myogenic response and impaired EDHF might participate in the 
development of essential hypertension, however their role in CRF-related hypertension is 
unknown. We investigated whether myogenic response and EDHF are altered in subtotally 
nephrectomized (sNX) rats and whether these changes are modifiable by chronic treatment 
with ACE inhibitor.  
 
Methods: In a pressure arteriograph, myogenic constriction and EDHF-mediated relaxation 
were evaluated in small mesenteric arteries isolated from male Wistar rats 15 weeks after 
either SHAM operation (n=7), sNX (n=12) or sNX followed by 9 week treatment with 
lisinopril (sNX+LIS, 2.5 mg/kg, n=13).  
 
Results: Surprisingly, myogenic response was reduced in hypertensive CRF rats (maximal 
myogenic tone: 37±2 and 18±4%, p<0.01; peak myogenic index: -0.80±0.08 and -
0.40±0.12 %/mmHg, p<0.05 in SHAM and sNX respectively). At the same time EDHF-
mediated relaxation was impaired as well (maximal response: 92±2 and 77±5%, p<0.01; 
pD2: 6.9±0.1 and 5.3±0.1, p<0.05). Both myogenic response and EDHF were inversely 
related to the severity of renal failure and restored by treatment with lisinopril to levels 
found in SHAM animals. 
 
Conclusion: Major constrictive (myogenic) and dilatory (EDHF) mechanisms of small 
systemic arteries are impaired in hypertensive CRF rats. These alterations do not seem to 
participate in the development hypertension, being rather directly related to the severity of 
renal impairment. Both systemic vascular changes might be restored by renoprotective 
treatment with ACE inhibitor. 
 




Chronic renal failure (CRF) is associated with increased cardiovascular morbidity and 
mortality1,2. Structural and functional alterations of peripheral blood vessels are likely to be 
involved in many of the cardiovascular complications occurring in CRF. Abnormal 
function of large conduit arteries characterized by reduced arterial compliance may result in 
increased pulse pressure and the development of left ventricular hypertrophy, both 
independent prognostic factors for cardiovascular mortality in patients with end-stage renal 
disease3,4. On the other hand, compromised reactivity of small systemic arteries may 
contribute to the increased peripheral resistance and development of hypertension in CRF. 
In fact, hypertension, the ultimate cardiovascular risk factor, occurs in 80-90% of patients 
with end-stage renal disease5. 
Several alterations in peripheral vasomotor mechanisms are implicated in CRF, among 
which, endothelial dysfunction have received a great deal of attention. Endothelial 
dysfunction due to oxidative stress-mediated loss of nitric oxide (NO) vasodilation, was 
proposed to account for hypertension in rats subjected to subtotal nephrectomy (sNX)6,7. 
However, apart from NO, other endothelium-derived mediators are involved in the 
regulation of peripheral vascular tone. Yet unknown factor termed endothelium-derived 
hyperpolarizing factor (EDHF) relaxes the underlying vascular smooth muscle cells by 
opening potassium channels and hyperpolarizing the cell membrane8. Interestingly, in small 
resistance arteries such as small mesenteric artery, EDHF-mediated relaxation represents 
the principal endothelial vasomotor mechanism accounting for vast majority of 
endothelium-dependent vasodilation9-11. Several authors have shown that EDHF might be 
compromised in large conduit arteries of rats with sNX12,13. However EDHF-relaxation in 
small peripheral vasculature during hypertensive CRF has not been addressed thoroughly. 
In addition to decreased local vasodilatory capacity, exaggerated contractile abilities of 
peripheral vessels have been reported in various forms of hypertension. Excessive 
contractile response of small arteries to increases in intravascular pressure, termed 
myogenic constriction14 might contribute to elevated peripheral resistance in spontaneously 
hypertensive rats (SHR)15-17. It is unknown whether a similar mechanism occurs in 
hypertension associated with sNX. Interestingly, we previously found that the level of 
myogenic constriction may be inversely related to EDHF-mediated dilation, suggesting that 
both mechanisms share common signaling pathways, probably interacting at the level of 
vascular Ca2+-regulated potassium channel18. Therefore, the aim of the present study was to 
assess changes in myogenic contractility and EDHF-mediated vasodilation of small 
systemic arteries in rats with experimental CRF induced by sNX. We hypothesized that 
small mesenteric arteries of rats with experimental CRF display increased myogenic 
reactivity and decreased EDHF-mediated dilation as these mechanisms could be inversely 
related. Since systemic vascular alterations might play a role in the development of 
hypertension and cardiovascular damage in CRF our secondary aim was to explore whether 
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these mechanisms are modifiable by renoprotective treatment with the angiotensin-





Male Wistar rats, 12-13 weeks of age (n=40, Harlan, Zeist, The Netherlands) were housed 
under standard conditions at the animal facilities of the University of Groningen. Animals 
had free access to food (standard rat chow containing 0.3% sodium, Hope Farms, Woerden, 
The Netherlands) and drinking water throughout the study. Experiments were approved by 
the local Animal Ethical Committee. 
 
Surgery 
Under anaesthesia with isoflurane 3% in N2O/O2 (2:1), sNX was performed by excision of 
the right kidney and subsequent infarction of approximately 2/3 of contralateral kidney by 
ligation of two to three branches of the left renal artery. SHAM animals underwent the 
same procedure and were closed after manipulation and decapsulation of the kidneys 
without being nephrectomized. Postoperatively, the rats were allowed to recover for one 
week. 
 
Experimental design and in vivo measurements 
Following surgery, systolic blood pressure (SBP) and urinary protein excretion were 
determined weekly. 6 weeks after the operation, nephrectomized rats were stratified based 
on proteinuria and divided in untreated (sNX, n=12) and treated (lisinopril; sNX+LIS, 
n=13) rats. SHAM rats (n=7) were left untreated. Lisinopril was dissolved in the drinking 
water at a dose of 2.5 mg/kg body weight. Subsequently, rats were followed up to 15 weeks 
after surgery. Shortly before sNX (baseline), at 6 weeks (stratification) and 15 weeks after 
sNX (termination), blood samples were collected for the determination of plasma 
creatinine. SBP was measured as the mean of three consecutive measurements in awake, 
restrained animals by means of the tail-cuff method (IITC Inc., Woodland Hills, CA, USA). 
Urinary protein excretion was determined by placing the rats in metabolic cages for 24 
hours and protein concentration was analyzed by TCA (Nephelometer Analyzer II, Dade 
Behring, Marburg, Germany). Creatinine concentration was measured colorimetrically 
(Chema Diagnostica, Jesi (AN), Italy). Upon termination under isoflurane in N2O/O2, the 
remnant kidney and heart were removed and weighted. The mesenteric arterial bed was 
excised for investigation of vascular function.  
 
Preparation and cannulation of small mesenteric arteries 
Third-order branches in mesenteric arterial bed were isolated, cleaned from perivascular 
tissue and transferred to an arteriograph system for pressurized arteries (Living System 
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Instrumentation, Burlington, VT, USA). Each artery was cannulated at both ends with glass 
micropipettes, secured, and the lumen of the vessel was filled with Krebs solution through 
the micropipettes. Intraluminal pressure was set at 60 mmHg and was held constant 
(without flow) by a pressure servo system (Living System Instrumentation, Burlington, VT, 
USA). The vessel chamber was continuously recirculated with warmed (37°C) and 
oxygenated (5% CO2 in O2) Krebs solution with a pH of 7.4. Subsequently, the chamber 
was transferred to an inverted light microscope with a video camera attached to a viewing 
tube. Lumen diameter was continuously registered by a video dimension analyzer (Living 
System Instrumentation, Burlington, VT, USA).  
 
Determination of arterial reactivity and experimental protocol 
Prior to the experiments, arteries were allowed to equilibrate for 40 minutes. To test for 
viability of smooth muscle cells and endothelium, arteries were pre-constricted with a 
thromboxane A2 analogue (U46619, 30 nmol/L) and relaxed with a single dose of 
acetylcholine (100 µmol/L). Following wash-out, myogenic reactivity was investigated by 
constructing active pressure-diameter curves in normal Krebs solution. These were obtained 
over a pressure range of 20–160 mmHg in steps of 20 mmHg. After each stepwise increase 
in intraluminal pressure, lumen diameter was registered when a stable diameter 
(contraction) was reached (~ 5 min). Subsequently, the pressure was set back to 60 mmHg 
and the arteries were allowed to stabilize for 20 minutes before the EDHF-mediated 
vasodilation was investigated. To address EDHF-dependent relaxation, the vessel was pre-
contracted with U46619 (30 nmol/L). Thereafter, the concentration-response curve to 
acetylcholine (3.10-8- 3.10-5 mol/l) was determined in the presence of indomethacin (10 
µmol/L) and Nω-monomethyl-L-arginine (L-NMMA, 100 µmol/L) in order to block 
cyclooxygenase and nitric oxide synthase, respectively. Previously, we showed that the 
remaining relaxation under these conditions is mediated by EDHF, since it is completely 
abrogated either by calcium-regulated potassium channels inhibitors charybdotoxin (100 
nmol/L) and apamin (500 nmol/L)11,18 or by high concentration (40 mmol) of KCl9. Finally, 
after perfusing the system with calcium-free Krebs solution supplemented with ethylene 
glycol-bis-(b-amino ethyl ether) tetraacetic acid (EGTA, 2 mmol/L), passive pressure-
diameter step curves were obtained over a pressure range of 20-160 mmHg. 
 
Solutions and drugs 
Vessel segments were perfused with Krebs solution of the following composition (in 
mmol/L): NaCl 120.4, KCl 5.9, CaCl2 2.5, MgCl2 1.2, NaH2PO4 1.2, glucose 11.5, 
NaHCO3 25.0). Lisinopril was purchased from Astra-Zeneca (The Netherlands). All other 
compounds were purchased from Sigma (St. Louis, MO, USA). Stock solution of 
indomethacin was prepared in 64 mmol/l NaHCO3. 
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Data analysis 
Data are expressed as mean ± SEM; n values represent the number of investigated rats as 
well as the number of investigated arteries since one artery segment per rat was used for the 
same protocol. To characterize myogenic responsiveness, the following parameters were 
calculated from the pressure-diameter curve of each individual artery:  
1. Myogenic tone, describing myogenic behaviour of an artery at a given pressure, was 
expressed as percent decrease in active diameter from the maximally dilated (passive) 
diameter determined at the same pressure in calcium-free/EGTA solution, i.e., myogenic 
tone (%) = 100 [(DCa-free – DCa)/DCa-free], where D is the diameter in calcium-free (DCa-free) 
or calcium-containing (DCa) Krebs. For every individual artery segment maximal myogenic 
tone was determined as the maximal value over the studied pressure range.  
2. Myogenic index, describing myogenic reactivity of an artery in response to a pressure 
change, e.g. the slope of active pressure-diameter relationship, was calculated for every 20 
mmHg pressure step (∆P) as a percentage change in corresponding active diameter D, i.e. 
myogenic index (%/mmHg) = 100 [(∆D/D)/∆P]. A negative value indicates active luminal 
reduction in response to an increase in pressure and provides the evidence of myogenic 
behaviour independently from passive diameters of the vessel19. For each individual artery 
peak myogenic index denotes the largest value of all the pressure steps studied.  
EDHF-dependent concentration-response curves to acetylcholine were expressed in 
percentage of pre-constriction to thromboxane A2 analogue U46619. The curves were 
characterized by maximal relaxation (Emax) and negative logarithm of acetylcholine molar 
concentration causing half-maximal relaxation (pD2). Statistical differences for vascular 
parameters, proteinuria, systolic blood pressure, creatinine, body and organ weights, water 
intake and urinary output were determined by Student’s independent t-test. Differences in 
myogenic and EDHF curves among experimental groups were tested using Bonferroni post 
hoc multiple comparisons applied to ANOVA for repeated measures. The relationships 
between vascular reactivity and in vivo data were calculated using Spearman’s 





Following the nephrectomy 6 rats died because of uremia before the stratification, and 2 
animals of the sNX group died later. Consequently 32 rats completed the study and were 
eligible for the full protocol analysis at termination, (sNX, n=12; sNX+LIS, n=13 and 
SHAM, n=7). Prior to surgery, baseline values (week 0) of body weight, water intake, 
urinary output and plasma creatinine, proteinuria and blood pressure (Table 1) were similar 
in the three experimental groups.  
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Table 1. Clinical characteristics of experimental animals (SHAM-operated, subtotally 
nephrectomized- sNX and subtotally nephrectomized rats treated with lisinopril 2.5 mg/kg- 
sNX+LIS) measured at the baseline (week 0), stratification (week 6) and termination (week 
15 after the operation).  
 
Variable SHAM sNX sNX+LIS 
    
Body Weight (g)    
Baseline             week 0 321±4 338±17 330±8 
Stratification      week 6 427±9 419±12 393±14 
Termination       week 15 512±10 490±15 472±14 
    
Water intake (ml/24h)    
Baseline             week 0 21±2 28±3 34±2 
Stratification      week 6 26±2 45±3* 42±3* 
Termination       week 15 24±1 47±4* 47±4* 
    
Urine output (ml/24h)    
Baseline             week 0 10±1 14±2 17±3 
Stratification      week 6 14±2 23±2* 24±2* 
Termination       week 15 13±1 33±4* 32±4* 
    
Proteinuria (mg/24h)    
Baseline             week 0 20±3 20±2 30±7 
Stratification      week 6 26±2 86±20* 117±25* 
Termination       week 15 39±9 354±38* 183±42*,#
    
Plasma creatinine (µmol/l)    
Baseline             week 0 46±5 44±2 47±4 
Stratification      week 6 47±4 77±4* 77±8* 
Termination       week 15 57±5 100±16* 77±16 
    
Systolic blood pressure (mmHg)    
Baseline             week 0 124±6 122±3 124±3 
Stratification      week 6 134±4 163±9* 155±6* 
Termination       week 15 136±8 173±6* 139±9#
    
Left ventricle weight (mg/g body weight)    
Termination       week 15 2.1±0.1 2.7±0.2* 2.4±0.1* 
    
Wet kidney weight (mg/g body weight)    
Termination       week 15 3.3±0.1 4.7±0.2* 4.7±0.3* 
 
* p<0.05 compared with SHAM at the same time point 
# p<0.05 compared with sNX at the same time point 
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In vivo data 
Within 6 weeks after sNX, the animals from both nephrectomized groups (sNX and 
sNX+LIS) developed severe renal failure characterized by increased SBP (Figure 1A), 
proteinuria (Figure 1B), elevated plasma creatinine levels and when compared to SHAM 
operated rats (Table 1, stratification). Additionally, water intake and urine output were 
higher in sNX and sNX+LIS group compared to SHAM animals (Table 1, stratification). 
At this time point, no differences were found in any of the measured parameters between 
the sNX and sNX+LIS groups.  
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Figure 1. The development of A) systolic blood pressure (mmHg) and B) proteinuria 
(mg/24h) in time after the subtotal nephrectomy. Note that after the development of the 
disease, the rats were stratified to different treatment groups at week 6. SHAM operated 
rats, sNX- subtotally nephrectomized and sNX+LIS- subtotally nephrectomized treated with 
lisinopril 2.5 mg/kg, * p<0.05 compared with SHAM; # p<0.05 compared with sNX 
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Renal disease progressed further in sNX animals, whereas the progression was slowed 
down by ACE-i. Upon sacrifice, 15 weeks after the operation, sNX rats displayed elevated 
SBP (Figure 1A), severe proteinuria (Figure 1B), double plasma creatinine levels, higher 
water intake, urine output, kidney and left ventricle mass (Table 1, termination) as 
compared to age-matched SHAM rats. ACE-i treatment substantially reduced proteinuria 
compared with sNX group, although the levels were still higher than in SHAM animals. 
Plasma creatinine levels and left ventricle mass tended to be lower in the sNX+LIS group, 
which was however not statistically significant. Increased SBP in the sNX group was 
restored by ACE-i to the levels measured in SHAMs (Table 1, termination) and had no 




As shown in Figure 2A, passive diameters of small mesenteric arteries did not differ among 
the experimental groups over the whole pressure range, suggesting no apparent changes in 
maximal relaxant ability of the investigated arteries. Similarly, no differences were 
observed in the receptor-mediated contraction to the thromboxane A2 analogue U46619 
(data not shown). Small mesenteric arteries developed a substantial myogenic tone 
dependent on the intraluminal pressure applied to the vessel. Active diameters were 
significantly higher in the sNX group over the pressure range of 100-160 mmHg when 
compared with SHAM (Figure 2A). As a consequence, myogenic tone was blunted over 
this pressure range (Figure 3A). Threshold for the development of active myogenic 
constriction, indicated by negative myogenic index, was shifted in sNX rats to 80-100 
mmHg pressure step as compared to 60-80 mmHg in SHAM rats (Figure 2B). Furthermore, 
the arteries of sNX rats displayed less pronounced negative values of myogenic index at 
pressure steps 60-80, 80-100 and 100-120 mmHg when compared with SHAM animals, 
indicating less steep slope of active pressure-diameter curve in this pressure range (Figure 
2B). Maximal myogenic tone (p=0.001, Table 2) and peak myogenic index (p=0.004, Table 
2) were also impaired in the vessels isolated from sNX rats. Interestingly, chronic treatment 
with lisinopril reversed active responses to pressure (Figure 2A). Consequently, myogenic 
tone was restored over the whole pressure range (Figure 3A) and maximal myogenic tone 
was comparable to the SHAM values (p=0.03 compared to sNX, Table 2). Additionally, the 
myogenic index was reversed to more negative values in sNX+LIS group at pressure steps 
60-80, 80-100 mmHg (Figure 2B). 
 
EDHF-mediated vasodilation 
A single dose of acetylcholine induced significantly lower endothelium-dependent 
relaxation in the sNX group (100±3, 87±2 and 101±5 % of precontraction level for SHAM, 
sNX and sNX+LIS, respectively), suggesting an impairment in endothelium-mediated 
responses. EDHF-mediated relaxation of small mesenteric arteries was significantly 
diminished after sNX as compared to SHAM arteries (Figure 3B). The acetylcholine curve 
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performed under blockade of cyclooxygenase and nitric oxide synthase showed a reduction 
in both maximal response Emax (p= 0.009, Table 2) and pD2 values (p= 0.006, Table 2) in 






























































Figure 2. A) Diameters of small mesenteric arteries in response to stepwise increase of 
intraluminal pressure in the presence (black symbols, active tone) or absence (white 
symbols, passive tone) of extracellular calcium and B) calculated myogenic index (in % of 
active diameter/mmHg) developed in response to stepwise increase of intraluminal 
pressure studied in SHAM operated, subtotally nephrectomized (sNX) and subtotally 
nephrectomized rats treated with lisinopril 2.5 mg/kg (sNX+LIS) 15 weeks after the 
operation. * p<0.05 compared with SHAM; # p<0.05 compared with sNX 
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ACE-i treatment effectively restored blunted EDHF-dependent dilation observed in vessels 
from sNx rats (Figure 3B). Rats from sNX+LIS displayed increased Emax (p= 0.04) and pD2 
(p= 0.04) values of EDHF-acetylcholine curve when compared to sNX animals (Table 2). 
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Figure 3. Impaired A) myogenic tone (in % of passive diameter) and B) EDHF-dependent 
vasodilation (as acetylcholine-induced relaxation in % of precontraction) in small 
mesenteric arteries of subtotally nephrectomized (sNX) rats as compared to SHAM-
operated, and subtotally nephrectomized rats treated with lisinopril 2.5 mg/kg (sNX+LIS). 




To characterize the role of blood pressure changes in the development of renal damage after 
sNX and in the renoprotective effects of ACE-i, we analyzed relationship between the 
clinical parameters. SBP correlated with both proteinuria and plasma creatinine (r= 0.64, p= 
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0.02 and r= 0.66, p= 0.02, respectively) in sNX+LIS group, but not in sNX group (r= 0.18, 
p= NS and r= 0.12, p= NS, respectively).  
EDHF-dependent relaxation positively correlated with acetylcholine-induced response, 
suggesting that EDHF represents principal endothelial vasodilatory mechanism in small 
mesenteric arteries (r= 0.61, p= 0.002, all groups included). To test our hypothesis on the 
relation between myogenic constriction and EDHF-dependent relaxation we performed 
correlation analysis in sNX animals. However, no relation was observed between these two 
parameters in small mesenteric arteries used in this study (r= 0.06, p= NS). When 
investigating whether beneficial effects of ACEi on both vascular parameters in sNX+LIS 
group might be interrelated,, we did not find any relation between EDHF and myogenic 
tone either (r= 0.25, p= NS). Similarly, no correlation was found between maximal total 
acetylcholine-induced response and myogenic tone (r= 0.11, p= NS and r= 0.20, p= NS for 
sNX and sNX+LIS group respectively), suggesting no role for endothelium-mediated 
mechanisms in myogenic tone changes.  
 
 
Table 2. Comparison of vascular reactivity in small mesenteric arteries of SHAM operated, 
subtotally nephrectomized (sNX) and subtotally nephrectomized rats treated with lisinopril 
2.5 mg/kg (sNX+LIS) 15 weeks after the operation.  
 
 SHAM sNX sNX+LIS 
    
Myogenic tone     
Maximal myogenic tone (% of passive diameter) 37±2 18±4* 33±5#
Peak myogenic index  (% of active diameter/mmHg) -0.80±0.08 -0.40±0.12* -0.68±0.15 
    
EDHF vasodilation    
Emax (% of precontraction) 92±2 77±5* 88±2#
pD2  6.5±0.1 5.9±0.1* 6.3±0.1#
 
EDHF- endothelium-dependent hyperpolarizing factor, Emax- maximal relaxation, pD2- 
negative logarithm of the acetylcholine concentration causing half maximal responses. * 
p<0.05 compared with SHAM; # p<0.05 compared with sNX 
 
 
To address the role of renal failure and hypertension in the development or ACE-i mediated 
reversal of systemic vascular changes, additional correlation analyses were performed in 
sNX and sNX+LIS animals, respectively. Interestingly, in sNX rats maximal myogenic 
tone and maximal EDHF-dependent dilation of small mesenteric arteries inversely 
correlated or tended to correlate with proteinuria as a marker of renal damage, (Figure 4A, 
B; r= -0.60, p= 0.04 and r= -0.52, p= 0.08 for maximal myogenic tone and maximal EDHF 
dilation, respectively), but not with SBP (r= 0.06, p= NS and r= -0.02, p= NS, for maximal 
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myogenic tone, and maximal EDHF dilation, respectively). When the treated group was 
analyzed, an inverse correlation of borderline significance was found between myogenic 
tone and proteinuria (Figure 4A; r= -0.53, p= 0.06), but not between EDHF dilation and 
proteinuria (Figure 4B, r= -0.04, p= NS). No significant correlations were observed 
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B
Proteinuria (mg/24h)
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Figure 4. Correlation between individual values of proteinuria (mg/24h) and A) maximal 
myogenic tone (% of passive diameter) and B) maximal EDHF-mediated relaxation 
(maximal relaxation in % of precontraction) of small mesenteric arteries in subtotally 






Chronic renal failure (CRF) is associated with altered arterial tone of the systemic 
vasculature, which may contribute to elevated blood pressure and accelerated rate of 
cardiovascular events observed in renal patients. In the current study, we demonstrate that 
two major vasoregulatory mechanisms of small mesenteric arteries, namely myogenic 
constriction and EDHF-mediated vasodilation, are impaired in a rat model of subtotal 
nephrectomy (sNX) with hypertension. Both vascular alterations in this experimental model 
might be reversed by renoprotective therapy with an ACE inhibitor. 
Rats with sNX employed in the current study displayed characteristic features of CRF, as 
evidenced by severe proteinuria and almost doubled plasma creatinine levels, increased 
fluid intake, elevated urine production and increased renal mass, probably due to 
compensatory renal growth20. CRF was accompanied by an increase in blood pressure, a 
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complication frequently occurring in patients with end-stage renal disease and the ultimate 
risk factor for cardiovascular events5. The severity of hypertension did not correlate with 
the markers of renal damage, suggesting extrarenal factors may be involved in the increase 
of systemic blood pressure. Since hypertension in CRF is associated with increased 
peripheral resistance21, systemic vascular changes might well contribute to CRF-associated 
elevations in blood pressure. Furthermore, a significant body of evidence suggests that 
myogenic response of small peripheral arteries is enhanced in SHR rats15-17 implying that 
enhanced intrinsic reactivity of resistance arteries to increased pressure might be involved 
in elevated peripheral resistance in hypertension. However, as suggested by our current data 
this does not seem to be the case in CRF-associated hypertension. In contrast to our 
hypothesis, in sNX we observed a reduction in myogenic response of small mesenteric 
arteries, characterized by the impaired myogenic tone in the pressure range of 100-160 
mmHg and altered myogenic index resulting in a shifted threshold for the development of 
active myogenic constriction to higher pressures. To our knowledge, the only other study 
investigating myogenic response of small resistance arteries in CRF did not find any 
difference between myogenic reactivity of small cremaster arteries in sNX and SHAM-
operated rats22. Differences in anatomic localization, vascular diameter and function may 
account for the observed discrepancy with our data. Collectively however, both studies 
suggest that changes in systemic myogenic response do not contribute to the development 
of CRF-associated hypertension. Consequently, mechanisms other than excessive local 
myogenic reactivity, such as volume overload, overactivation of renin-angiotensin or 
sympathetic system, are probably responsible for increased peripheral resistance in CRF. 
The observed reduction of myogenic tone might represent a compensatory mechanism 
counteracting the increase in peripheral resistance in CRF. However, we found the level of 
myogenic tone not to be related with severity of hypertension, but rather with the severity 
of renal disease, suggesting that myogenic tone is specifically modulated by the state of 
renal insufficiency. Furthermore, the reduction of systemic myogenic tone was completely 
reversed after chronic treatment with lisinopril. Since ACE-i therapy resulted in a complete 
reversal of elevated systolic blood pressure and prevented the progression of renal damage, 
all antihypertensive, renoprotective and/or specific local effects of ACE-i (e.g. resulting 
from local ACE inhibition) might play a role in myogenic tone reversal. A positive 
correlation between blood pressure and severity of renal damage in treated animals suggests 
that antihypertensive and renoprotective effects of ACEi might be related. However, it is 
likely that kidney-related mechanisms modulate myogenic reactivity after ACE-i treatment, 
since the level myogenic tone was associated with renal damage rather than with blood 
pressure. 
In addition to a reduction in smooth-muscle mediated myogenic mechanisms we also found 
an alteration in the major endothelium-dependent vasodilatory mechanism of small 
mesenteric artery, e.g. EDHF. Our data are in agreement with studies showing impaired 
EDHF-mediated relaxation in large conduit arteries of experimental animals with CRF12,23. 
However it is difficult to assess to which extent compromised EDHF relaxation of 
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resistance arteries contributes to CRF-associated hypertension, since impaired EDHF 
relaxation was also demonstrated in CRF-rats without hypertension, suggesting that CRF 
per se is associated with disturbed EDHF-mediated relaxation24. Our finding of a 
correlation between EDHF-mediated relaxation and markers of renal failure, but not 
hypertension, may support this view. Moreover, EDHF is differently modulated in various 
forms of hypertension ranging from altered25,26 to elevated EDHF relaxations in some 
animal models27-30. In latter cases, EDHF might compensate for reduced nitric oxide 
bioavailability. Therefore the role of altered EDHF relaxation in CRF-related hypertension 
will have to be defined further.  
The mechanisms responsible for concomitant decrease of myogenic constriction and 
EDHF-mediated dilation of systemic arteries in CRF cannot be directly inferred from this 
study. In contrast to our hypothesis we could not confirm a direct antagonistic relation 
between these two parameters. Similarly, ACEi-induced changes in endothelium (EDHF)- 
and myogenic- mediated mechanisms do not seem to be correlated either, suggesting that 
endothelial and smooth-muscle mediated mechanisms are altered independently in CRF. 
Thus, rather than a result of endothelial dysfunction, myogenic alterations might be a 
consequence of inappropriate chronic stimulation of sympathetic31, endothelin32 or renin-
angiotensin33 systems occurring in CRF. Myogenic tone is strongly potentiated by 
vasoconstricting agents, such as noradrenaline34, endothelin-116, and angiotensin-II35,36 and 
the chronic overactivation might result in its adaptive downregulation. Involvement of 
renin-angiotensin system is also supported by the finding of complete reversal of systemic 
myogenic tone after chronic treatment with ACEi. Interestingly, the angiotensin AT1 
receptor is involved in changes of myogenic reactivity observed in mesenteric arteries after 
experimental heart failure35. Yet, specific molecular mechanisms responsible for myogenic 
alterations will still have to be worked out. Although we cannot fully exclude the possibility 
of a generalized contractile defect on the level of smooth muscle cells, we found no 
differences in reactivity to the thromboxane A2 agonist and no change in general contractile 
ability was reported previously in this model and vascular bed24. Therefore, signaling 
mechanisms relatively specific for pressure-induced vasoconstriction are more likely to be 
involved, including altered activity or mechanosensitive, voltage- or calcium-regulated ion 
channels14. One may speculate on the role of smooth muscle membrane Ca2+-regulated 
potassium large conductance channels (BKCa), closure of which is implicated in myogenic-
induced depolarization14,37, whereas opening is involved in endothelium-induced 
hyperpolarization8,38. Reduced availability of BKCa channel might possibly explain the 
concomitant defect in myogenic tone and EDHF-mediated dilation in CRF. In line with 
renin-angiotensin system overactivity hypothesis, angiotensin II has been shown to inhibit 
vascular smooth muscle KCa channels39. However, further studies are needed to explore the 
mechanisms underlying vascular changes in CRF. 
In conclusion, the present study revealed impaired myogenic constriction and EDHF-
dependent dilation of small mesenteric arteries in a rat model of CRF with hypertension. 
The alterations in systemic vasoactive mechanisms do not seem to participate in the 
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development of CRF-associated hypertension, being rather directly related to the severity of 
renal impairment. Furthermore, both systemic vascular changes might be reversed by the 
renoprotective treatment with an ACE inhibitor. 
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Endothelial dysfunction (ED) seems to be a crucial mediator of increased cardiovascular 
risk observed among patients with chronic kidney disease (CKD). Importantly, systemic 
ED does not only occur in patients with severe renal failure, but also in individuals with 
earlier stages of CKD. Close association between microalbuminuria and systemic ED 
renders renal vascular function an important marker for the severity of cardiovascular 
damage. Furthermore, alterations of the renal endothelium might be actively involved in the 
progression of renal end-organ damage. Recently, experimental evidence showed that 
interindividual variability in endothelial function of healthy rats predicts the susceptibility 
to renal damage and the efficacy of renoprotective treatment. Therefore, a specific 
manipulation of renal and systemic ED might provide benefit in various stages of CKD. 
Thus, ED may represent an ideal therapeutic target not only for treatment, but also for 
primary prevention of renal disease.  
 




Chronic kidney disease (CKD) represents a major worldwide health care and economic 
problem. Apart from the enormous number of patients with chronic renal failure requiring 
treatment by dialysis of transplantation, there is also a constantly raising number of 
individuals suffering from earlier stages of CKD. In the United States, a total of 8 million 
individuals are estimated to have a GFR of less than 60 ml/min/1.73 m2 and another 12 
million had evidence of microalbuminuria1. CKD is associated with increased prevalence of 
cardiovascular disease and in fact, patients with CKD have even higher chance to 
experience a cardiovascular event than to progress to renal failure2. Early detection of 
individuals at risk for renal impairment might therefore prevent both renal failure and 
cardiovascular-related burden in these patients.  
Endothelial injury is currently recognized as a common denominator of vascular damage in 
various conditions associated with increased cardiovascular risk, including CKD. Several 
important aspects of endothelial dysfunction (ED) in CKD have recently received a great 
deal of attention. Firstly, the occurrence of systemic ED in various stages of CKD has been 
proposed as an explanation for the accelerated rate of cardiovascular events associated with 
impaired renal function. Moreover, specific intrarenal ED could play an active role in the 
development and progression of renal damage itself. Finally, recent data suggest that the 
renal endothelium might be involved in the individual susceptibility to renal damage and 
might govern the sensitivity to renoprotective treatment. In this chapter, we discuss these 
aspects of ED in CKD (Figure 1) and propose that the endothelium represents a specific 
target for early detection and prevention of both renal and cardiovascular damage 
progression in patients with CKD.  
 
Endothelial dysfunction, general considerations 
Based on vascular research carried out over the last 25 years, the endothelium, inner lining 
of the vasculature, is now recognized as the principal regulator of vascular function 
(recently reviewed by3,4). Endothelial dysfunction (ED), defined as alterations in the normal 
properties of the endothelium that are inappropriate for preservation of organ function5, is 
characterized by loss of protective endothelial characteristics in favour of deleterious 
mechanisms. ED is now recognized as a crucial event in the initiation and progression of 
atherosclerosis and a common denominator for conditions associated with elevated 
cardiovascular risk, including hypertension, diabetes, dyslipidemia, obesity or smoking6. In 
all these states, ED is characterized by altered production and/or decreased bioavailability 
of nitric oxide (NO), the most extensively studied endothelial mediator, and excessive 
production of reactive oxygen species. 
Several estimates of ED are available in clinics, most of them are however difficult to 
interpret. Plasma levels of endothelial markers, such as vWF, PAI-1, or soluble adhesive 
and chemoattractant molecules are frequently used to estimate the state of systemic ED. 
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Unfortunately, they do not provide any information on endothelial function of clinically 
relevant vascular beds (e.g. coronary or renal). Localization of ED might be of paramount 
importance when investigating the role of the endothelium in the progression of specific 
end-organ damage as the structural and functional properties of the endothelium differ 
among vascular beds (e.g. renal versus systemic resistance arteries). Specificity of 
endothelial function measurements might be achieved by assessment of vascular tone in a 
defined vascular bed (Table 1).  
 
↑Cardiovascular risk
Systemic endothelial dysfunctionRenal endothelial dysfunction
?
Microalbuminuria
Susceptibility to renal injury



















Figure 1. The role of renal and systemic endothelial function in the progression of the 
end-organ damage in various stages of chronic kidney disease. 
Renal endothelial dysfunction might be involved in the susceptibility of the individual to 
renal injury, the progression of renal end-organ damage to the stage of renal insufficiency 
and may possibly co-determine the variability in renoprotective therapeutic response. 
Microalbuminuria and ESRD are also associated with systemic endothelial dysfunction, 
which is critically involved in the development of cardiovascular end-organ damage. The 
exact relations between renal and systemic endothelial function are not completely 
understood. Arrows depict the mutual relations. The most important mechanisms of 
endothelial dysfunction are also denoted. NO-nitric oxide, EDHF-endothelium-derived 
hyperpolarizing factor, ADMA- asymmetric dimethylarginine, HCys- homocysteine, ROS- 
reactive oxygen species. 
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Table 1. Methods available for assessment of endothelial function in defined vascular beds 
in humans. 
 
Vascular bed Method Comment 
   
Systemic Flow-mediated dilation (FMD) Non invasive measurements of diameter 
changes in conduit brachial artery by 
Doppler ultrasound after postischemic 
induction of flow, mainly NO-dependent  
   
 Forearm blood flow (FBF) Invasive measurement of flow in forearm 
microcirculation by strain gauge venous 
pletysmography, local infusion of 
endothelium-activating substances 
(acetylcholine)  
   
 Microcirculation Non-invasive laser digital Doppler flow 
measurements in skin microcirculation,  
endothelium-activating substances 
(acetylcholine) applied locally by 
iontophoresis  
   
 Isolated vessels Subcutaneous arteries from skin biopsies 
   
Coronary Coronary angiography Functional angiogram after intracoronary 
infusion of acetylcholine 
   
Renal Renal blood flow changes 
afterNO-modulating agents 
Measurements of renal hemodynamics  
after L-NAME or L-arginine infusion 
 
 
Chronic renal failure is associated with systemic endothelial dysfunction  
It has long been recognized that the last stage of CKD, end-stage renal disease, is invariably 
associated with systemic ED7, a finding that has been interpreted as an important event in 
the development of renal insufficiency-related cardiovascular complications. This may not 
be that surprising since renal patients usually have several of the conventional 
cardiovascular risk factors such as hypertension, dyslipidemia or diabetes, all of which are 
associated with ED. However, several data suggest that the occurrence of these events can 
not be solely explained by traditional risk factors and that additional ‘kidney-specific’ 
mechanisms may contribute to the CKD-related ED. 
Many authors report elevated plasma markers of endothelial injury, such as vWF, 
fibrinogen or thrombomodulin in patients on maintenance dialysis8,9. Others have 
confirmed localized impaired endothelium-dependent vasodilation in peripheral vascular 
beds of uremic patients in vivo7,10,11, as well as in isolated vascular preparations12. 
Interestingly, peripheral vasodilatory ED was not only found in dialyzed subjects, but also 
in patients with moderate renal failure even when adjusted for hypertension, blood glucose 
and serum cholesterol13. In this study, the severity of systemic ED was proportionally 
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related to the degree of renal dysfunction. A study by Kari et al. demonstrated the presence 
of ED in uremic children without hypertension and lipid alterations, suggesting a renal 
failure specific effect14. In experimental animal studies, 5/6 nephrectomy resulting in 
chronic renal failure within several weeks is also associated with ED in both resistance15 
and conduit arteries16 even without the presence of concomitant hypertension. Therefore, it 
is now widely accepted that malfunction of the kidneys elicits profound deleterious effects 
on systemic vascular endothelium.  
The majority of the studies investigating the mechanisms of ED in chronic renal failure has 
focused on the systemic NO deficiency as the principal event leading to ED. Functional 
evidence of impaired stimulated NO bioactivity in forearm vasculature of hemodialysis 
patients was provided by Passauer et al.11,17. Mechanisms responsible for altered NO 
activity have not been completely elucidated yet, however some non-traditional risk factors 
relatively specific for uremia are being extensively discussed. Firstly, chronic renal failure 
is believed to be a state of excessive oxidative stress, as demonstrated in numerous 
experimental and clinical studies18,19. Reactive oxygen species result in premature 
inactivation of NO and its decreased bioavailability. The involvement of increased 
oxidative stress in systemic ED is further supported by a direct relation between 
endothelium-dependent vasodilation and plasma markers of oxidative stress20 and 
beneficial effect of antioxidant treatment on ED in patients with chronic renal failure21,22. 
Hyperhomocysteinemia might be a specific condition responsible for excessive generation 
of reactive oxygen species in chronic renal failure as it is found in the majority of renal 
patients23 and has been shown to adversely affect NO production24 and endothelial 
function25. Finally, in dialyzed patients elevated plasma levels of endogenous competitive 
inhibitors of constitutive nitric oxide synthase (eNOS), such as asymmetric 
dimethylarginine (ADMA), are found26. It has been proposed that this substance may in 
vivo reach the plasma levels relevant for significant inhibition of NO production27. Thus, 
while prevailing evidence shows that chronic renal failure is a state of systemic NO 
deficiency, the exact role of ‘kidney-specific’ mechanisms has yet to be characterized. 
Although not yet systematically addressed, several data suggest that mechanisms other than 
reduced NO bioavailability might be responsible for ED in patients with chronic renal 
failure. Additionally to NO, prostaglandins and endothelium-derived hyperpolarizing factor 
(EDHF) are released from the endothelium upon stimulation with acetylcholine. Most of 
the authors did not observe any contribution of prostaglandins to ED in experimental 
models of chronic renal failure, arguing against the important role of these mediators in 
renal insufficiency-related systemic ED. However, one human study reported that inhibition 
of cyclooxygenase by diclofenac acutely improves endothelium-dependent dilation in the 
forearm of the patients with mild to moderate renal insufficiency28. The authors speculate 
that beneficial effect of diclofenac might be attributed to inhibition of prostanoid 
endothelium-derived contracting factor (EDCF) or decreased production of 
cyclooxygenase-derived free radicals. In addition to nitric oxide and prostaglandins, yet 
another mediator, termed EDHF, is responsible for acetylcholine-induced endothelial 
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relaxation. We29 and others15,16 demonstrated reduced EDHF-dependent dilation in small 
resistance and conduit arteries of 5/6 nephrectomized rats. Under normal physiological 
conditions EDHF is responsible for the majority of the acetylcholine-induced relaxation in 
small arteries, where it prevails over NO-dependent mechanisms30. However, the role of 
EDHF in ED is not clearly defined since its identity remains illusive. Several mediators, 
such as cytochrome P450 metabolites of arachidonic acid, potassium ions, hydrogen 
peroxide or gap junctions have been proposed to account for EDHF-mediated dilation in 
various vascular beds31. It is however recognized that all these mechanisms involve the 
opening endothelial Ca2+-sensitive potassium channels with small (SKCa) and intermediate 
(IKCa) conductance. Kohler et al. showed altered expression of these channels in vascular 
endothelium of 5/6 nephrectomized rats32. However, the only study addressing EDHF-
mediated vasodilation in uremic humans failed to show any changes in forearm non-
NO/prostaglandin vasodilation in hemodyalized patients11. Additional studies need to be 
performed to answer the question whether impaired EDHF-dependent ED, as observed in 
animal models, may occur also in humans and to which extent it may participate in the 
development of renal insufficiency-related cardiovascular complications.  
Although it is now established that chronic renal failure represents a state of systemic NO 
and possibly EDHF-mediated ED, the role of ED in the excessive occurrence of 
cardiovascular risk of renal patients will have to be further clarified. Pannier et al. reported 
a direct relation between forearm post-ischemic endothelial vasodilation and markers of 
end-organ cardiovascular damage including intima-media thickness of common carotid 
artery and left ventricular hypertrophy33 in subjects on hemodialysis. Several plasma 
markers of ED or molecules potentially involved in ED, including ADMA, 
hyperhomocysteine and PAI-134-37, all have been shown to be related with future 
cardiovascular morbidity and mortality in longitudinal studies in hemodialysis patients. So 
far, the only evidence available for such prognostic value of specific vasomotor endothelial 
dysfunction has been reported by London et al.38. They have shown that flow-mediated 
vasodilation was related with all-cause mortality in patients with end-stage renal disease 
with 60 months median follow-up. Thus, the current data support the view of systemic ED 
being a cardiovascular risk factor in patients with chronic renal failure. 
 
Systemic endothelial dysfunction and microalbuminuria 
Although most of the clinical data regarding systemic ED in CKD has been collected in 
uremic patients on dialysis, ED is often present in milder stages of renal insufficiency13,39. 
Moreover, the severity of ED might be related to the degree of renal insufficiency in renal 
patients22, further suggesting a crucial link between kidney and systemic vascular damage. 
Interestingly, systemic ED can be already detected in subjects with minor increases in 
urinary protein excretion, which may be a marker of initial renal injury. A minor increase in 
protein (albumin) excretion (microalbuminuria) might be interpreted as the reflection of 
impaired glomerular endothelial function. Therefore it has been hypothesized (Steno 
hypothesis) that microalbuminuria reflects the specific renal feature of generalized vascular 
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dysfunction40. The view of the kidney as an organ reflecting general vascular damage has 
stemmed from numerous studies showing the predictive value of microalbuminuria for 
cardiovascular mortality in diabetic and high risk non-diabetic individuals41,42. Recently, the 
PREVEND study reported predictive value of microalbuminuria for all-cause mortality in 
the general population with low cardiovascular risk43, suggesting that minor renal injury 
might be an early indicator of systemic vascular damage. 
ED estimated from elevated plasma levels of endothelial markers44,45 or measured as 
endothelium-dependent dilation in systemic vascular beds46 is found in diabetic or 
hypertensive patients with microalbuminuria compared to normoalbuminemic counterparts. 
Furthermore, a direct inverse relationship has been found between systemic acetylcholine-
induced dilation and microalbuminuria in diabetic patients47. Finally, microalbuminuria is 
associated with increased permeability to albumin in peripheral vessels in both diabetics48 
and clinically healthy subjects49. Altered endothelium-dependent vasodilation could be also 
found in clinically healthy subjects with microalbuminuria50 as well as in subjects with 
asymptomatic proteinuria51, e.g. in populations with minimal presence of other 
cardiovascular risk factors. At present, it remains unclear whether minor renal damage itself 
adds a new risk to the systemic vasculature or whether microalbuminuria represents just a 
reflection of a more severe, generalized cardiovascular phenotype. In support of the latter 
hypothesis, some authors suggest that generalized ED precedes the development of 
microalbuminuria, as the plasma levels of endothelial markers such as vWF are strongly 
related to de novo development of microalbuminuria in the follow-up of diabetic or healthy 
cohorts52,53.  
Only a small number of studies addressed the mechanisms responsible for selective 
contribution of increased urinary protein (albumin) excretion to systemic ED. Elliot et al. 
has found blunted vasoconstriction in response to the NOS inhibitor L-NAME in forearm 
vasculature of insulin-dependent diabetic patients with microalbuminuria as compared to 
normoalbuminuria, suggesting loss of NO-dependent vasodilation54. In another study, 
Stehouwer et al. demonstrated that the presence of microalbuminuria was associated with 
impaired flow (NO)-mediated systemic vasodilation in elderly individuals with and without 
diabetes55. Mechanisms responsible for potential NO deficiency in microalbuminuric 
patients might involve excessive oxidative stress. Giner et al.56 found the elevated levels of 
markers of peripheral oxidative stress in hypertensive patients with microalbuminuria 
compared to normoalbuminurics. Similar results were reported from diabetic patients57. 
Recently, higher plasma levels of homocysteine were related with the occurrence of 
microalbuminuria58,59 in diabetic populations, rendering homocysteinemia a potential 
mechanism responsible for increased oxidative stress and ED in microalbuminuria. 
Interestingly, animal data suggest that systems other than NO might be affected by minor 
renal impairment. EDHF–mediated dilation is reduced in coronary arteries of Munich 
Wistar Fromter (MWF) rat model of spontaneous albuminuria60. In yet another model of 
spontaneous renal disease, the Fawn-Hooded rat, slightly elevated urinary protein excretion 
at a young age has already been associated with a selective EDHF defect in systemic 
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resistance arteries61. However, since in such animal models it is difficult to dissociate 
between the effect of renal impairment itself and concomitant hypertension, the altered 
EDHF-mediated relaxation in systemic vasculature related to minor renal injury will need 
to be further confirmed.  
Several studies investigated whether markers of systemic ED are related to cardiovascular 
risk in microalbuminuric patients. Plasma markers related to ED, such as levels of VCAM-
162 and homocysteine63, predicted mortality in diabetic patients with microalbuminuria. 
However, no such prognostic value has been reported for endothelium-dependent 
vasodilation. Nevertheless, the relation between putative renal and systemic ED seems to be 
established and may help to explain the increased occurrence of cardiovascular 
complications in patients with minor renal injury.  
 
Renal endothelial dysfunction and the progression of renal damage 
It is generally agreed that ED might be crucially involved in the development of systemic 
end-organ damage associated with renal dysfunction. However, ED might have profound 
consequences for the progression of damage in the kidney itself. Proteinuria or 
microalbuminuria may be the reflection of elevated glomerular permeability, in which 
endothelium might be involved. It suggests that at least some aspects of endothelial 
dysfunction might be present in very early stages of renal disease progression. 
Microalbuminuria predicts the rate of progression of renal function loss in diabetic patients 
and general population64,65, raising the possibility that renal ED is involved in the 
progression of renal disease. Interestingly, the conditions associated with increased risk of 
renal impairment, including hypertension, diabetes or aging are all characterized by 
impaired renal endothelial function both in humans66-68 and experimental animals69-71. 
Endothelial injury might play a prominent role in hemodynamic adaptations of the kidney 
to renal injury, which are responsible for the progressive nature of kidney damage. 
According to the most prevailing concept, remnant nephrons, e.g. those surviving the initial 
damaging event, adapt to the increased hemodynamic load by allowing higher 
intraglomerular pressure and hyperfiltration to compensate for reduced filtration. 
Glomerular hyperfiltration seems to represent the key event in the development of 
glomerulosclerosis, thus creating a vicious circle of additional nephron loss. Endothelium-
derived NO has been long defined as a key regulator of glomerular pressure and renal 
perfusion72. Administration of the NO synthase inhibitor L-NAME leads to severe 
glomerular hypertension, glomerulosclerosis, interstitial fibrosis and eventually renal 
failure in rats73-76. On the other hand, administration of NO precursor L-arginine attenuates 
proteinuria and glomerular hypertension in experimental chronic renal failure induced by 
5/6 nephrectomy77. Interestingly, direct renal hemodynamic NO dysfunction has been 
scarcely addressed in chronic renal failure. Recently, Okuda et al. reported impaired 
endothelium-mediated vasodilation of afferent and efferent arterioles in subtotally 
nephrectomized dogs, which was attributed to the increased levels of endogenous NO 
synthase inhibitor ADMA due to lower activity of its degrading enzyme dimethylarginine 
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dimethylaminohydrolase (DDAH). These data suggest that increased ADMA levels might 
represent the important mechanism of renal ED. However, reduction in other than 
hemodynamic properties of NO, including inhibition of mesangial growth and extracellular 
matrix production, limitation of leucocyte influx and adhesion, may importantly contribute 
to the progression of renal disease. Kang et al. highlighted the role of proliferative 
properties of glomerular microvascular endothelium in the progression of renal disease78. 
They showed that L-NAME treatment lead to the loss of microvascular endothelium and 
loss of the endothelial proliferative response in 5/6 nephrectomized rats79. Overall, although 
not precisely characterized, renal ED might crucially contribute to the development and 
progression renal end-organ damage. 
 
Renal endothelial function and variation in the susceptibility to renal damage 
Several authors have tried to linked endothelial damage in the kidney to progression of 
renal damage, recognizing renal ED as an early event in the renal pathophysiology. This 
has led to the hypothesis that renal endothelium is not only involved in the progression, but 
also in the susceptibility to renal damage. Interindividual differences in susceptibility to the 
development of renal disease are long recognized from clinical studies. The systemic 
factors including hypertension or diabetes represent the ultimate risk for renal damage, 
however the majority of patients with these disorders would never develop nephropathy. 
Additional evidence of the predisposition to renal disease is represented by clustering of 
renal disease with a specific racial and ethnic background80,81. Comparably, specific animal 
strains spontaneously developing renal disease have been described suggesting a role of 
genetic components in susceptibility to CKD82. Although the genetic background of CKD is 
a subject of intensive research, the involved genes have not been identified yet83,84.  
The role of the endothelium and /or NO in the predisposition to renal disease has been 
recently proposed by some investigators. An inbred strain of the Wistar-Furth rat is largely 
resistant to the development of renal damage after 5/6 nephrectomy85 or after puromycin 
aminonucleoside injection86 as compared to the widely used Sprague-Dawley strain. Low 
level of NOS inhibition with no impact on disease progression in the Sprague Dawley rat, 
converted Wistar Furth rat into a model of rapidly progressive renal disease87. Similar data 
were presented by using C57B16 mouse, a strain highly resistant to the development of 
nephrectomy-induced renal damage88. In our laboratory, we addressed the role of 
endothelial function in the susceptibility to end-organ damage using different approaches. 
Not only the various inbred strains differ in their sensitivity to organ damage, but also the 
animals of the same outbred strain such as the Wistar rat. When renal damage is induced by 
a well-defined uniform damaging procedure, such as 5/6 nephrectomy or standard injection 
of adriamycin, individual animals develop renal disease of highly variable severity. Some 
healthy rats seem to be more susceptible to end-organ damage than others. To investigate 
the factors responsible for this variability, we measured endothelium-mediated vasodilation 
in small renal arteries of these healthy animals. Following these measurements renal 
damage was induced. Interestingly, nitric oxide-mediated vasodilatory ability of renal 
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arteries measured in healthy kidney inversely predicted the subsequent development of 
proteinuria and focal glomerulosclerosis after 5/6 nephrectomy89 and adriamycin 
nephrosis90. The rats with more pronounced endothelial nitric oxide-mediated relaxation 
seem to be protected against end-organ damage. This is in agreement with the protective 
role of nitric oxide against the development of renal damage. However, many questions 
remain unanswered. We measured vasomotor endothelial function, but it is unclear whether 
the renal endothelium provides direct hemodynamic protection against renal damage, or 
whether it is just a reflection of other protective properties of nitric oxide. Support for the 
latter explanation comes from the fact that the predictive value of NO-mediated dilation is 
found in models with various etiology of renal disease, e.g. 5/6 nephrectomy with 
hemodynamic-mediated injury and adriamycin nephrosis with nephrotoxic agent-induced 
damage. Interestingly, recent data suggest that the predictive value of endothelial 
vasomotor function is found in yet another rat model, in which renal damage is induced by 
combined unilateral nephrectomy and myocardial infarction91. The second important 
question is whether this predictive ability of renal endothelium may have a genetic basis. 
Polymorphisms of endothelial nitric oxide synthase have been associated with end-stage 
renal disease in several studies92,93. Clearly, additional experiments need to be performed, 
however the current evidence point out that interindividual differences in endothelial 
function might account for the variability in the susceptibility to renal injury.  
 
Endothelial function and variability in renoprotective therapeutic response 
Recognizing the important role of ED in the development of both systemic and renal end-
organ damage, the endothelium might represent a valid therapeutic target. A wide spectrum 
of treatments has been shown to improve ED in several conditions. However, it is very 
difficult to assess to which extent this improvement contributes to the prevention or 
regression of end-organ damage, since these beneficial agents often possess 
antihypertensive, antilipidemic or hypoglycemic properties thus additionally targeting 
traditional cardiovascular risk factors.  
The beneficial effect of several interventions has been tested in patients with chronic renal 
failure. Interestingly, restoration of renal function, e.g. by transplantation, is associated with 
reversal of systemic ED94. Dialysis might also acutely improve systemic ED, which could 
be attributed to removal of elevated ADMA95 or homocysteine levels96. In contrast, other 
studies highlight dialysis-induced oxidative stress, which may eventually lead to impaired 
endothelial function97. Decreasing oxidative stress by antioxidant treatment might improve 
endothelial function in some vascular beds21. Attempts for NO bioavailability restoration 
either by L-arginine supplementations or by decreasing homocysteine levels with folic acid 
administration have led to disappointing results98-100. Recently, the beneficial effect of 
cyclooxygenase inhibition has been reported28. Additionally, in experimental settings, 
selective restoration of EDHF-mediated dilation was achieved by chronic angiotensin AT1 
receptor blocker losartan15. As previously stated, it is not known whether observed 
beneficial endothelial effects would translate to the reduction of cardiovascular risk. In this 
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respect, it is important to mention the results of the recent studies in hemodialysis patients, 
in which treatment with acetylcysteine101 and vitamin E102 were associated with a lower 
incidence of cardiovascular events, suggesting that targeting oxidative stress associated 
with endothelial dysfunction might prove a useful therapeutic strategy in chronic renal 
failure.  
ED in the peripheral vasculature is also an emerging treatment target in patients with 
minute renal injury manifested as microalbuminuria. Several studies have been performed 
in diabetic patients, mainly investigating the effect of drugs interfering with the renin-
angiotensin system, such as ACE inhibitors (ACEi) and angiotensin AT1 receptor blockers 
(ARB). Although ACEi might improve some aspects of endothelial function in diabetic 
microalbuminurics, this is not always associated with reduction in microalbuminuria103-105. 
Furthermore, reduction in microalbuminuria by ARB was not accompanied by 
improvement of endothelium-dependent vasodilation106. Therefore, it seems that 
improvement of microalbuminuria is not always related to the improved systemic ED, at 
least in diabetic patients. The exact relation between renal and systemic ED will have to be 
defined, since lowering of microalbuminuria efficiently prevents cardiovascular events in 










































Figure 2. Renal endothelial function of healthy rat predicts the antiproteinuric effect of 
ACE inhibition. 
Endothelium-dependent relaxation measured in small renal arteries of healthy animals (in 
arbitrary units of Area Under dose-response Curve to Acetylcholine- AUC) predicts the 
reduction in proteinuria after 10 weeks therapy with lisinopril (2.5mg/kg) preceded by 6 
weeks of chronic renal disease induced by 5/6 nephrectomy.  
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Importantly, specific lowering of microalbuminuria translates in the reduction of renal 
events in several populations. Parving et al. showed that lowering of albuminuria with 
ARB irbesartan is dose-dependently associated with reduced progression to diabetic 
nephropathy in hypertensive type II diabetics independent of blood pressure control109. This 
may also suggest that reversal of ED might play a role in the inhibition of renal disease 
progression. Many of the agents known to improve ED, including ACEi, ARB, 
vasopeptidase inhibitors and probably statins, have been shown to inhibit the progression of 
renal disease. Furthermore, all these agents have profound effects on renal hemodynamics 
thus potentially interfering with endothelium-dependent control of renal function. 
Among the renoprotective treatments, blockade of renin-angiotensin system seem to 
provide superior protection as compared to other drugs. In patients, ACEi effectively 
reduce proteinuria, glomerulosclerosis and decline of renal function. The antiproteinuric 
effect of ACEi is a valid index of therapeutic efficacy since it predicts long-term effect on 
renal disease110. Comparably to the rate of renal disease progression, the response to ACE 
inhibition is highly variable among individuals, suggesting that some patients are resistant 
while others are more sensitive to renoprotection by ACEi111. Several factors have been 
implicated in this variability of therapeutic response, including variability in severity of 
systemic complications (e.g. hypercholesterolemia, hypertension, obesity, insulin 
resistance), volume status and/or genetic background. Given the potential role of 
endothelium in the therapeutic effects of ACEi, we studied whether variability in renal 
endothelial function represent a factor involved in variability of ACEi antiproteinuric 
response. In the experimental setting described above, we measured vasomotor endothelial 
function in healthy Wistar rats. The animals were subsequently subjected to 5/6 
nephrectomy and developed severe renal damage within 6 weeks. From this time point on, 
the rats were treated by ACEi lisinopril during additional 10 weeks. Antiproteinuric 
response to ACEi was highly variable in these rats and was not related to the level of blood 
pressure or volume status. However, ACEi antiproteinuric response was strongly predicted 
by baseline endothelial function (Figure 2). The rats with more pronounced endothelial 
vasodilation were found to benefit less from ACEi112. Therefore, in contrast to the 
predictive value of endothelial function for the progression of renal damage, better renal 
endothelial function was associated with less beneficial outcome. This suggests that 
individual variability in antiproteinuric response might be independent of the severity of 
renal damage and that specific endothelial effects of ACEi might be involved in their 
renoprotective effects. Indeed, ACEi lowers the level of oxidative stress thereby preventing 
reduction in NO bioavailability, and retards the degradation of bradykinin, an NO-releasing 
autacoid. In fact, angiotensin II-induced release of NO is an important physiologic 
mechanism to counteract the excessive renal vasoconstriction113. The present results only 
allow speculation on the role of NO in predictive value of endothelial function for 
antiproteinuric effects of ACEi. It might be hypothesized that individuals with well-
preserved endothelium (eventually NO) seem to be less dependent on activity of 
angiotensin II after the induction of renal damage and thus resistant to the beneficial effects 
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of ACEi. Alternatively, the favorable effects of ACEi might be directly related to their NO-
releasing ability. Individuals with saturated mechanisms of NO production might be less 
sensitive for additional ACEi-induced NO release. Clearly, more data on this subject are 
required, however at present it seems possible that variability in endothelial function among 




Endothelial dysfunction seems to be a crucial mediator of increased cardiovascular risk 
observed among patients with CKD. Importantly, systemic ED does not only occur in 
patients with severe renal failure, but also in the individuals with earlier stages of renal 
impairment. Close association between microalbuminuria and systemic ED renders renal 
vascular function an important marker for the severity of cardiovascular damage. 
Furthermore, changes in renal endothelium might be actively involved in the progression of 
renal end-organ damage. Recently, variability in endothelial function of healthy individuals 
emerged to predict the susceptibility to renal damage and the efficacy of renoprotective 
treatment (Figure 1). Therefore, a specific manipulation of renal and systemic ED might 
provide benefit in various stages of CKD. ED thus represents an ideal therapeutic target not 
only for treatment, but also for primary prevention of renal disease.  
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Chronic kidney disease (CKD) is currently viewed as a generalized vasculopathic state 
associated with multiple alterations in various vascular beds. Moreover, the kidney can be 
regarded as an organ, where vascular changes are immediately and sensitively detected by 
protein (albumin) excretion, already in early stages of vascular disease. The vascular 
changes have been often considered a consequence of renal disease. However, the fact that 
several forms of vascular dysfunction occur early in the pathophysiology of CKD has 
brought the possibility that vascular changes may actually preceed and maybe even 
determine the progression of renal end-organ damage. This thesis provides data on the role 
of intrarenal and systemic vascular reactivity in early renal pathology in animal models of 
experimental and spontaneous renal disease. Chapter 2 introduces the concept, in which 
microalbuminuria, an early marker of CKD, is associated with both renal and systemic 
vascular dysfunction. Furthermore, we suggest that therapies targeted to improve early 
endothelial dysfunction may provide benefit in the primary prevention of CKD and related 
cardiovascular alterations.  
 
Endothelial function predicts the susceptibility to renal end-organ damage 
Early vascular changes observed in the individuals with microalbuminuria suggest the role 
of vascular alterations in the development of CKD. Development of renal damage varies 
among individuals despite similar levels of blood pressure and it has been proposed that 
genetic factors might be responsible for increased susceptibility to CKD1,2. Previously, it 
has been shown that variability in endothelial function among healthy rats of outbred 
Wistar rat strain predicts the susceptibility of the individual animals to renal injury after 5/6 
nephrectomy (5/6Nx)3. In chapter 3 we demonstrated the predictive property of intrarenal 
endothelial function in yet another model of experimental renal damage induced by 
combined unilateral nephrectomy (UnX) and myocardial infarction (MI). We found that 
individuals with pronounced endothelium-dependent vasodilation of small renal arteries 
developed lower proteinuria and glomerulosclerosis after UnX+MI. This correlation 
suggests the presence of an intrarenal vascular factor determining the susceptibility to renal 
damage induced by cardiac injury. Together with observations from the 5/6 nephrectomy 
model, it is suggested that hemodynamic alterations mediated by endothelial reactivity may 
play a role in the development of experimental end-organ damage irrespective of how this 
damage is inflicted. The present findings implicate that modulation of endothelial function 
might provide protection against the development of end-organ damage in patients after MI.  
In chapter 4 we tested the concept of the predictive value of endothelial function in an 
experimental model with a different etiology of renal damage, i.e., nephropathy induced by 
the nephrotoxic drug adriamycin. In contrast to previous models, the rats with prominent 
endothelial relaxation seem to be more prone to the development of renal damage after 
injection of adriamycin. These contrasting findings suggest that predictive value of renal 
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vascular function is critically dependent on the type of renal injury and etiology of 
progressive renal damage. However, we additionally found a positive significant correlation 
between the resulting proteinuria and the level of renal blood flow measured before the 
induction of injury. This might indicate that in this model, the endothelium-mediated 
hemodynamic status of the kidney determines the extent of renal damage through 
regulation of drug delivery to the kidney. Yet, in agreement with hemodynamic models of 
5/6Nx and UnX+MI, individuals with pronounced nitric oxide (NO)-mediated vasodilation 
also seem to be protected against the toxic renal damage, regardless of the total 
endothelium-mediated vasodilation. Therefore, NO seems to play a protective role in 
various models of renal injury. Thus, assessment of NO-mediated relaxation may provide 
more consistent information on the susceptibility to renal end-organ damage than total 
endothelial response. This is in line with the protective role of NO against renal damage, 
described by several other authors4,5. Consequently, drugs aiming at increasing renal NO 
bioavailability might prove effective in prevention of renal end-organ damage, induced 
either by nephron number reduction, nephrotoxic drug or myocardial infarction.  
 
Endothelial and myogenic dysfunction precede end-organ damage in spontaneous 
renal disease 
Spontaneous animal models prone to the development of renal damage provide a valuable 
tool to define the genetic background for susceptibility to renal injury2. In line with the 
hypothesis of the predictive value of endothelial function for the development of renal 
damage, in chapter 5 we describe endothelial dysfunction, preceding the development of 
proteinuria in the Fawn Hooded hypertensive (FHH) rats, a model of spontaneous 
hypertension-associated renal disease6, when compared to FHL rats, a related strain 
resistant to hypertension and renal impairment. In this case, however, rather than NO, 
excessive production of cyclooxygenase-derived constrictive prostanoids was responsible 
for the impaired renal endothelial vasodilation prior to the development of renal injury. 
This suggests a specific mechanism of vascular alteration, possibly related to minor 
elevations of systemic blood pressure in this inbred strain. Furthermore, in the same arteries 
prior to the development of renal damage, we observed impaired myogenic reactivity, an 
additional vasoactive mechanism probably involved in the altered renal hemodynamics, 
hyperfiltration and renal injury, as previously described in other models of spontaneous 
renal disease7-9. Interestingly, both endothelial and VSMC-mediated changes were specific 
for the renal vasculature and were not observed in systemic resistance or large conduit 
arteries, arguing against an a priori relationship between renal and systemic vascular 
dysfunction in CKD. Yet, another endothelial mediator, EDHF, seems to be impaired in the 
early course of renal disease in small systemic arteries. This suggests that renal injury might 
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Myogenic response and EDHF are impaired in systemic vasculature in experimental 
CKD 
Whereas renal vascular changes may determine the severity of renal end-organ damage, 
impaired systemic reactivity might participate in CKD-related complications, such as 
hypertension. In chapter 5 we found impaired systemic vascular reactivity in a model of 
spontaneous renal disease prior to the development of end-organ damage. In chapter 6 we 
explored the systemic vascular reactivity in the experimental model of 5/6 nephrectomy. 
Two principal local vasomotor mechanisms in small systemic resistance arteries, VSMC-
mediated myogenic constriction and endothelium-mediated EDHF-dependent relaxation 
were concomitantly altered in this setting, arguing against the hypothesis of their mutual 
inverse relationship10. In this case, myogenic reactivity represents rather a beneficial 
mechanism counteracting elevated peripheral resistance, whereas loss of EDHF might 
actively participate in the development of CKD-related cardiovascular problems. 
Importantly, renoprotective therapeutic intervention in the renin-angiotensin system 
reversed both systemic vascular changes providing a useful therapeutic strategy to prevent 
CKD-related cardiovascular alterations.  
 
Conclusions and future perspectives 
The association of endothelial dysfunction with cardiovascular disease has represented one 
of the major issues of cardiovascular medicine in recent 20 years11-14. Currently, it becomes 
more and more clear that vascular changes may be involved in earlier stages of chronic 
disease development and may even determine the susceptibility to organ damage. Based on 
our results, measurements of endothelial function may provide a useful prognostic tool to 
identify individuals prone to end-organ impairment. A similar concept has been proposed 
for endothelial function in cardiac and systemic arteries in predicting cardiovascular 
outcomes, however, the majority of studies included high risk individual15-17 in contrast to 
our healthy experimental animals. In kidney, our experimental results will have to be 
confirmed by human studies. Furthermore, a specific test of nitric oxide-mediated 
vasodilation should be preferred to total endothelium-mediated vasodilation, as the other 
endothelial mediators may not properly reflect the sensitivity to renal injury. Although it 
cannot be concluded from our experiments whether the observed variability in endothelial 
function is genetically determined, several other authors suggest that the decrease 
expression of nitric oxide synthase (NOS) is associated with susceptibility to renal 
damage18,19. Moreover, clinical studies showed an association between polymorphisms of 
endothelial NOS and CKD in various patient populations20,21. Additionally, endothelial 
function might be a determinant of renoprotective therapeutic response as suggested in 
chapter 7. Dietary or pharmacologic strategies, such as plant-derived antioxidants or drugs 
interfering with the renin-angiotensin system, known to interfere with endothelial function, 
may prove beneficial in primary preventive strategies against CKD and related 
cardiovascular events. In addition to the endothelium, VSMC-mediated myogenic response 
may provide a novel therapeutic target for prevention of early hyperfiltration and 
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subsequent renal pathology. Further characterization of the heterogeneous mechanisms 
underlying arterial reactivity in various vascular beds will help to further define the intricate 
relation between renal and systemic vasculature and the role of vascular tone regulation in 
the development of chronic end-organ damage.  
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Patienten met een chronische nierziekte overlijden in meer gevallen aan hart- of 
vaataandoeningen dan aan de nieraandoening zelf. Een mogelijke verklaring voor dit 
fenomeen is de aanwezigheid van gegeneraliseerde vaatschade als gevolg van het falen van 
de nieren. De relatie tussen vaatschade en nierziekte lijkt echter tweeledig. Recent 
onderzoek suggereert dat de vaatdysfunctie mogelijk het beloop van de progressie van 
nierschade mede kan bepalen. Deze hypothese is gebaseerd op de bevinding dat patiënten 
met reeds aanwezige vaatfunctiestoornissen een gering verhoogde hoeveelheid eiwit in de 
urine (microalbuminurie) hadden, maar nog geen nierfunctieverlies vertoonden. 
Microalbuminurie, het eerste teken van een nieraandoening, ontstaat als het gevolg van 
lekkage in de bloedvatwand van de nier en wordt beschouwd als de weerspiegeling van 
gegeneraliseerde vaatschade, ook in het systemische vaatbed. Dit zou betekenen dat de nier 
een orgaan is waarin de mate van vaatdysfunctie relatief eenvoudig en in een vroeg stadium 
geconstateerd zou kunnen worden. Onderliggende mechanismen van vaatstoornissen bij 
nieraandoeningen en hun relatie met eind-orgaan schade zijn echter niet voldoende 
onderzocht.  
Vaatdysfunctie wordt gekenmerkt door veranderingen in de lokale regulatie van de 
vaattonus. De tonus van de kleine weerstands arteriën wordt bepaald door de werking van 
de gladde spiercel en het endotheel, de cellaag die de binnenbekleding van de vaten vormt. 
Het endotheel speelt een belangrijke rol bij de regulatie van de vaattonus, onder andere 
door het afgeven van vaatverwijdende mediatoren. De functie van het endotheel wordt 
getest door middel van acetylcholine-gemedieerde dilatatie. Vermindering van vaatdilatatie 
wordt endotheeldysfunctie genoemd. Het weerspiegelt niet alleen het gebrek aan 
vaatverwijdend vermogen van het endotheel, maar ook de achteruitgang in andere 
fysiologische eigenschappen ervan. Endotheelschade wordt tegenwoordig gezien als vroege 
stap in het ontwikkelen van atherosclerose en is daarmee een risico-indicator voor hart- en 
vaatziekten. Endotheel afhankelijke dilatatie wordt gemedieerd door het afgeven van 
verschillende biologisch actieve mediatoren, met name stikstof oxide (NO), prostaglandines 
en een zogenoemde endothelium-derived hyperpolarizing factor (EDHF). De bijdrage van 
deze stoffen aan de endotheelafhankelijke relaxatie verschilt tussen de specifieke 
vaatbedden, zoals b.v. nier-, hart- en perifere vaten. Daardoor variëren ook de mechanismen 
van de endotheeldysfunctie in de verschillende vaatbedden en hun rol in het ontwikkelen 
van eindorgaanschade. Het is daarom van groot belang de relaties tussen de specifieke 
organen en vaatdisfunctie te begrijpen in ziektes waarbij sprake is van gegeneraliseerde 
vaatschade, zoals een chronische nierziekte. Naast het endotheel draagt de gladde spiercel 
van de vaatwand bij aan de regulatie van de vaattonus. De gladde spiercel reageert op 
verhogingen in de bloeddruk met contractie, ook wel myogene respons genoemd. Dit 
mechanisme in de nierarteriën beschermt de nier tegen het schadelijke effect van een 
verhoogde bloeddruk. Verder draagt de myogene response in het systemisch vaatbed bij aan 
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de regulatie van de perifere weerstand en bepaald hierdoor mede de systemisch bloeddruk. 
Over de rol van gladde spiercel afwijkingen in hart- en vaatziektes is nog verassend weinig 
bekend. 
Dit proefschrift bestudeert in detail de rol van de vaatfunctie, zowel het endotheel als de 
myogene respons, in de ontwikkeling van eindorgaanschade in spontane en experimentele 
(geïnduceerde) diermodellen van nierschade. Hoofdstuk 2 introduceert het klinisch concept 
van de relatie tussen microalbuminurie en systemische endotheeldysfunctie. Dit hoofdstuk 
geeft een samenvatting van zowel experimentele als klinische data, die laten zien dat 
endotheeldysfunctie vooraf gaat aan en voorspellend is voor het ontstaan van 
microalbuminurie, chronische nierziekte en geassocieerde hart- en vaatziekten. Mogelijk 
kan behandeling gericht op het verbeteren van endotheeldysfunctie worden toegepast als 
primaire preventie ervan. 
 
Endotheelfunctie voorspelt de ontwikkeling van chronische, experimentele nierschade 
Individuen vertonen aanzienlijke variatie in hun gevoeligheid voor het ontwikkelen van 
chronische nierziekte. Deze variatie blijkt gedeeltelijk onafhankelijk te zijn van de 
klassieke (systemische) risicofactoren zoals hoge bloeddruk, diabetes of verstoringen van 
vetspiegels in het bloed. Dit suggereert dat onbekende, intrarenale factoren medebepalend 
zijn voor het ontwikkelen van nierschade. Aangezien endotheeldysfunctie al vroeg in de 
pathogenese van eindorgaanschade een rol lijkt te spelen was de initiële hypothese dat het 
functioneren van de niervaten de gevoeligheid voor nierschade bepaald. In hoofdstuk 3 
wordt aangetoond dat de endotheelfunctie gemeten als acetylcholine-gemedieerde dilatatie 
van kleine nierarteriën in gezonde Wistar ratten, voorspellend is voor de mate van 
nierschade na het aanbrengen van een nefrectomie gecombineerd met een hartinfarct. Deze 
data illustreren dat de variatie in niervaatfunctie, die onder normale omstandigheden 
aanwezig is, de mate van de nierschade die als gevolg van de verminderde functie van de 
andere organen ontstaat, mede kan bepalen. Daarnaast zou de modulatie van de intrarenale 
endotheelfunctie beschermend kunnen werken tegen de achteruitgang in nierfunctie in 
patiënten met een hartinfarct. Het concept van de voorspellende waarde van 
endotheelfunctie voor het ontwikkelen van nierschade wordt in hoofdstuk 4 getest in een 
ander experimenteel model van nierschade, namelijk adriamycine-geïnduceerde nefropatie. 
Na het meten van de vaatfunctie werd de nierschade aangebracht door het eenmalig 
inspuiten van het nefrotoxische middel adriamycine. Het resultaat was dat de ratten met een 
goede basale, NO-afhankelijk relaxatie beschermd waren tegen de adriamycine-
geïnduceerde nierschade. Aan de andere kant, dieren met een uitgesproken goede 
acetylcholine-geinduceërd totale endotheelrelaxatie (die gemedieërd is door het 
gecombineerde effect van NO, prostaglandines en EDHF) ontwikkelden meer nierschade. 
Deze data demonstreren dat de voorspellende waarde van de endotheelfunctie sterk 
afhankelijk is van de bijdrage van de onderliggende mediatoren. De beschermende rol van 
NO komt overeen met data in de literatuur die een beschermend effect van NO bij 
nierziekten laten zien. De omgekeerde relatie tussen de totale endotheelrelaxatie en de 
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nierschade bij adriamycine nefrose zou verklaard kunnen worden door de rol van het 
endotheel in de regulatie van de nierdoorbloeding tijdens het inspuiten van adriamycine. In 
het tweede deel van deze studie werd aangetoond dat ratten met een uitgesproken goede 
nierdoorbloeding, gemeten net voor het inspuiten van adriamycine, geneigd zijn meer 
nierschade te ontwikkelen. Dit suggereert dat de aanvoer van het nefrotoxische middel in de 
nier medebepalend is voor de ontwikkeling cq. inductie van nierschade in dit diermodel. 
Deze bevindingen kunnen tot een nieuwe risicoinschatting en behandelingsstrategie bij 
patienten met nierziekten leiden. Het meten van specifieke NO-gemedieërde relaxatie zou 
een betere prognostisch parameter kunnen zijn dan de totale, acetylcholine-gemedieerde 
dilatatie. Daarnaast zouden geneesmiddelen gericht op het verbeteren van de NO activiteit 
het onstaan en/of de progressie van chronisch nierziekten kunnen voorkomen. 
 
Endotheel- en myogene dysfunctie gaan vooraf aan eindorgaan schade in een 
spontaan nierziekte model 
Naast de modellen waarin de nierschade wordt aangebracht door een experimentele 
ingreep, bestaan er ook rattenstammen met een specifieke genetische achtergrond waardoor 
de nierschade zich spontaan ontwikkelt. Gezien de relatie met de humane situatie is het 
belangrijk te bestuderen of de voorspellende waarde gezien in de experimentele modellen 
bevestigd kan worden in de zich spontaan ontwikkelende nierziekten. In hoofdstuk 5 wordt 
de endotheel- en myogene dysfunctie van de kleine nierarteriën bestudeerd die vooraf gaat 
aan het ontwikkelen van nierschade in de zgn. Fawn-Hooded Hypertensieve (FHH) rat. 
Deze rat ontwikkelt reeds op jonge leeftijd spontaan hypertensie-geassocieërde nierschade, 
in tegenstelling tot de FHL stam, waarin de nierfunctie nagenoeg onaangetast blijft. 
Inderdaad werd een verminderde endotheelafhankelijke dilatatie van de nierarteriën 
gevonden in jonge FHH ratten, maar niet in jonge FHL ratten. Dit als gevolg van 
overmatige productie van vaatvernauwende prostaglandines en vrije zuurstof radicalen. 
Tegelijkertijd bleek ook de myogene respons van de niervaten in de FHH stam sterk 
verminderd. Daardoor is de beschermende werking van myogene contractie tegen de 
verhoogde bloeddruk (hypertensie) aangetast. Dit zou kunnen leiden tot intraglomerulaire 
hypertensie en het ontwikkelen van nierschade in de FHH rat. Zowel afwijkingen in het 
endotheel en de gladde spiercel bleken selectief veranderd in de niervaten, maar niet 
aanwezig in de systemische vasculatuur. Deze waarneming pleit tegen een directe relatie in 
vaatdysfunctie tussen niervaten en systemische vaten in de zich ontwikkelende nierziekte. 
In kleine mesenteriale arterieën, die de perifere weerstandsvaten vertegenwoordigen, was 
de EDHF-afhankelijke endotheel relaxatie echter selectief verminderd, waarschijnlijk door 
het ontwikkelen van de hypertensie in de FHH stam. In het algemeen lijkt de endotheliale- 
en myogene functie echter selectief aangetast in de kleine nierarterieën, ook in dit 
diermodel van spontaan nierziekte voorafgaand aan het ontstaan van eind orgaanschade. 
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Endotheel- en myogene dysfunctie in perifere weerstandsvaten als gevolg van 
experimenteel nierfunctieverlies is te herstellen met een ACE-remmer 
Terwijl de voorspellende waarde van de vaatfunctie voor eindorgaanschade een relatief 
nieuw concept representeert, is het schadelijke effect van de nierfunctieverlies op de 
perifere vaatfunctie al langer bekend. De verhoogde bloeddruk, systemische hypertensie, 
vertegenwoordigd de meest voorkomende geassocieerde aandoening bij chronische 
nierziekten. Het is echter niet bekend of de lokale vaatdysfunctie betrokken is bij het 
ontstaan van hypertensie bij nierpatiënten. In hoofdstuk 6 wordt de vaatfunctie van 
mesenteriale vaten bestudeerd in een diermodel van chronisch nierziekte geïnduceerd door 
het verwijderen van 5/6 deel van het nierweefsel (nefrectomie). In de kleine 
weerstandsvaten, zoals mesenteriale arteriën, zijn gladde spiercel-gemedieerde myogene 
constrictie en endotheel-gemedieerde EDHF-afhankelijke relaxatie de belangrijkste lokale 
mechanismen betrokken bij de regulatie van de vaattonus. In onze studie was experimenteel 
nierfalen geassocieerd met gelijktijdige reductie van myogene constrictie en EDHF-
afhankelijke dilatatie. Verminderde endotheel-afhankelijke relaxatie zou kunnen bijdragen 
aan de nierfalen-gerelateerde verhoging in de systemische bloeddruk, terwijl de reductie in 
myogene constrictie lijkt te dienen als compensatie mechanisme tegen de toegenomene 
perifere weerstand. In het tweede gedeelte van de studie werd aangetoond dat de 
behandeling met de ACE-remmer lisinopril beide vaatveranderingen hersteld. De 
interventie in het renine-angiotensine systeem is derhalve een mogelijk effectieve 
therapeutische strategie voor het moduleren van de systemische vaatafwijkingen en het 
verminderen van het toegenomen cardiovasculaire risico.  
 
Conclusies en toekomstperspectief 
De rol van endotheeldysfunctie in het ontwikkelen van cardiovasculaire eindorgaanschade 
behoorde in de afgelopen decennia tot een van de meest onderzocht onderwerpen in de 
vaatbiologie. Nog steeds lijken de mechanismen en de relatie tussen deze twee fenomenen 
niet definitief vastgesteld. Het onderzoek gepresenteerd in dit proefschrift ondersteunt de 
hypothese dat vaatziekte vooraf gaat aan het ontwikkelen van eindorgaanschade en de 
ontwikkeling ervan mede bepaald. Vaatdysfunctie zou derhalve vroeg en selectief in de nier 
gedetecteerd kunnen worden. Deze bevindingen bieden enkele klinisch relevante 
perpectieven. 
Ten eerste zou het meten van de endotheelfuctie toegepast kunnen worden als een 
parameter voor individuele risicoinschatting in vroege stadia van nierziekten of zelfs in 
gezonde individuen. Om dit concept tot een klinische toepassing te brengen moeten de data 
geverifieerd worden in humane studies. Daarnaast blijft de discussie met betrekking tot de 
meest universeel toepasbare methode voor het meten van endotheelfunctie in de mens nog 
steeds open. Uit de dierexperimenten beschreven in dit proefschrift blijkt ook dat specifiek 
NO-afhankelijke endotheel dilatatie een nog beter voorspellende parameter zou kunnen zijn 
dan de totale, acetylcholine-geïnduceerde vasodilatatie. NO blijkt dus de meest belangrijke 
beschermende mediator tegen het ontstaan van nierschade te zijn.  
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Ten tweede representeert het verbeteren van endotheelfunctie en dan met name de NO 
activiteit in de nier een behandelingstrategie, die het beloop en de uitkomst van 
aandoeningen in nierpatienten gunstig zou kunnen beïnvloeden. Misschien zou hierdoor het 
ontwikkelen van nierziekten zelfs wel kunnen worden voorkomen. Enkele van de meest 
klinisch succesvolle nierbeschermende interventies, met name gericht op het renine-
angiotensine systeem, interferereert ook met de endotheelfunctie. Met betrekking tot de 
renoprotectieve effecten van ACE-remmers blijkt uit hoofdstuk 7 dat de endotheel 
afhankelijke dilatatie de sterkte van het renoprotectieve effect van ACE-remmers voorspelt. 
Daarmee lijkt de relatie tussen de endotheelfunctie en nierbeschermend effect van ACE 
remmers aangetoond.  
Tenslotte speelt naast het endotheel ook de reactiviteit van de gladde spiercel een 
belangrijke rol in het ontstaan van nierschade. De myogene respons zou medebepalend 
kunnen zijn voor de gevoeligheid voor het ontwikkelen van nierschade. Nieuwe 
farmacologische strategieën gericht op het verbeteren van myogene functie moeten nog 
ontwikkeld worden. Gebaseerd op het betere begrip van de heterogene mechanismen die 
een rol spelen bij de vaatdysfunctie in diverse vaatbedden kunnen zo betere behandelingen 
van eindorgaanschade in chronische nierziekte en gerelateerde hart- en vaataandoeningen 
gerealiseerd worden.  
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Zhrnutie a závery 
 
Chronická choroba obličiek (chronic kidney disease- CKD) predstavuje v sučasnosti 
významný medicínsky a ekonomický problém. Najvýraznejšou manifestáciou CKD je 
chronické obličkové zlyhanie pri výraznom znížení funkcie obličiek, ktoré vyžaduje liečbu 
hemodialýzou alebo transplantáciou. Avšak mnohonásobne väčší počet chorých má 
známky obličkového poškodenia (zvýšené vylučovanie proteínov- mikroalbuminúria, 
proteinúria, prípadne poškodenie potvrdené histologickým vyšeterením bioptickej vzorky) 
bez výraznejšieho zníženia filtračnej schopnosti obličiek. Títo pacienti už v skorých 
štádiách CKD majú enormne zvýšené riziko kardiovaskulárnych ochorení a existuje u nich 
oveľa väčšia pravdepodobnosť srdcovo-cievnej príhody ako samotnej progresie 
obličkového ochorenia do štádia obličkového zlyhania. Výskyt CKD je teda významným 
kardiovaskulárnym rizikovým faktorom a je spojený s prítomnosťou generalizovanej 
vaskulopatie. Donedávna sa biomedicínsky výskum väčšinou orientoval na odhalenie 
faktorov, vďaka ktorým zníženie obličkovej funkcie vedie k poškodeniu periférnych ciev. 
V posledných rokoch sa však ukazuje, že vzťah medzi vaskulopatiou a nefropatiou je 
obojstranný a cievna dysfunkcia môže predchádzať vzniku chronickej choroby obličiek 
a dokonca i hrať významnú úlohu pri rozvoji orgánového poškodenia. 
Táto práca popisuje niekoľko experimentálnych štúdií skúmajúcich vzťah medzi 
vaskulárnou dysfunkciou a rozvojom chronického obličkového poškodenia a s ním 
spojených kardiovaskulárnych problémov. 
Kapitolu 2 tvorí súhrn prác publikovaných vo vedeckej literatúre, ktoré sumarizujú vzťah 
medzi mikroalbuminúriou a endotelovou dysfunkciou. Mikroalbuminúria, čiže zvýšené 
vylučovanie albumínu v moči (30-300 mg za 24 hodín) je veľmi skorým indikátorom 
obličkového poškodenia. Výskyt mikroalbuminúrie je relatívne častý v populácii 
hypertonikov (20-30%), diabetikov (20-40%) a dokonca i v bežnej populácií (5-8%). Je 
veľmi zaujímavé, že prítomnosť mikroalbuminúrie je spojená s výskytom 
kardiovaskulárnych ťažkostí v prierezových štúdiách. V longitudinálnych klinických 
štúdiách hodnota albuminúrie dokonca predpovedá výskyt kardiovaskulárnej morbidity 
a mortality. Tento významný vzťah sa vysvetľuje hypotézou, že zvýšená permeabilita pre 
albumín v obličke je znakom generalizovaného poškodenia cievneho endotelu vo viacerých 
cievnych riečištiach. Niektoré práce naznačujú, že endotelová dysfunkcia je prítomná 
dokonca skôr ako sa objaví mikroalbuminúria. Oblička by tak mohla reprezentovať orgán, 
v ktorého funkcii sa odráža stav funkcie cievneho endotelu. Samotná endotelová dysfunkcia 
môže byť teda určujúcim faktorom pri rozvoji obličkového a srdcovocievneho poškodenia. 
Použitie farmakologických postupov zameraných na zlepšenie funkcie endotelu, ako 
napríklad liečiv interferujúcich s renín-angiotenzínovým systémom, predstavuje 
potenciálnu terapeutickú stratégiu pre primárnu prevenciu mikroalbuminúrie, a teda aj 
predchádzanie CKD a s ňou súvisiaceho kardiovaskulárneho rizika. 
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Individuálna variabilita endotelovej funkcie predpovedá rozsah experimentálneho 
obličkového poškodenia 
Vyššie uvedené klinické výsledky naznačujú, že endotelová funkcia môže hrať významnú 
úlohu pri vzniku a rozvoji CKD. U  individuálnych pacientov, či experimentálnych zvierat 
sa sklon k obličkovému poškodeniu líši čiastočne nezávisle od prítomnosti a závažnosti 
systémových rizikových faktorov ako sú hypertenzia či diabetes mellitus. Experimentálne 
i klinické štúdie naznačujú, že tento sklon je spoluurčovaný geneticky a určití jednotlivci 
môžu byť predisponovaní ku vzniku CKD. Avšak gény či faktory zodpovedné za túto 
predispozíciu dosiaľ nie sú známe. V kapitole 3 uvádzame výsledky experimentálnej 
štúdie, v ktorej sme testovali hypotézu, či individuálna variabilita endotelovej reaktivity 
môže byť faktorom určujúcim predispozíciu k obličkovému poškodeniu. Endotelová 
funkcia bola meraná acetylcholínovým vazodilatačným testom na malých 
preglomerulárnych artériiách izolovaných z obličiek získaných pri unilaterálnej nefrektómii 
zdravých potkanov kmeňa Wistar. Následne bol u týchto potkanov indukovaný  
experimentálny infarkt myokardu podviazaním ľavej koronárnej artérie. Ten v spojení 
s unilaterálnou nefrektómiou v priebehu 16 týždňov vyvolal štrukturálne a funkčné 
poškodenie zostávajúcej obličky. Úroveň endotelovej reaktivity meraná u zdravých 
potkanov predpovedala závažnosť obličkového poškodenia, ktoré vzniklo po indukcii 
kombinovanej nefrektómie a infarktu myokardu. Potkany s výraznou od endotelu závislou 
dilatačnou schopnosťou obličkových artérií vykazovali nižšiu úroveň proteinúrie 
a glomerulárnej sklerózy, markerov obličkového orgánového poškodenia. Tieto dáta 
naznačujú existenciu intrarenálneho faktora, ktorý ovplyvňuje endotelovú funkciu 
obličkových ciev a spoluurčuje predispozíciu individuálnych zvierat k rozvoju obličkového 
poškodenia indukovaného dysfunkciou vzdialeného orgánu. Modulácia endotelovej funkcie 
u pacientov s infarktom myokardu môže poskytnúť ochranu pred obličkovým poškodením 
a z neho vyplývajúcim zvýšením kardiovaskulárneho rizika.  
V kapitole 4 sme horeuvedený koncept endotelovej funkcie ako prediktívneho parametra 
pre rozvoj obličkového poškodenia testovali u ďalšieho experimentálneho modelu 
s odlišnou etiológiou chronickej choroby obličiek- nefropatie indukovanej jednorázovou 
injekciou nefrotoxickej látky adriamycínu. Okrem toho sme sa pokúsili tento koncept 
rozpracovať sledovaním mechanizmov, ktoré potenciálne môžu hrať úlohu pri regulácii 
relaxácie závislej od endotelu. Aplikácia acetylcholínu vyvolá uvoľnenie troch hlavných 
skupín mediátorov- oxidu dusného (NO), zmesi vazokonstrikčných a vazodilatačných 
prostaglandínov a dosiaľ bližšie necharakterizovaného faktora, označovaného EDHF 
(hyperpolarizačný faktor odvodený od endotelu). Aj u zvierat s adriamycínovou nefropatiou 
predpovedala ich od endotelu závislá relaxačná schopnosť závažnosť obličkového 
poškodenia. Zvieratá s výraznou špecifickou reaktivitou závislou od NO boli chránené pred 
rozvojom adriamycínom indukovanej nefropatie. Tento výsledok je v súlade s  mnohými 
publikáciami preukazujúcimi protektívne vlastnosti NO pri orgánovom poškodení. Na 
rozdiel od NO, u potkanov s markantnou celkovou od endotelu závislou relaxačnou 
schopnosťou (určenou spoločným efektom NO, prostaglandínov a EDHF) sa rozvinula 
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závažnejšia nefropatia. Znamená to, že prediktívna hodnota endotelovej funkcie je silne 
závislá od sledovaného vazoaktívneho mediátora a experimentálneho modelu. Opačný 
vzťah medzi celkovou endotelovou relaxáciou a renálnym výsledkom u modelu 
adriamycínovej nefropatie je možné vysvetliť úlohou endotelu v regulácií krvného prietoku 
obličiek počas podania adriamycínovej injekcie. V druhej časti našej štúdie sme ukázali, že 
u zvierat s vysokým krvným prietokom obličiek, meraným tesne pred podaním 
nefrotoxickej injekcie, sa rozvinulo závažnejšie obličkové poškodenie. Tento výsledok 
podporuje vysvetlenie, že akútny prítok nefrotoxickej látky do obličky počas injekcie je tak 
isto spoluurčujúcim faktorom renálneho poškodenia u tohto experimentálneho modelu. 
Uvedené dáta môžu viesť k novým diagnostickým a terapeutickým možnostiam u pacientov 
s CKD. Meranie špecifickej od NO závislej endotelovej relaxácie u zdravých osôb môže 
byť lepším diagnostickým indikátorom predispozície jednotlivých pacientov k rozvoju 
CKD ako meranie celkovej od endotelu závislej reaktivity. Liečivá, ktoré zasahujú do 
tvorby a biologickej aktivity NO sa môžu uplatniť v primárnej prevencii obličkového 
poškodenia.  
 
Endotelová a myogénna cievna dysfunkcia predchádza rozvoju orgánového 
poškodenia u spontánne sa rozvíjajuceho obličkového ochorenia 
Okrem experimentálnych modelov, u ktorých sa obličkové poškodenie vyvolá 
experimentálnym zásahom existujú aj „inbredné“ kmene potkanov so špecifickým 
genetickým pozadím, u ktorých sa spontánne v mladom veku rozvinie obličkové zlyhanie. 
Zaujímavou otázkou zostáva, či vaskulárna dysfunkcia hrá úlohu aj pri rozvoji tohto 
spontánneho genetického orgánového poškodenia. Preto sme v kapitole 5 tejto práce 
hodnotili reaktivitu malých obličkových artérií u kmeňa hnedoškvrnného hypertenzného 
potkana (Fawn-hooded hypertensive rat- FHH), u ktorého sa v mladom veku spontánne 
rozvinie hypertenzné obličkové poškodenie. To je charakterizované proteinúriou 
a glomerulosklerózou, ktoré môžu vyústiť až do obličkového zlyhávania. Na rozdiel od 
FHH potkana, geneticky príbuzný hnedoškvrnný potkan s nízkym tlakom (Fawn-hooded 
low pressure rat- FHL) je rezistentný voči tomuto obličkovému orgánovému poškodeniu. 
V súlade s našou hypotézou sme pozorovali endotelovú dysfunkciu malých 
preglomerulárnych artérií izolovaných z obličiek 7 týždňového FHH potkana, teda ešte 
pred vznikom štrukturálneho a funkčného obličkového poškodenia, v porovnaní s rovnako 
starými FHL potkanmi. Nadmerná produkcia kontraktilných prostaglandínov a voľných 
kyslíkových radikálov boli zodpovedné za pozorované endotelové poškodenie u FHH 
potkanov. Okrem endotelu závisí tonus malých artérií aj od reaktivity cievneho hladkého 
svalu. Hladký sval reaguje na zvýšenie intravaskulárneho tlaku kontrakciou a následným 
zvýšením napätia cievnej steny. Táto odpoveď sa nazýva myogénna a je významným 
fyziologickým mechanizmom ochraňujúcim orgány pred nadmerným zvýšením prietoku 
krvi pri zvýšení systémového tlaku. V obličke chráni myogénny mechanizmus glomerulus 
pred vznikom intraglomerulárnej hypertenzie, ktorá sa považuje za spúšťací faktor pri 
vzniku chronického obličkového poškodenia. Preto sme v našej štúdii pri charakterizácii 
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vaskulárneho poškodenia predchádzajúceho rozvoju CKD porovnávali aj myogénnu 
reaktivitu obličkových artérií FHH a FHL potkana. FHH potkany vykazovali výrazne nižšiu 
myogénnu reaktivitu ako FHL, čo môže hrať spolu s endotelovou dysfunkciou významnú 
úlohu pri vzniku spontánnej CKD u tohto kmeňa. Je zaujímavé, že endotelové aj 
hladkosvalové mechanizmy boli selektívne poškodené v obličkových cievach, a nie 
v periférnych rezistentných artériách izolovaných z mezetéria, či vo veľkých elastických 
cievach (aorta) FHL a FHH potkanov. Tieto dáta teda nepotvrdzujú priamy vzťah medzi 
vaskulárnym poškodením v obličkách a na periférii, ktorý sa používa na vysvetlenie 
zvýšeného kardiovaskulárneho rizika u CKD. Preto si presné mechanizmy generalizovanej 
vaskulárnej dysfunkcie pri spontánnej CKD vyžadujú ďalšie podrobné štúdium. Selektívne 
poškodenie endotelových a myogénnych mechanizmov v obličkových cievach predchádza 
rozvoju spontánného orgánového poškodenia pri CKD. 
 
Endotelová a myogénna dysfunkcia periférnych rezistentných ciev pri 
experimentálnom obličkovom zlyhaní je reverzibilná po použití ACE inhibítorov 
V predchádzajúcich kapitolách sme sa sústredili na výskum cievnych zmien 
predchádzajúcich vzniku a rozvoju orgánového poškodenia pri CKD. Avšak ani 
mechanizmy vaskulárnych zmien, ktoré vznikajú ako dôsledok CKD nie sú dosiaľ 
uspokojivo vysvetlené. V kapitole 6 tejto práce sme preto sledovali zmeny od endotelu 
a hladkého svalu závislých mechanizmov periférnych rezistentných artérií pri vzniku 
arteriálnej hypertenzie v dôsledku experimentálnej CKD. Skúmali sme dva 
najvýznamnejšie lokálne mechanizmy regulujúce tonus periférnych artérií: od EDHF 
závislú endotelovú relaxáciu a hladkým svalom sprostredkovanú myogénnu kontraktilitu 
malých mezenteriálnych artérií izolovaných z potkanov, u ktorých bolo obličkové 
zlyhávanie a následná hypertenzia vyvolané odobratím jednej obličky a podviazaním dvoch 
vetiev obličkovej artérie na kontralaterálnej strane. To malo za následok infarkt 2/3 
zostávajúceho funkčného parenchýmu u druhej obličky (5/6 nefrektómia). 15 týždňov po 
indukcii obličkového zlyhania sme v periférnych rezistentných cievach pozorovali súčasné 
poškodenie od EDHF závislej endotelovej relaxácie a myogénnej kontraktility. Zatiaľčo 
znížená relaxačná schopnosť periférnych ciev môže prispievať k rozvoju hypertenzie po 
indukcii CKD, zmenšená kontrakčná reaktivita je pravdepodobne kompenzačným 
mechanizmom namiereným proti zvýšenej periférnej rezistencii. V druhej časti našej štúdie 
sme ukázali, že obe tieto vaskulárne zmeny sú modifikovateľné chronickou terapiou ACE 
inhibítorom lisinoprilom. Terapeutický zásah do renín-angiotenzínovej kaskády teda 
predstavuje účinnú stratégiu liečby systémového vaskulárneho poškodenia a predchádzania 
kardiovaskulárnych komplikácií spojených s rozvojom chronického obličkového zlyhania. 
 
Závery a perspektívy 
Úloha endotelovej dysfunkcie pri rozvoji srdcovocievnych ochorení patrí k najviac 
skúmaným otázkam kardiovaskulárnej medicíny v posledných desaťročiach. Avšak 
mechanizmy zodpovedné za tento proces a jeho presné miesto v patofyziológii orgánového 
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poškodenia nie sú dosiaľ dostatočne charakterizované. Experimentálne výsledky 
prezentované v tejto práci podporujú hypotézu, že vaskulárna dysfunkcia predchádza 
a spoluurčuje rozsah orgánového poškodenia pri chronickom ochorení obličiek. Oblička je 
zároveň orgánom, ktorý umožňuje skorú detekciu cievneho poškodenia 
a kardiovaskulárneho rizika (napr. meraním mikroalbuminúrie). Tieto závery ponúkajú 
niekoľko klinicky relevantných perspektív.  
V prvom rade, meranie od endotelu závislej reaktivity sa môže stať potenciálnym 
diagnostickým parametrom umožňujúcim zhodnotenie renálneho, prípadne 
kardiovaskulárneho rizika v skorom štádiu ochorenia, možno dokonca i u zdravých osôb. 
Tento koncept si však vyžaduje potvrdenie platnosti v klinickej praxi za pomoci 
humánnych štúdií. Zároveň ostáva otvorenou otázka, aký endotelový test je najlepším 
indikátorom orgánového rizika. Dáta v predkladanej práci naznačujú, že meranie 
špecifickej od NO závislej endotelovej reaktivity môže poskytnúť lepšiu prediktívnu 
informáciu ako celková acetylcholínom indukovaná endotelová relaxácia. NO teda 
pravdepodobne reprezentuje najvýznamnejší protektívny mechanizmus proti rozvoju 
obličkového poškodenia. 
Po druhé, zlepšenie endotelovej dysfunkcie môže tvoriť perspektívnu terapeutickú stratégiu 
pri chronickom poškodení obličiek. Potenciálne by dokonca takýto prístup mohol zabrániť 
vzniku obličkového ochorenia, a teda umožniť primárnu prevenciu CKD. Je zaujímavé, že 
niektoré v súčasnosti najúspešnejšie renoprotektívne intervencie, napr. zásah do renín-
angiotenzínovej kaskády, majú preukázaný aj protektívny účinok na endotel. Kapitola 7 
tejto práce poskytuje súhrn, ktorý sumarizuje účinnosť endotelprotektívnych stratégií pri 
liečbe CKD. Zároveň v súvislosti s renoprotektívnym účinkom ACE inhibítorov uvádza 
originálne experimentálne dáta dokazujúce, že od endotelu závislá reaktivita malých 
obličkových ciev predpovedá variabilitu v renoprotektívnej účinnosti ACE inhibítorov a tak 
priamo ukazuje vzťah medzi endotel modulujúcim a renoprotektívnym účinkom týchto 
liečiv.  
Na koniec táto práca ukazuje, že okrem endotelu, aj reaktivita buniek hladkej svalovny ciev 
môže hrať významnú úlohu pri vzniku obličkového poškodenia. Úroveň myogénnej 
reaktivity preglomerulárnych artérií môže spoluurčovať predispozíciu ku CKD. Nové 
farmakologické stratégie namierené na zlepšenie renálnej myogénnej dysfunkcie sú ešte 
v štádiu základného výskumu. Lepšie pochopenie heterogénnych mechanizmov 
zodpovedných za vaskulárnu dysfunkciu v renálnych, periférnych, či koronárnych 
riečištiach môže viesť k zlepšeniu terapie a primárnej prevencie orgánového poškodenia pri 
CKD a s ňou súvisiacich srdcovocievnych problémov.  
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